Autophagy controls the hippocampal postsynaptic organization and affects cognition in a mouse model of Fragile X syndrome

Autophagy controls the hippocampal postsynaptic organization and affects cognition in a mouse model of Fragile X syndrome | Research Square window.SnipcartSettings = { analytics: { enabled: false } }; (function() { var accessVector = localStorage.getItem('access_vector') || ''; window.dataLayer = window.dataLayer || []; if (accessVector) { window.dataLayer.push({ user: { profile: { profileInfo: { snid: accessVector } } } }); } })(); (function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src='https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);})(window,document,'script','dataLayer','GTM-K279D39R'); Browse Preprints In Review Journals COVID-19 Preprints AJE Video Bytes Research Tools Research Promotion AJE Professional Editing AJE Rubriq About Preprint Platform In Review Editorial Policies Our Team Advisory Board Help Center Sign In Submit a Preprint Cite Share Download PDF Article Autophagy controls the hippocampal postsynaptic organization and affects cognition in a mouse model of Fragile X syndrome Ziyan Zhang, Cameron Keyser, Yaxin Li, Breandan J. Rosolia, Morgan W. Porch, and 5 more This is a preprint; it has not been peer reviewed by a journal. https://doi.org/ 10.21203/rs.3.rs-4415392/v1 This work is licensed under a CC BY 4.0 License Status: Published Journal Publication published 10 Sep, 2025 Read the published version in Molecular Psychiatry → Version 1 posted 5 You are reading this latest preprint version Abstract Dysregulated spine morphology is a common feature in pathology of many neurodevelopmental and neuropsychiatric disorders. Overabundant immature dendritic spines in the hippocampus are causally related to cognitive deficits of Fragile X syndrome (FXS), the most common form of heritable intellectual disability. Recent findings from us and others indicate autophagy plays important roles in synaptic stability and morphology, and autophagy is downregulated in FXS neurons. However, the mechanism remains unclear. In this study, we identified that activated autophagy degrades the eukaryotic initiation factor 4G1 (eIF4G1) and postsynaptic density protein-95 (PSD-95) in hippocampal neurons of Fmr1 KO mice and FXS neurons from patients, which subsequently corrected the dysregulated postsynaptic organization and actin assembly, the critical processes determining synaptic maturation and density. Centrally activating autophagy in hippocampus degrades eIF4G1 and PSD-95, restores actin dynamics, and improves cognition of Fmr1 KO mice. In human neurons derived from patients diagnosed with both FXS and intellectual disability, activating autophagy corrected the aberrant actin assembly. Thus, our findings revealed a previously unappreciated mechanism through which autophagy affects actin assembly and synaptic organization, suggesting a critical role of autophagy in regulating structural synaptic plasticity in healthy and diseased conditions. Biological sciences/Neuroscience Biological sciences/Drug discovery Fragile X syndrome Autophagy Cognition deficits Postsynaptic organization Figures Figure 1 Figure 2 Figure 3 Figure 4 Figure 5 Figure 6 Introduction Fragile X syndrome (FXS) is the most frequent form of heritable intellectual disability and the leading genetic cause of autism 1 – 3 . In patients with Fragile X syndrome, a CGG trinucleotide repeat located in the 5’-UTR of the fragile X messenger ribonucleoprotein 1 ( Fmr1 ) gene expands from ~ 50 to > 200, resulting in hypermethylation of the promoter region and epigenetic silencing of the Fmr1 gene 4 – 7 . Fragile X Messenger Ribonucleoprotein 1 (FMRP), the gene expression product of Fmr1 , is an RNA binding protein that tightly regulates the trafficking, localization, and translation of a vast number of neuronal mRNAs critical to neural development, synaptic plasticity, and dendritic spine architecture 1 , 8 – 12 . Loss of FMRP and subsequent overabundance of neuronal proteins in the brains of patients and mouse models of FXS induces a complex and debilitating neurological phenotype, including impaired cognition and social interactions, hyperactivity, attentional deficits, seizures, hypersensitivity, autistic behaviors, and autonomic dysfunction 1 , 2 , 13 – 17 . However, effective treatment for FXS in humans remains unmet. Dendritic spines are the postsynaptic compartments that receive most of the excitatory input in the brain 18 . The neuroanatomical hallmark of Fragile X is an overabundance of long and thin (immature) dendritic spines 19 – 22 , which is associated with dysregulated group 1 mGluR-dependent long-term depression (LTD) in hippocampal neurons 23 – 28 . Correcting the aberrant spines has been shown to rescue, at least partially, the deficits of cognition, social behaviors, behavioral flexibility, and sensory processing in mouse models of FXS 22 – 29 . Importantly, recent findings reported that the altered actin dynamics critically account for the aberrant spines and related symptoms in FXS 28 , 30 , 31 . Actin is the most abundant cytoskeletal protein in dendritic spines and exists in dynamics between two states: monomeric globular (G-actin) or polymeric filamentous actin (F-actin) 32 , 33 . F-actin provides structural support for the stability and morphology of spines 32 , 33 . Dendritic spine morphogenesis, neurite formation, synapse formation/elimination, and synaptic plasticity all require fine-tuned remodeling of the actin cytoskeleton through the upstream signaling pathways 32 – 35 . Mouse models of FXS indicated an abnormally increased level of F-actin in the spines at cortex and hippocampus, which is causally related to increased spine density, immature spine morphology, and behavioral deficits 24 , 30 , 31 . To develop translational therapeutic strategies for FXS, mechanisms underlying the dysregulated spine density and morphology need to be explored. Autophagy is a key regulator of cell growth, differentiation, and survival 36 – 38 . In neurons, autophagy plays an important role in protein degradation, synapse elimination, axonal homeostasis, and synaptic plasticity 23 , 39 – 47 . At presynaptic sites, autophagy is critical to vesicular release, and impaired autophagy results in increased size of the presynaptic compartment and enhanced neurotransmitter release 48 . On the postsynaptic side, autophagy is critical to spine elimination and synapse maturation 23 , 49 , 50 . Cargo adaptor molecules such as p62, which bind components of the autophagic machinery, recognize and bind ubiquitinated proteins, enabling their engulfment by autophagosomes targeted for degradation 36 . Reduced autophagy in the brains of humans diagnosed with autism is associated with an accumulation of ubiquitinated proteins 49 . Recent findings revealed that autophagy is downregulated in neurons at hippocampus of a FXS mouse model 23 and in neurons derived from FXS patients 51 . Activation of autophagy leads to rescued synaptic morphology and behavioral deficits 23 , 51 . However, it is still unclear how dysregulated autophagy could affect synapses and behaviors. A critical mechanism implicated in the defects of spine morphology, exaggerated mGluR-LTD, and impaired cognition associated with Fragile X is the overabundance of neuronal proteins 1 , 8 , 9 . In this study, our initial analysis with proteomics revealed that 289 of the 549 overabundant proteins in the hippocampus of Fmr1 KO mice are targets of autophagic protein degradation, indicating a strong correlation between autophagy and pathology of FXS. Further analysis indicates that these 289 proteins may mediate the correlation by affecting postsynaptic organization. Activation of autophagy rescued the aberrant postsynaptic morphology and cognitive behaviors. Proteomics analysis further narrowed that 42 of the 289 proteins may mediate the rescuing effects. Mechanistic studies revealed that among the protein targets, eukaryotic initiation factor 4G1 (eIF4G1) and postsynaptic density protein-95 (PSD-95) are critical. Autophagy degrades eIF4G1 and PSD-95 proteins, corrects the dysregulated postsynaptic organization and actin dynamics, and rescues the spine and cognitive deficits. These findings are validated with FXS mouse model with neuron-specific autophagy deficit, FXS mouse model with brain-specific autophagy activation, and human FXS neurons derived from of patient pluripotent stem cells. Altogether, our findings reveal a critical role of autophagy in regulating structural synaptic plasticity in healthy and diseased conditions and identify autophagy as a novel therapeutic target for Fragile X syndrome. Results Proteomic analysis reveals the correlation between downregulated autophagy and FXS. FXS individuals and animal models are characterized with overabundance of hundreds of neuronal proteins 1 , 8 , 9 . Although most of the overabundances are moderate, the affected proteins together crucially induce complex dysregulated signal pathways, aberrant synapses, and behavioral deficits in FXS 1 , 8 , 9 . To maintain the correct number of proteins, the balance between protein synthesis and degradation must be fine-tuned. In neurons, autophagy plays an important role in protein degradation 39 . Brains from humans diagnosed with autism show reduced autophagy and accumulated ubiquitinated proteins 49 . We previously reported that autophagy is downregulated in hippocampal neurons of Fmr1 KO mice 23 . To estimate the role of downregulated autophagic protein degradation in synaptic defects of FXS, we compared proteins increased in hippocampus of Fmr1 KO ( Fmr1 −/y ) mice vs. WT mice with proteins increased in hippocampus of WT mice when autophagy was inhibited by a pharmacological inhibitor, Chloroquine (CQ) 52 . The results indicated that 549 proteins were significantly increased ( p < 0.05) in hippocampus of Fmr1 KO mice vs. WT mice (Fig. 1 A and Dataset S1 ). 289 of these 549 proteins (52.6%) overlapped with proteins significantly increased in hippocampus of mice injected with CQ vs. Vehicle ( Dataset S2 ), indicating that these 289 proteins are either directly degraded by autophagy or indirectly affected by the downregulated autophagy. Thus, the result indicated that downregulated autophagy plays an important role in the protein overabundance and pathology of FXS. To further estimate the contribution of autophagy to FXS, we performed a Gene Ontology (GO) biological processes enrichment analysis based on the 289 proteins. Fragile X syndrome is a neurodevelopmental disorder, and its pathology primarily affects synaptic functions and morphology in neurons 2 , 48 . The GO analysis results indicated that “Synaptic vesicle priming”, “Dendritic spine development”, “Dendrite development”, “Regulation of synapse structure or activity”, and “Synapse organization” are among the most statistically enriched GO terms ( Supplemental Fig. 1 and Dataset S3 ), suggesting that these 289 proteins are tightly related to the morphology and functions of synapses and dendritic spines, where most of the post-synaptic sites located. Proteins need to be located at certain cellular components to execute the relevant biological processes. Thus, profiling the subcellular components where proteins are located can further explore their roles 53 . GO analysis on Cellular Component (GOCC) with background of brain expression genes demonstrated that synapses and spines are the top (Fold enrichment > 1 and p < 0.05) neuronal subcellular components where these 289 proteins are located (Fig. 1 B and Dataset S4 ). The aberrant spines, synapses and neural circuits are considered as neurological basis for cognitive and behavioral deficits in FXS 48 , 54 . Indeed, the Synaptic Gene Ontologies (SynGO) database (version 20231201) 55 shows the most enriched synaptic component for these 289 proteins is the postsynaptic site (Fig. 1 C and Dataset S5 ). SynGO biological process analysis further indicated that the biggest number of the genes are involved in the process of “organization’ of synapses (Fig. 1 D and Dataset S6 ). Thus, our findings suggest that impaired autophagy crucially contributes to the pathology of FXS, and the protein targets affecting postsynaptic organization in hippocampus may mediate the process. Restoring the impaired autophagy may potentially rescue the synaptic and cognitive deficits. Pharmacological activation of autophagy in hippocampal neurons of Fmr1 KO mice. Rilmenidine is an FDA-approved, blood-brain barrier (BBB) permeable anti-hypertensive agent by activating ADRA2/a2-adrenoceptors, imidazoline-1 receptors and sympathetic nervous system in the brain 56 , 57 . In addition, Rilmenidine also activates autophagy, improves energy metabolism, reduces oxidative stress, and affects ageing processes 56 – 59 . Rilmenidine can significantly activate autophagy in neurons of a Huntington’s Disease mouse model and a mutant SOD1-induced amyotrophic lateral sclerosis mouse model 60 , 61 . Pharmacokinetic assay with HPLC-MS/MS shows after intraperitoneal ( i.p. ) injection, Rilmenidine crossed the BBB, leading to comparable concentrations in the brain and plasma ( Supplemental Fig. 2A, B ). To optimize the dose and timeline for Rilmenidine injection, we tested the dose and time effects of Rilmenidine on autophagy in mouse hippocampus. When autophagy flux is inhibited, the cargo adaptor protein, p62 accumulates 36 – 38 . Two hours post injection, both 10 mg/kg and 100 mg/kg dosages significantly reduced p62 protein levels, indicating activated autophagy in the hippocampus ( Supplemental Fig. 3A ). Time-course effect indicated that 10 mg/kg of Rilmenidine injection started to significantly reduce p62 levels 2 hr post injection, and the effect lasted until 8 hr post injection ( Supplemental Fig. 3B ). Thus, to activate autophagy in brain, mice received daily i.p. injection of Rilmenidine at 10 mg/kg for 1 week 60 (Fig. 2 A). This treatment did not significantly affect the body weight and length of mice ( Supplemental Fig. 4 ). Consistent with the proteomics data, p62 was markedly increased in the hippocampus from Fmr1 KO vs . WT mice (Fig. 2 B, C). Rilmenidine reduced the elevated p62 abundance in Fmr1 KO mice to a similar level as WT mice. Immunostaining of p62 with brain sections shows that Rilmenidine reduced the accumulated p62 proteins in CA1 neurons of Fmr1 KO mice (Fig. 2 D, E). Upon initiation of autophagy, LC3-II becomes associated with the autophagosomal membrane and is subsequently degraded in lysosomes as a part of autophagic cargo 36 . We next assessed autophagy flux as rates of LC3-II turnover by comparing LC3-II levels in the presence and absence of lysosomal inhibitors 62 . Net LC3-II flux decreased in hippocampal neurons cultured from Fmr1 KO mice vs. WT mice, which was reversed by treating with Rilmenidine (Fig. 2 F, G). Because neurons lack ability to dilute damaged material through cell division 63 , efficient and quick autophagic degradation of cargos are required to maintain the neuronal health 63 , 64 . In hippocampal neurons of wild type mice, where autophagy is already efficient in normal condition, Rilmenidine treatment only slightly reduced cargo protein p62 levels ( Supplemental Fig. 5A-D ). Collectively, these findings indicate that Rilmenidine restores the downregulated autophagy in the hippocampus of Fmr1 KO mice. Activation of autophagy mitigated the aberrant spine and cognitive deficits in Fmr1 KO mice. Hippocampal neurons of patients with FXS and Fmr1 KO mice exhibit an excess of dendritic spines and immature spine morphology 27 , 65 . To examine the effect of pharmacological activation of autophagy on spine morphology, we first injected Fmr1 KO mice and WT mice with Rilmenidine or vehicle as seen in Fig. 2 A, and assessed dendritic spine morphology (Fig. 2 H). Fmr1 KO mice showed increased spine density on dendrites of CA1 pyramidal neurons compared with WT mice, while Rilmenidine corrected the increased spine density of Fmr1 KO mice to near that of WT mice (Fig. 2 I). Next, we examined the impact of Rilmenidine on spine maturation by classifying spines as stubby and mushroom-shaped (mature) or spindly, filopodial-like protrusions (immature). CA1 neurons from Fmr1 KO mice exhibited a marked decrease in the percentage of mushroom/stubby spines and a marked increase in the percentage of long, filopodial-like protrusions, relative to that of WT (Fig. 2 J), consistent with previous findings 23 , 27 , 65 . Rilmenidine increased the percentage of mature spines of Fmr1 KO mice to near WT levels (Fig. 2 J). Rilmenidine treatment did not significantly alter the spine density in WT hippocampal CA1 neurons and only slightly reduced percentage of immature spines ( Supplemental Fig. 5E-G ). Thus, activation of autophagy by Rilmenidine corrected abnormalities in the spine density/morphology of hippocampal neurons in Fmr1 KO mice. Patients with FXS exhibit cognitive deficits 1 , 2 , 66 and Fmr1 KO mice display deficits in visual memory 67 , 68 . We next examined the impact of activating autophagy on cognition of Fmr1 KO mice. The novel object recognition task assesses visual memory and takes advantage of the innate tendency of wild-type mice to spend more time exploring a novel vs. a familiar object 69 . Vehicle-treated WT mice showed a strong preference for the novel object (Fig. 2 K, L and Supplemental Fig. 6 ). Fmr1 KO mice injected with vehicle spent approximately equal times exploring the novel and familiar objects, indicating no preference for the novel object and impaired cognition. Fmr1 KO mice injected with Rilmenidine spent more time exploring the novel vs. familiar object, indicating preference to novel object and rescued cognition (Fig. 2 K, L and Supplemental Fig. 6 ). We next examined the effects of Rilmenidine on contextual memory with the contextual fear condition test. In this assay, mice were exposed to a distinctive environmental context in which they received a shock. On the testing day (24 hr after the shock), they were returned to either the same (familiar) or a different (novel) context (Fig. 2 M). Fmr1 KO mice exhibited profound memory deficits on the testing day, as evidenced by lack of freezing response in the familiar context (Fig. 2 N). Fmr1 KO mice treated with Rilmenidine indicated a significantly higher percentage of freezing in the familiar context on testing day, comparable to Fmr1 KO mice treated with the vehicle, demonstrating that activating autophagy enhanced the memory of the association between context and an aversive event. In addition to cognitive tests, effects of Rilmenidine on other behavioral deficits reported with Fmr1 KO mice were also examined 25 , 70 . Rilmenidine treatment failed to rescue the impaired nest building behavior ( Supplemental Fig. 7A, B ) and the increased center time (open field test, Supplemental Fig. 7C, D ) of Fmr1 KO mice. Fmr1 KO mice exhibited higher levels of self-grooming, a repetitive behavior 70 , which are significantly reduced by Rilmenidine ( Supplemental Fig. 7E ). Collectively, Rilmenidine corrected abnormalities in spine density/structure and cognitive deficits associated with Fmr1 KO mice. The rescuing effects on FXS phenotypes rely on activation of autophagy in neurons. To identify the role of dysfunctional autophagy in cognitive deficits in FXS, we first knocked down Atg 7 (autophagy-related 7 gene), a key component of autophagy, in hippocampal neurons of wild type mice and then observed their cognitive behaviors. Adino-associated virus (AAV) expressing Syn-Cre-GFP were injected bilaterally to hippocampus of wild type ( Atg7 w/w ), heterozygous Atg7 floxed (f) mice ( Atg7 w/f ), and homozygous Atg7 f/f mice ( Supplemental Fig. 8A-C) . The expression of Cre significantly reduced ATG7 protein level and increased p62 levels in hippocampus of both heterozygous Atg7 w/f and homozygous Atg7 f/f mice, indicating compromised autophagy ( Supplemental Fig. 8D-F) . Hippocampal neuronal knockdown of Atg 7 induced deficits in the visual memory of Fmr1 KO mice, demonstrated by the decreased preference to the novel object ( Supplemental Fig. 8G-I) . Expression of Cre in hippocampal neurons also lead to decreased freezing response in both heterozygous Atg7 w/f and homozygous Atg7 f/f mice, indicating cognitive deficits ( Supplemental Fig. 8J ). Thus, knockdown of Atg 7 in hippocampal neurons leads to similar cognitive deficits as observed in FXS, suggesting that dysfunctional autophagy in hippocampal neurons plays a critical role in this process. Rilmenidine activates autophagy and affects several cellular processes, downstream of imidazoline receptors 56 , 71 . To distinguish the contribution of neuronal autophagy to the rescuing effect of Rilmenidine, we next examined whether neuron-specific knockdown of Atg7 can reverse the drug-induced rescue. To do so, we bred WT or Fmr1 KO ( Fmr1 −/y ) mice with Atg7 f/f mice and Synapsin1-Cre mice ( Cre +/− ), resulting in WT and Fmr1 KO mice with neuron-specific Atg7 knockout (Fig. 3 A). From these crosses, we obtained the compound mice, termed WT: Cre −/− : Atg7 f/f (as WT control), Fmr1 −/y : Cre −/− : Atg7 f/f (as Fmr1 KO control), and Fmr1 −/y : Cre +/− : Atg7 f/f ( Fmr1 KO mice with neuron-specific Atg7 knockout). We then injected Rilmenidine or vehicle into these mice as in Fig. 2 A. Atg7 knockout was confirmed with reduced ATG7 protein expression in hippocampal tissues of the Fmr1 −/y : Cre +/− : Atg7 f/f mice ( Supplemental Fig. 9 ). Then, we examined autophagy activity in the hippocampus. Fmr1 KO control mice ( Fmr1 −/y : Cre −/− : Atg7 f/f ) injected with the vehicle showed increased p62 levels in hippocampal tissues vs. WT controls (WT: Cre −/− : Atg7 f/f ) injected with the vehicle (Fig. 3 B, C). Rilmenidine significantly reduced p62 protein levels in Fmr1 KO control ( Fmr1 −/y : Cre −/− : Atg7 f/f ) mice but failed to do so when Atg7 is neuron-specifically knocked out ( Fmr1 −/y : Cre +/− : Atg7 f/f ). Rilmenidine successfully corrected the increased spine density of Fmr1 KO mice but failed to do so in the Fmr1 KO mice with neuron-specific Atg7 knockout (Fig. 3 D, E). Moreover, Rilmenidine failed to increase the percentage of mature spines in the Fmr1 KO mice with neuron-specific Atg7 knockout (Fig. 3 D, F). Behavioral tests indicated that Rilmenidine administration significantly improved cognition as measured by novel object recognition (Fig. 3 G, H, I) and contextual fear conditioning (Fig. 3 J) and in Fmr1 KO control mice but not in Fmr1 KO mice with neuron-specific Atg7 knockout. Thus, inhibition of autophagy in neurons largely compromised the rescue effects, indicating that the rescuing relies on activation of autophagy in neurons. Identification of downstream protein targets mediating autophagy’s rescuing effects. To investigate the mechanisms underlying how activated autophagy regulates spine density/morphology, we conducted proteomics to profile the altered proteins in hippocampus of Fmr1 KO mice injected with Rilmenidine. Indeed, we identified 549 proteins that significantly increased in the hippocampus of Fmr1 KO mice vs. WT mice (Fig. 4 A). Importantly, 42 of these 549 proteins were successfully reduced by Rilmenidine in Fmr1 KO mice (Fig. 4 B), and identified as direct or indirect targets of autophagic protein degradation as being significantly upregulated by the autophagy inhibitor in WT mice (Fig. 4 C). Thus, these overlapped 42 proteins (Fig. 4 D, Dataset S7 , and labeled in Fig. 4 A, B, and C ) may serve as the downstream targets of autophagy to rescue the synaptic and cognitive deficits of FXS. GO biological process analysis confirmed that these 42 proteins play important roles in neurons and synapses. “Glutamate secretion”, “Ionotropic glutamate receptor signaling pathway”, “Neuron recognition”, “Cell morphogenesis involved in neuron differentiation” and “Neuron projection morphogenesis” are among the most significant categories (Fig. 4 E, Dataset S8 ). To further identify the relevance of these 42 proteins with autism-related synaptic and behavioral deficits, we searched the SFARI Gene database. Searching results revealed that mutations of 7 among these 42 genes ( Dlg4, Eif4g1, G3bp2, Ntrk2, Rap1gap, Psmd6 and Cpeb4 , as shown in Fig. 4 F) are associated with autism cases and Dlg4 (encoding PSD-95 protein) and Eif4g1 (encoding eIF4G1 protein) are reported with the highest numbers of autism cases (Fig. 4 F). According to the literature, PSD-95, eIF4G1, G3BP2, NTRK2, Rap1GAP, and CPEB4, may potentially be degraded by autophagy, because they can be ubiquitinated 72 – 77 and autophagy degrades ubiquitinated proteins 78 . Thus, dysregulated PSD-95 and eIF4G1 may play strong roles in inducing autistic symptoms and behavioral deficits. To validate the proteomic changes of PSD-95 and eIF4G1 in neurons, we performed Western blot analysis in cultured hippocampal neurons ( Supplemental Fig. 10A ). Consistent with the proteomics data, PSD-95 and eIF4G1 protein levels are significantly increased in Fmr1 KO vs. WT hippocampal neurons and decreased by Rilmenidine ( Supplemental Fig. 10B ). Autophagy degrades ubiquitinated proteins 78 and downregulated autophagy in mouse brain is associated with accumulated ubiquitinated proteins 49 . Indeed, both total (Input) and ubiquitinated (IP) PSD-95 and eIF4G1 are increased in cultured hippocampal neurons when autophagy is inhibited by chemical inhibitors (Fig. 4 G-J and Supplemental Fig. 11 ), indicating that PSD-95 and eIF4G1 are direct protein targets of autophagic protein degradation. Neurons from Fmr1 KO mice exhibited markedly elevated total and ubiquitinated PSD-95 and eIF4G1 (Fig. 4 G-J), indicating that ubiquitinated PSD-95 and eIF4G1 are not degraded efficiently in Fmr1 KO neurons. Rilmenidine treatment significantly accelerated the degradation of PSD-95 and eIF4G1, shown by both decreased total and ubiquitinated PSD-95 and eIF4G1 proteins in Fmr1 KO neurons (Fig. 4 G-J, and Supplemental Fig. 11 ). In Fmr1 KO mice with neuron-specific autophagy inhibition ( Atg7 knockout), Rilmenidine failed to reduce the levels of PSD-95 and eIF4G1 proteins in the hippocampus ( Supplemental Fig. 12 ), further indicating that the Rilmenidine-induced degradation of PSD-95 and eIF4G1 requires autophagy. mRNA levels of PSD-95 and eIF4G1 were not affected by Rilmenidine, excluding the possibility that the altered protein levels are caused by changes in mRNAs ( Supplemental Fig. 13 ). Altogether, these results indicate that eIF4G1 and PSD-95 are downstream targets of autophagy and may be responsible for the regulation on synaptic morphology. PSD-95 is a synaptic scaffolding protein crucially contributing to the stabilization and organization of postsynaptic structure, as many neurotransmitter receptors and postsynaptic cytoskeleton molecules are anchored to it 23 , 79 , 80 . When PSD-95 is upregulated, it leads to an overabundance of immature spines in hippocampal neurons 23 , 79 . We previously reported that decreasing the PSD-95 levels by genetic manipulation of mTORC1 is associated with reduced spine density and increased maturation in hippocampal neurons 23 . Results from the current study indicated that Rilmenidine significantly reduces the PSD-95 level in the spine area ( Supplemental Fig. 14 ), demonstrating that degrading PSD-95 to affect postsynaptic stability is one pivotal mechanism through which autophagy rescues spine deficits in FXS. Activation of autophagy degrades eIF4G1 to regulate actin dynamics in spines. We next explored the role of eIF4G1 in autophagic regulation of spine morphology. Our results indicate that the protein level of eIF4G1 in Fmr1 KO neurons is increased in the soma (Fig. 5 A and B ), dendrites, and spines of neurons (Fig. 5 C and D ). Importantly, the increase in spine area is more significant than in soma (increased by 276% in spines vs. 43% in soma), suggesting that eIF4G1 may locally mediate autophagy’s regulation on spine morphology. The spine structure and morphology are majorly supported and determined by polymeric filamentous actin (F-actin), and Cofilin1 protein critically and directly catalyze depolymerization of F-actin to monomeric G-actin (actin dynamics) to destabilize spines and modify spine morphology 35 , 81 , 82 . Ras-related C3 botulinum toxin substrate 1 (Rac1) is an upstream regulator of Cofilin1 activity by inducing serine-3 phosphorylation of Cofilin1, primarily through p21-activated kinase (PAK)/LIM kinase, as well as through forming the Rac1-WAVE regulatory complex 30 , 83 . eIF4G1 has been recently shown to crucially affect the assembly of Rac1-WAVE complex and downstream actin dynamics 31 , 84 . The assembled Rac1-WAVE complex inactivates Cofilin1 by phosphorylating serine-3 residue and slows down the F-actin depolymerization 30 , 83 . Thus, we hypothesized that activated autophagy degrades eIF4G1, reducing the interaction between eIF4G1 with eIF4E, to release eIF4E (Fig. 5 E). The released eIF4E sequesters cytoplasmic FMRP-interacting protein 1 (CYFIP1), the essential component of Rac1–WAVE regulatory complex, and subsequently halt the assembly of Rac1-WAVE complex, which reduces Cofilin1 phosphorylation and enhances F-actin depolymerization (Fig. 5 E) 31 , 85 . Indeed, knockdown of eIF4G1 with shRNA in neurons significantly reduced the binding of eIF4G1 with eIF4E ( Supplemental Fig. 15A-E ), and enhanced the binding of eIF4E with CYFIP1( Supplemental Fig. 15A, F ), indicating that manipulating eIF4G1 protein levels is able to affect the interaction of eIF4E/CYFIP1 to potentially regulate Rac1–WAVE regulatory complex. Thus, we next examined the binding of eIF4E with eIF4G1 or CYFIP1 through co-immunoprecipitation in hippocampal tissues of WT and Fmr1 KO mice with/without Rilmenidine treatment (Fig. 5 F). The input protein level of eIF4G1 in vehicle-treated Fmr1 KO mice ( Fmr1 KO) is significantly higher than vehicle-treated WT mice (WT) ( Supplemental Fig. 16A ). Consistently, there is more eIF4G1 immunoprecipitated with eIF4E in Fmr1 KO vs . WT mice, indicating an enhanced binding of eIF4E with eIF4G1 (Fig. 5 G). Rilmenidine reduced the level of eIF4G1 in both input ( Supplemental Fig. 16A ) and immunoprecipitants with eIF4E (Fig. 5 G), indicating that, by degrading eIF4G1, Rilmenidine treatment releases eIF4E from its binding with eIF4G1 in Fmr1 KO mice. Subsequently, although there is a marginally lower level of total CYFIP1 in Fmr1 KO mice ( Supplemental Fig. 16B ), more CYFIP1 proteins are co-immunoprecipitated with eIF4E in Rilmenidine treated vs. vehicle treated Fmr1 KO mice (Fig. 5 H), indicating that the released eIF4E from eIF4G1 binds and sequesters CYFIP1. We then used PAK-PBD beads to pull down Rac1-associated components of the Rac1-WAVE complex and examined whether sequestering CYFIP1 to eIF4E blocks the binding of CYFIP1 with Rac1 (Fig. 5 I). The results show that more CYFIP1 was pulled down together with Rac1 in Fmr1 KO vs. WT mice, and Rilmenidine significantly reduced the level of CYFIP1 interacting with Rac1 (Fig. 5 J, K), indicating that there is less CYFIP1 forming the Rac1–WAVE regulatory complex in Rilmenidine treated Fmr1 KO mice. As the assembly of Rac1–WAVE complex was suppressed, Rilmenidine treatment subsequently reduced Cofilin1 S-3 phosphorylation in Fmr1 KO mice (Fig. 5 L, M by immunostaining and Supplemental Fig. 17 by Western blot), indicating increased Cofilin1 activity. The F-actin/G-actin ratio in the hippocampal synaptic fraction is increased in Fmr1 KO mice vs. WT (Fig. 5 N, O). As a result of the increased Cofilin1 activity, Rilmenidine significantly reduced the F-actin/G-actin ratio, indicating that Rilmenidine accelerates F-actin depolymerization to affect spine morphology. The direct imaging of F-actin also confirmed that Rilmenidine reduced the F-actin levels in the dendritic area of cultured hippocampal Fmr1 KO neurons (Fig. 5 P, Q). In summary, our findings indicated that autophagic degradation of eIF4G1 elevates Cofilin1 activity and F-actin depolymerization to mediate the rescuing effects on spine density/morphology in FXS. Brain Rilmenidine infusion activates hippocampal autophagy and rescues deficits in FXS mice. Because Rilmenidine passes the blood-brain barrier freely as indicated by us and others 57 , systemic i.p. injection of Rilmenidine activates autophagy in both peripheral tissues and the brain. To estimate the contribution of autophagy in the brain, especially in the hippocampus, to the rescue effects, we directly delivered Rilmenidine daily for 7 days to the lateral ventricles (close to the hippocampus) through cannulation ( Supplemental Fig. 18A, B ) 86 . Rilmenidine significantly reduced p62 accumulation, indicating activated autophagy in the hippocampus of Fmr1 KO mice vs. Fmr1 KO mice infused with vehicle ( Supplemental Fig. 18C, D ). Rilmenidine infusion also significantly reduced the protein levels of PSD-95 and eIF4G1 in the hippocampus of Fmr1 KO mice ( Supplemental Fig. 18C, E, F ). Since the hippocampus is the primary brain region for cognition, we next examined whether central delivery of Rilmenidine rescues the impaired cognition of Fmr1 KO mice. Consistent with the results from the systemic injection, Rilmenidine infusion to the lateral ventricles significantly increased the freezing reaction time of Fmr1 KO mice, indicating improved cognition ( Supplemental Fig. 18G ). The infusion of Rilmenidine also improved the visual memory of Fmr1 KO mice, demonstrated by increased interaction time with the novel object ( Supplemental Fig. 18H, I ). Mechanistic analysis indicated that Rilmenidine infusion corrected the increased F-actin/G-actin ratio in the hippocampal synaptic fraction of Fmr1 KO mice, which implies that Rilmenidine infusion targets actin assembly for the rescue effect ( Supplemental Fig. 18J, K ). In general, our results demonstrate that central delivery of Rilmenidine activates autophagy and regulates actin assembly in the hippocampus of Fmr1 KO mice, contributing to the rescued cognition. Effects of activation of autophagy on human FXS neurons. Currently, there are still no clinical trials that can unambiguously show efficacy on FXS, mostly because of the gap between animal models and humans 3 , 87 . Thus, we next assessed whether autophagy is downregulated in neurons derived from human FXS induced pluripotent stem cells (iPSCs), and neurons from an unaffected male individual were used as control (Fig. 6 A) 88 , 89 . The human FXS iPSCs were created from fibroblasts isolated from a male patient diagnosed with FXS (full mutation) and intellectual disability 88 (Fig. 6 A). As epigenetic silencing of the Fmr1 gene in FXS is caused by hypermethylation in its promoter region, we examined methylation on CpG islands in the Fmr1 promoter of the iPSCs. The results show that FXS iPSCs have highly methylated CpG islands in the promotor, while the control iPSCs show nearly zero (Fig. 6 B, Dataset S9 ). Assessment of Fmr1 gene expression with immunostaining of FMRP indicated that there is no FMRP expression in neurons derived from FXS iPSCs, while the neurons from control iPSCs show strong FMRP expression (Fig. 6 C). Consistent with Fmr1 KO mice, neurons derived from FXS iPSCs show increased p62 accumulation vs. control, indicating downregulated autophagy (Fig. 6 D, E). Rilmenidine treatment significantly reduced the p62 accumulation, indicating activated autophagy. Protein levels of PSD-95 and eIF4G1 are also increased in neurons derived from FXS iPSCs vs. control human neurons (Fig. 6 F-I). Consistent with the mouse data, PSD-95 and eIF4G1 protein levels are significantly decreased by Rilmenidine (Fig. 6 F-I). Further, neurons derived from FXS iPSCs show upregulated phosphorylation of Cofilin1 at S3 and increased F-actin/G-actin ratio vs . control, indicating dysregulated actin assembly ( Supplemental Fig. 19, and Fig. 6 J, K). When activating autophagy via Rilmenidine, both Cofilin1 phosphorylation and F-actin/G-actin ratio decreased to similar levels as control. F-actin imaging confirmed that Rilmenidine reduced the F-actin levels in the dendritic area of neurons derived from FXS iPSCs (Fig. 6 L, M). We further validated our major findings with one more iPSC line (FX08-23) derived from a patient with FXS and diagnosis with intellectual disability ( Supplemental Fig. 20A, B ). 88 , 89 The results indicated that Rilmenidine treatment significantly reduced p62 accumulation in neurons derived from FX08-23 iPSCs ( Supplemental Fig. 20C, D ). Protein levels of PSD-95 and eIF4G1 are increased in neurons derived from FX08-23 FXS iPSCs vs. control, which are significantly decreased by Rilmenidine ( Supplemental Fig. 20E-H ). F-actin imaging indicated that Rilmenidine significantly reduced the F-actin levels in dendritic area of neurons derived from FX08-23 iPSCs ( Supplemental Fig. 20I-J ). Thus, our results indicated that human FXS neurons show downregulated autophagy and dysregulated actin assembly, and activating autophagy corrected these defects. Discussion Autophagy plays crucial roles in regulating synaptic structure, development, and plasticity and dysregulated autophagy is involved in many neurological disorders such as autism, stroke, and neurodegenerative diseases 23 , 38 , 39 , 90 – 92 . Autophagy critically affects the stability and morphology of postsynaptic structures 23 , 49 , 50 , yet the mechanism remains unclear. Activating autophagy with Rapamycin has been shown to activate the synaptic pruning and ameliorate the social deficits in Tsc2 +/− ASD mice 49 . In this study, our findings revealed that activation of autophagy in the hippocampus of Fmr1 KO mice rescued the aberrant spine morphology and improved cognition by affecting postsynaptic organization and actin dynamics. Currently, there is still no effective treatment for Fragile X in humans 87 and nearly all targeted treatments failed in clinical trials 3 , 87 . One explanation is that, because FMRP influences hundreds of proteins and signal pathways, single targeted treatments are insufficient to rescue the complex dysregulated pathways and symptoms in FXS 87 . Thus, it is believed that treatments targeting multiple proteins and pathways are more likely to effectively reverse the multitude of changes in FXS brain 87 . Our findings revealed that, in hippocampus of a FXS mouse model, autophagy degrades multiple protein targets to affect synapse structures and functions on different levels. Among the 42 protein targets, PSD-95 is a scaffolding protein regulating postsynaptic origination and stability 79 , and eIF4G1 regulates assembly of actin filaments, the major cytoskeletal elements of postsynaptic terminals 28 , 85 . It has been reported that PSD-95 is ubiquitinated by the E3 ligase Mdm2 and degraded by proteasome, when dysregulated, causing increased spine density 79 . Our results show that ubiquitinated PSD-95 is also degraded by autophagy to affect spine stability. In the brains of an autistic mouse model caused by Cullin3 gene deficiency, elevated eIF4G1 protein levels lead to increased spine density and impaired social behaviors 93 . In addition to PSD-95 and eIF4G1, it is possible that others of these 42 proteins, such as NTRK2 and CPEB4, are also targets of autophagic degradation and regulate synaptic functions. Altered dendritic spine density and morphology are associated with many brain disorders, including neuropsychiatric diseases, autism, and neurodegenerative diseases 94 . However, the therapeutic strategy to correct spines in these diseases is still lacking. Dysregulation of autophagy has been extensively reported in neurodevelopmental and neurodegenerative disorders 23 , 49 , 90 , 95 – 97 . It has also been well established that the cytoskeleton system plays critical roles in regulating autophagy through affecting autophagosome biogenesis, trafficking of autophagic components, and other processes 98 . In this study, we revealed a previously unappreciated pathway in which organization of actin cytoskeleton is regulated by autophagy through the degradation of eIF4G1 to affect the WAVE complex, which subsequently affects the stability and morphology of synapses. Several studies have recently reported that inhibition of eIF4G1 affects actin assembly by regulating the competition between eIF4E and Rac1 to bind CYFIP1 28, 31 . The fact that Cyfip1 heterozygote mice mimic key aspects of the Fragile X phenotype, such as overabundance of filopodial spines and exaggerated mGluR-LTD further indicates that eIF4G1-CYFIP1-Rac1-Cofilin1 pathway is critical for the regulation of spine morphology and functions 85 . Besides their role in regulating actin assembly, eIF4G1 and eIF4E are also critical for the initiation of translation 84 . Thus, reduced eIF4E/eIF4G1 binding by Rilmenidine may also affect spine morphology by interfering with protein translation. Pharmacologically inhibiting the interaction between eIF4G1/eIF4E suppressed translation and has been used to affect spine morphology in autism mouse models 93 , 99 . Our results show that activation of autophagy by Rilmenidine reduced protein synthesis by ~ 20% in primary hippocampal Fmr1 KO neurons ( Supplemental Fig. 21 ). Thus, autophagy may affect spine morphology by regulating both actin assembly and protein translation. Rilmenidine is a classical imidazoline type 1 receptor (I1R/IRAS/Nischarin) agonist in mammals 100 . Nischarin can bind activated PAK1, the Rac1 effector, to inhibit Rac1/PAK1 activation 101 . Since activated Rac1/PAK1 phosphorylates and activates LIM kinase, which directly phosphorylates and inactivates Cofilin1, Rilmenidine may also modulate Cofilin1 and F-actin assembly through Rac1/PAK1 signaling. In addition, Rilmenidine has been reported to stimulate the proapoptotic protein Bax and induce the perturbation of the mitochondrial pathway 102 . Mitochondrial ATP synthase leak in synapses is causally related to the aberrant Fragile X associated spine morphology and behaviors 22 . Thus, potential effects of Rilmenidine on synaptic mitochondrial function should also be considered. Our results demonstrated that activating autophagy through Rilmenidine treatment largely rescued the cognitive deficits in Fmr1 KO FXS mouse model. However, loss of FMRP in FXS impacts ~ 1,000 neuronal mRNAs and complex signal pathways which are critical to neural development, synaptic plasticity, and dendritic spine architecture 1 , 8 – 12 . Many of these pathways independently and synergistically contribute to the diverse phenotypes and deficits observed in FXS. Thus, it is important to emphasize that dysfunctional autophagy in hippocampus is unlikely to be solely responsible for all deficits in FXS. Indeed, we observed that Rilmenidine treatment failed to rescue the deficits of nest building and open field tests associated with Fmr1 KO mice. This suggests that effects of Rilmenidine treatment and activated autophagy in other brain regions and related behavioral deficits need to be further examined in future studies. Systemic administration of Rilmenidine may affect other tissues, such as heart and kidney, in addition to brain. Clinical trials show long-term administration of Rilmenidine is effective in both reducing left ventricular mass and decreasing blood pressure by decreasing vascular resistance 103 , 104 . In the kidney, clinical investigation reveals Rilmenidine reduces microalbuminuria in hypertensive type-2 diabetic patients, as well as preserve renal function during stress-induced high blood pressure 105 , 106 . Although our results indicated that there was no significant effect of Rilmenidine on body weight and growth of mice ( Supplemental Fig. 4A, B ), caution still needs to be exercised when considering Rilmenidine as a possible treatment option. To further address translational relevance, we verified dysfunctional autophagy and downstream pathways with human neurons derived from iPSCs generated from two individuals with FXS. While this provides initial validation in a human system, the use of two iPSC lines remains a limitation, as it does not fully capture the variability across individuals with FXS. In summary, our study identified a new role of autophagy in actin assembly, spine morphology, and cognitive deficits in Fmr1 KO mice. These findings identify autophagy as a therapeutic target for Fragile X syndrome. Dysregulated autophagy and its upstream regulator, mTORC1 signaling are implicated not only in FXS, but also in mouse models of other autism spectrum disorders, including Rett syndrome, TSC, PTEN , and 16p11.2 deletion 49 , 107 – 109 . Sulzer and colleagues show that overactivated mTOR suppresses autophagy in the brain of Tsc1 +/− and Tsc2 +/− mice, and that reduced autophagy impaired spine pruning of spines of cortical layer V pyramidal neurons and induced autistic behaviors 49 . Thus, findings in the present study suggest components of the autophagy pathway may represent promising therapeutic targets, not only for Fragile X syndrome, but also other ASDs. MATERIALS AND METHODS Animals. FVB.129P2-Pde6b + Tyr c−ch Fmr1 tm1Cgr /J ( Fmr1 KO) mice and FVB.129P2-Pde6b + Tyr c−ch /AntJ (WT) mice were obtained from The Jackson Laboratory as described. Floxed Atg7 ( Atg7 loxp/loxp ) mice (C57BL/6J background, from Dr. Ana Maria Cuervo’s lab in Albert Einstein College of Medicine) and Syn1-Cre mice (B6.Cg-Tg(Syn1-cre)671Jxm/J, Jackson lab, #003966) were bred with FVB background Fmr1 KO or WT mice for at least 5 generations. All mice were housed in a standard, pathogen-free animal facility with a 12 hr/12 hr light and dark cycle, and only male mice were used, because Fragile X syndrome is an X-linked disorder. Standard PCR was performed with tail tissues for genotyping 110 . Animal protocols were approved by the Institutional Animal Care and Use Committees of the Cleveland State University and Albert Einstein College of Medicine. Vectors and lentivirus . pLV-hSyn-RFP (Addgene, #22909) expressing RFP under control of Synapsin1 promoter was packaged into lentivirus with the third-generation system (VSVG, REV, and MDL, all from Addgene) and HEK293T cells (ATCC). Lenti viral vectors expressing shRNA for mouse Eif4g1 gene (TRCN0000100577, Sigma) or control non-targeting shRNA (Sigma) were packaged into lentivirus with the second-generation system (psPAX2 and pMD2.G, from Addgene) and HEK293T cells (ATCC). High-titer lentiviral stocks were produced by calcium phosphate–mediated transfection of HEK293T and purified via ultra-centrifugation 86 , 111 . Viral titers were determined by transducing HeLA cells. RFP fluorescence was examined by flow cytometry (Becton Dickinson LSR II Flow Cytometer) 72 hr after transduction. Final virus titer was diluted to 1 x 10 6 transducing units/µl. Cell culture, viral transduction, and immunocytochemistry. Primary hippocampal neurons were cultured from embryonic 18 (E18) mice, maintained in Neurobasal medium with B-27 supplement and GlutaMAX (Invitrogen), and used at DIV14 30 . Lentivirus expressing hSyn-RFP or shRNAs were added to medium at DIV10. For immunocytochemistry, neurons were fixed with 4% PFA, blocked with 5% normal goat serum (Vector Laboratories), and subjected to reaction with primary antibodies, followed with Alexa Fluor 488, 555 or 647 conjugated secondary antibodies (Invitrogen). After 3 washing with PBS, neurons were mounted with the VECTASHIELD® Antifade Mounting Media (Vector Laboratories) with DAPI. DAPI staining was used to reveal all cells. At least three coverslips per group and multiple areas per coverslip selected on a random basis were used for analysis. ZEISS LSM 980 with Airyscan 2 super-resolution confocal microscope (20 X and 60 X objectives, averaged four times and taken at 0.6 µm depth intervals) was used to obtain consecutive Z section images. Labeled neurons were chosen randomly for quantification and the integrated puncta fluorescent intensity for a given neuron was quantified/normalized to the area of the cell body. All images were processed using the Image J software (NIH). To ensure the comparability between preparations, the same staining procedure were used, and all corresponding groups were included in each experiment. Laser settings of the microscope were uniform across all preparations. Human induced pluripotent stem cells (iPSCs) culture and neural differentiation. Human FXS iPSCs (WC005i-FX11-7) and (WC005i-FX08-23) were created by reprogramming fibroblasts from male patients with FXS, and control iPSCs (WC008i-C603-4) were created from an unaffected male individual as previously reported. iPSCs were purchased from WiCell Research Institute (WI, USA) 88 . According to the providers’ protocol, the iPSCs were cultured and passaged in a culture medium including mTeSR™1 Medium (Stem Cell Technologies) in plates coated with Growth Factor Reduced Matrigel™ (Corning). Neural differentiation of iPSCs was performed according to previously published methods 112 , 113 . Briefly, iPSCs were dissociated with TrypLE Express (Thermo Fisher Scientific), and plated on Matrigel (Corning)-coated plates in the MEF-conditioned medium with FGF-2 (Waisman Biomanufacturing), and ROCK inhibitor (Tocris Bioscience). When cells grew to nearly confluent, neural differentiation was induced with a medium including: DMEM/F12: Neurobasal medium (50%/50%) (Thermo Fisher Scientific), 200 mM L-Glutamine (Thermo Fisher Scientific), 1% N2 supplement (Thermo Fisher Scientific), 0.5% B-27 supplement minus vitamin A (Thermo Fisher Scientific), and TGFβ/Smad inhibitors (10 µM SB431542 (Selleck) and 100 nM LDN193189 (Selleck)). Cells were then disassociated and re-plated on Matrigel-coated plates with the neural progenitor cell (NPC) medium including: Neurobasal medium (Thermo Fisher Scientific), 1% GlutaMAX (Thermo Fisher Scientific), 1% N2 supplement (Thermo Fisher Scientific), 0.5% B-27 (Thermo Fisher Scientific), 10 ng/ml FGF-2 and 10 µM ROCK inhibitor when plating. For neural differentiation, NPCs were re-plated on Matrigel-coated coverslips in a medium including: Neurobasal medium, 1% GlutaMAX, 1% N2 supplement, 1% B-27 minus Vitamin A, 200 nM ascorbic acid (Sigma), 1 µM cAMP (Sigma), 10 ng/ml BDNF (Cell Sciences), 10 ng/ml GDNF (Cell Sciences), 10 µM ROCK inhibitor, and 0.1 µM Compound E (Calbiochem) 114 . After two weeks, cells were fixed for immunostaining with antibodies for Tuj-1 (Mouse, R&D SYSTEMS), eIF4G1 (Rabbit, Cell Signaling), p62 (Rabbit, MBL) and FMRP (Rabbit, Abcam). Images were acquired using a Nikon confocal microscope. For analysis of CpG methylation in Fmr1 promoter region, FXS and control iPSCs (20,000 cells for each sample) were collected. The bisulfite treatment of genomic DNA and pyrosequencing analysis of the Fmr1 promoter region was performed by EpigenDx Inc (Hopkinton, MA) 88 , 115 . Cannulation and brain infusion. As we previously described 86 , 111 , using an ultra-precise mouse stereotactic frame (KOPF), a 26-gauge guide cannula (Plastics One, Inc.) was implanted into the lateral ventricle of anesthetized mice at the coordinates (Post bregma: 0.4 mm; Lateral to midline: 1 mm; Under bregma: 2 mm). Intra-lateral ventricular infusion was carried out with a 33-gauge internal cannula (Plastics One, Inc.) connected to a 10-µl Hamilton Syringe. Rilmenidine was dissolved in 1 µl artificial cerebrospinal fluid (aCSF) for injection. Injection of aCSF was used as vehicle control. In vivo adeno-associated virus (AAV) injection. Mice were anesthetized with 4% isoflurane and maintained in anesthesia with 1.5% isoflurane as described 111 . AAV encoding Syn-Cre-GFP (#105540, AAV9 from Addgene) was injected bi-laterally into hippocampus by means of a 10-µl Hamilton syringe with a 26-gauge needle with a stereotaxic frame (KOPF). The injection site was defined by the following coordinates: 2 mm posterior to bregma, 1.6 mm below the surface of the skull, and 1.8 mm lateral to the midline 111 . A total volume of 0.5 uL/ hemisphere at a flow rate of 0.1 µL/min were injected. The incision was closed with cyanoacrylate glue. After injection, animals were placed in a heated cage to recover. Quantitative RT-PCR. Total RNAs were isolated from hippocampal tissues using RNeasy® Mini Kit (Qiagen) and reverse-transcribed to cDNA using SuperScript™ First-Strand Synthesis System (Thermo Fisher Scientific). RNA concentration was measured by means of a Nanodrop (NanoDrop Technologies). Real-time qPCR was performed with SYBR™ Green PCR Master Mix (Thermo Fisher Scientific) for Dlg4 (NM_001109752.1) and Eif4g1 (NM_001005331), and normalized to β-actin (NM_007393). The primers used are: Dlg-4, Forward : 5”-TCCGGGAGGTGACCCATTC-3’; Reverse, 5’-TTTCCGGCGCATGACGTAG-3’; Eif4g1: Forward : 5”-AAGACCTCATCTCGCATCCG-3’; Reverse, 5’-TGTTCTCGGTGCTCTTCCATC-3’; β-actin : Forward, 5”-GGCTGTATTCCCCTCCATCG-3’; Reverse, 5’-CCAGTTGGTAACGCCATGT-3’. Reactions were performed in triplicate in a StepOnePlus real-time PCR system (Applied Biosystems) 34 . Golgi staining, spine morphology, immunolabeling and histology. The FD Rapid Golgi stain Kit (FD Neurotechnologies, MD, USA) was used to image spine morphology as described 23 , 30 . In brief, mouse brains were collected, quickly rinsed, immersed in Golgi impregnation solution, and stored in the dark at room temperature for 2 weeks. Brains were then transferred and stored in Solution C for 72 hr, and cut into 150 mm-thick sections with a cryostat at − 20ºC. Sections were transferred to microscope slides, rinsed, dehydrated, stained, and cleared. Spines on apical dendrites of hippocampal CA1 pyramidal neurons were imaged by means of a ZEISS LSM 980 with Airyscan 2 super-resolution confocal microscope with a 100 x oil immersion lens. Dendritic spine density was determined by counting the total number of spines along the apical dendrite from the soma to 130 µm distance on primary, secondary, and tertiary branches. Spines were classified as filopodial-like or mushroom-like/stubby in neurons using a categorization macro in Neurolucida software (MBF Bioscience), which excludes thin, branched, and detached spines 30 , 65 . Five CA1 pyramidal neurons per mouse and eight 10-µm segments per neuron were analyzed. Immunohistochemistry was performed on frozen brain sections from Fmr1 KO and WT mice as described 23 . Mice were anesthetized, transcardially perfused with 4% PFA, and brains were removed, post-fixed for 24 hr, and infiltrated with 20% – 30% sucrose. 12 µm-thick brain sections were cut, blocked with normal goat serum (Vector Laboratories), incubated with primary antibodies, and then reacted with Alexa Fluor 488 or 555 secondary antibodies (Invitrogen). Naïve IgG of the appropriate species was used as a negative control. DAPI staining in mounting medium (Vector Laboratories) was used to reveal all cells in brain sections. Images were acquired using a ZEISS LSM 980 with Airyscan 2 super-resolution confocal microscope. For data analysis, serial brain sections across the hippocampus were made at the thickness of single cell (10 µm), and every 5 sections were represented by one section for staining and quantification. A minimum of three sections per mouse and multiple hippocampal CA1 regions per section were selected on a random basis and used for analysis 116 . Images were taken at 0.6-µm depth intervals. The integrated puncta fluorescent intensity for each given CA1 region was quantified and assessed using Image J software. The same staining procedure was used to ensure the comparability between preparations, and all corresponding groups were included in each experiment. Laser settings of the microscope were uniform across all preparations 23 . Immunoprecipitation. Primary neurons were homogenized in ice-cold lysis buffer as described 23 . Hippocampal tissues were isolated from mice 4 hr post treatment and homogenized with a glass homogenizer. Cell and tissue homogenates were incubated with an anti-ubiquitin (Mouse Santa Cruz) antibody or an anti-eIF4E (mouse, Santa Cruz) antibody, and gently shaken overnight at 4°C. Supernatant with antibody was added to a slurry of IgG bound to agarose beads (Protein A/G, Pierce) and incubated with rocking at 25°C for 2 hr. Efficiency of IP was determined by comparing the abundance of immunoprecipitated protein in the supernatant and wash fractions. Synaptosome preparation. Briefly, 4 hr post treatment, hippocampus of Fmr1 KO and WT mice were removed, quickly rinsed with Milli-Q water, and homogenized in gradient buffer with protease and phosphatase inhibitors 117 . The homogenates were centrifuged at 1000g for 10 min. The supernatant was loaded on a Percoll discontinuous gradient (3%, 10%, 15%, and 23%) and centrifuged at 31,000g for 6 min in a Beckman centrifuge. Synaptosome fractions were collected from the 15–23% interface and centrifuged again at 20,000g for 10 min. The pellets were resuspended for Western blot. Protein concentrations of collected synaptosome fractions were measured with a BCA kit (Thermo Fisher Scientific). F-actin imaging. F-actin in cultured neurons was imaged by a high-affinity F-actin probe, phalloidin conjugated to Alexa Fluor 488 dye (ThermoFisher Scientific) 118 . Briefly, neurons were fixed, permeabilized and incubated with phalloidin staining solution at room temperature for 20 min. After being washed with PBS for 3 times, neurons were mounted with the VECTASHIELD® Antifade Mounting Media (Vector Laboratories) with DAPI. F-actin in neurons were imaged with a Nikon confocal microscope. Tissue preparation, Western blot, and antibodies. Hippocampal tissue was homogenized in RIPA lysis buffer supplemented with protease inhibitors (Thermo Fisher Scientific) and centrifuged at 12,000g for 10 min at 4°C to collect proteins. Primary neurons were lysed and centrifuged as above. Protein concentrations were measured with the BCA kit (Thermo Fisher Scientific) and Western blot were performed as described 23 , 119 . Band densities were quantified using Image J (NIH). Mouse hippocampus tissues were homogenized in lysis buffer with protease inhibitors as described in the manual (Cytoskeleton Inc). Large debris was removed by centrifugation at 12,000g (10 min, 4°C). The lysates were then incubated with GST-tagged PAK-PBD beads (Cytoskeleton Inc) for 2 hr at 4°C. GTP-Rac1 and associated proteins were precipitated from the lysates by the PAK-PBD beads. Finally, the beads were washed and resuspended in a SDS sample buffer for Western blot. F/G-actin ratio in synaptosomes of hippocampus was assessed as previously described 30 , 120 . Briefly, the synaptosome fractions were resuspended in a cold lysis buffer (10 mM K 2 HPO 4 , 100 mM NaF, 50 mM KCl, 2 mM MgCl 2 , 1 mM EGTA, 0.2 mM DTT, 0.5% Triton X-100, 1 mM sucrose, pH 7.0). Because F-actin is insoluble whereas G-actin is soluble in this buffer, F-actin and G-actin were separated by centrifuge at 15,000g for 30 min. The F-actin pellet was resuspended in the lysis buffer mixed with another buffer (1.5 mM guanidine hydrochloride, 1 mM sodium acetate, 1 mM CaCl 2 , 1 mM ATP, 20 mM Tris-HCl, pH 7.5) at 1:1 and then incubated on ice for 1 hour to convert F-actin into G-actin. The samples containing G-actin converted from F-actin were centrifuged again at 15,000g for 30 min and the supernatant was collected for Western blot. Primary antibodies used for Western blot include: rabbit anti-LC3-I/II (Novus), rabbit anti-p62 (MBL), rabbit anti-PSD-95 (Cell Signaling), mouse anti-Ubiquitin (Enzo), rabbit anti-ATG7 (Cell Signaling), rabbit anti-Cofilin1 (Cell Signaling), rabbit anti-phospho-Cofilin1-Ser3 (Cell Signaling), rabbit anti-eIF4G1 (Cell Signaling), rabbit anti-CYFIP1 (Millipore), rabbit anti-eIF4E (Cell Signaling), mouse anti-Rac1 (Millipore), mouse anti-puromycin (DSHB), rabbit anti-GAPDH (Cell Signaling) and rabbit anti-β-actin (Sigma). Antibodies for PSD-95, RFP (Thermo Fisher Scientific), rabbit anti-phospho-Cofilin1-Ser3 (Cell Signaling), rabbit anti-FMRP (Abcam), and eIF4G1 were used for immunocytochemistry with primary antibodies of chicken anti-MAP2 (Millipore) or mouse anti-Tuj-1 (R&D SYSTEMS). Primary antibodies of p62 and mouse anti-NeuN (Millipore) were used for the immunochemistry of brain sections. SUnSET Assay . Protein synthesis was assessed with sensing of translation (SUnSET) technique as previously described with modifications 93 , 121 . Briefly, primary neurons were treated with 5 µg/mL puromycin (Sigma) for 30 min. Protein synthesis was examined as puromycin incorporation in new synthesized proteins of cell lysates by Western-blot using an anti-puromycin antibody (PMY-2A4, DSHB). Western-blot of GAPDH (Cell Signaling) was used as a loading control. Novel object recognition test. The novel object recognition task was conducted in an isolated arena (40 cm length x 40 cm width and x 40 cm height) 69 . For habituation before the testing day, mice were allowed to explore the empty arena for 10 min. On the testing day (training and familiarization session), the mouse was placed in the center of the arena between, and equidistant from, two identical objects and allowed to freely explore for 10 min. The mouse was then placed in a holding cage for 24 hr. The next day (test session), one of the objects was replaced with a novel object. The mouse was placed in the arena for an additional 10 min. The time spent exploring each object was recorded by investigators blind to the grouping information with stopwatches. Mice’s movements were also recorded with ANY-maze Video Tracking System. Mice that did not spend a minimum of 10 s investigating one or both objects were excluded from the study. The preference index was calculated by dividing the time exploring the novel object by the total time exploring the two objects. Exploration was defined as orienting the nose toward the object with a distance < 2 cm between the nose and the object. Resting, grooming, or sitting on the object was not considered as exploration. Contextual fear conditioning. Cognition test with contextual fear conditioning was performed in a Freezeframe Chamber and analyzed by Actimetrics Software (Actimetrics) as previously described 69 . On the day of fear conditioning (day 1), mice were habituated in chamber 1 for 3 min, followed by two shocks of 0.7 mA (1 s each). Mice then remained in chamber 1 for 15 s after the shock. On day 2, mice were separated into two groups: one group was tested in chamber 1 in the same context with day 1 (familiar context), and the others were tested in chamber 2 with a different (novel) context. The percentage of time that a mouse shows freezing response in the 3 min test session on day 2 was recorded by the software. Nest building assay. Nest building was assessed as described 25 , 122 . Mice were single housed with a 2.5g Nestlet and left undisturbed for 24 hours. Nests were assessed on a rating scale of 1–5 as described before 122 . Untorn nest pieces were weighed. Open field and self-grooming tests. The open field test was performed in a 40 × 40 × 40 cm 3 arena for 10 mins 69 . The floor of the arena was divided into two zones: an ‘inner’ zone (containing the inner 25 × 25 cm 2 center square) and an ‘outer’ zone (the outermost area 15 cm from the walls). The times spent in ‘inner’ zone and ‘outer’ zone were recorded by investigators blind to the grouping information with stopwatches. Mice’s movements were recorded with ANY-maze Video Tracking System. Times spent in self-grooming were also recorded by investigators blind to the grouping information with stopwatches during the test. HPLC-MS/MS. The HPLC-MS/MS method was performed with a Shimadzu UPLC system (Columbia, MD), which consisted of a Prominence DGU-20A 3R inline degasser, two LC-30 AD pumps, a SIL-30 AC autosampler and a CBM-20A controller. The chromatographic separation was performed on a Kinetex C 18 column (50 mm × 2.1 mm, 1.3 µm) with a mobile phase consisting of acetonitrile-0.1% formic acid and water (50:50, v/v) at a flow rate of 0.3 ml/min. The temperature of the column was maintained at 36°C. The injection volume was 5.0 µl. Mass spectrometric detection was operated on an AB Sciex Qtrap 5500 mass spectrometer (Toronto, Canada) with negative electrospray ionization mode. The multiple reaction monitoring (MRM) function was used for quantification with the transitions of Rilmenidine and IS trimipramine-d3, which were detected at m/z 180.9→66.9 and m/z 297.8→103.2, respectively. The optimized ion source parameters were set as follows: ion spray voltage, 2000 V; ion source temperature, 550°C; nebulization gas 40 psi; auxiliary gas, 40 psi; curtain gas, 30 psi. Compound parameters were as follows: Rilmenidine: declustering potential, 23V; entrance potential, 6.5V; collision energy, 28V; Collision entrance potential, 15V. Trimipramine-d3: declustering potential, 40V; entrance potential, 5V; collision energy, 25V; Collision entrance potential, 15V. The stock solutions were prepared by dissolving Rilmenidine and trimipramine- d3 in methanol at 1.0 mg/ml. Then, the stock solution of Rilmenidine was serially diluted with methanol into a concentration gradient: 0.5, 1.0, 2.0, 5.0, 10, 20, 50, 100, 200, 500, 1000 ng/ml. Also, a 500 ng/ml working solution of trimipramine- d3 (IS) was prepared in methanol from its stock solution. The calibration standards were prepared as follows: after spiking with 100 µl of the corresponding standards solutions, 40 µl of trimipramine- d3 working solution, 100 µl of blank mouse plasma or brain homogenates (0.4 g blank brain tissue mixed with 2 ml PBS), and 800 µl of methanol were transferred into a 1.5 ml tube, and the mixture was then vortexed and centrifuged at 12,000g for 10 min. The supernatant was collected and dried with nitrogen, and then the residue was stored at -80°C and dissolved with 50% acetonitrile before analysis. A protein precipitation method was applied to extract Rilmenidine from mouse plasma and brain homogenate (0.4 g brain tissue mix with 2 ml PBS). Briefly, 100 µl of each sample, 40 µl of trimipramine- d3 (IS, 500 ng/ml), and 800 µl of methanol were combined in a 1.5 ml tube. Then, it was vortexed and centrifuged, and the supernatant was collected and dried with nitrogen as the calibration standard. The residue was stored at -80°C and dissolved with 100 µl 50% acetonitrile before analysis. Proteomics. Hippocampus were collected from mice 4 hr post treatments., homogenized, and analyzed with a tandem mass tags (TMT) labeling technique by Proteomics & Metabolomics Core, Lerner Research Institute, Cleveland Clinic 123 . Briefly, each of the mouse hippocampus was suspended in 150 µl 8 M urea Tris-HCl pH8 lysis buffer with freshly added protease inhibitor cocktail. Samples were homogenized by ultrasonication 15 s x 3 with 15 s intervals. Homogenized samples were centrifuged at 15000g for 15 min, and the supernatants were transferred to new 1.5 ml tubes. Protein concentrations of the samples were determined by a BCA kit. 50 µg of protein from each sample were taken. The samples were reduced by dithiothreitol, alkylated by iodoacetamide, and precipitated by cold acetone (-20°C) overnight. Samples were centrifuged at 8000g for 5 min at 4°C, and the supernatants were removed. Protein pellets were air-dried, dissolved, digested overnight. Digested peptide samples were labeled with TMTpro 16plex tags according to the protocol from the manufacture’s instruction. The Thermo Scientific Fusion Lumos mass spectrometry system with the Dionex 15 cm x 75 µm id Acclaim Pepmap C18, 2µm, 100 Å reversed-phase capillary chromatography column was used. 5 µl volumes of the extract were injected and the peptides eluted from the column by an acetonitrile/0.1% formic acid gradient at a flow rate of 0.3 µl/min were introduced into the source of the mass spectrometer on-line. The digest was analyzed using a TMT-MS2 method. Over 4900 proteins were identified in the samples. The results of proteomics were first subjected to overlap analysis. To assess the significance of the overlap between the protein lists, hypergeometric tests were performed. The hypergeometric distribution models show the probability of the number of overlapping genes between two subsets drawn without replacement. The null hypothesis posits that the overlap between each two lists is due to random chance. The cumulative distribution function (CDF) of the hypergeometric distribution was used to compute the probability of observing an overlap greater than or equal to the observed value. The lists of overlapped proteins were then analyzed by PANTHER Overrepresentation Test (PANTHER 18.0) with Mus Musculus database as a reference list. The protein candidates were classified into annotated GO categories of biological processes/cellular components and compared with the Mus Musculus database of brain-expressed genes ( https://mouse.brain-map.org/ ) as the background to determine whether they are overrepresented or underrepresented for a given GO biological process/cellular component. For the SynGO ontology enrichment analyses, we uploaded 289 identified proteins (Gene ID) to the website ( https://www.syngoportal.org/index.html ) and compared with database of synaptic proteins (updated version 20231201). Fold enrichment is defined as the ratio of proteins classified in each GO category from the experimental dataset relative to the number of proteins predicted to be in the same GO category from the reference dataset. Bonferroni correction for multiple testing was applied for statistics. Statistical analysis. Statistical analysis used is detailed in figure legends. Data are presented as the mean ± s.e.m. The expected sample sizes for primary cultures and animal studies were estimated based on analysis with G*Power 3.1 software and our previous studies. Mice that met the inclusion criteria (described in legends) were randomly assigned to experimental and control groups using a computer-generated random number sequence to ensure unbiased allocation. To minimize bias, researchers conducting tests and data collection were blinded to group allocation. Primary neurons were allocated to treatment or control groups using a random number. All plates and wells were labeled with anonymous codes, and experimenters were blinded to the treatment conditions until data analysis. The Kolmogorov–Smirnov test was used to analyze normal distribution of data. The student’s t-test (unpaired) and one-way ANOVA with post hoc Tukey’s test, was used to establish statistical significance using Originpro (OriginLab). All tests are two-sided when applicable. The variance between groups was assessed with Levene’s test ( p < 0.05) using Originpro (OriginLab), which indicated no significant differences in variance. n = the number of animals or biological repeats (cultures) used in the analysis. For animal experiments, animals exhibiting signs of illness or significant deviations in weight (> 10% deviation from group mean) were excluded. Cell samples were excluded if they met any of the following criteria: Low viability (< 90%), Microbial contamination, Morphological abnormalities. All the exclusion criteria were pre-established. Statistical significance was defined as p < 0.05. Bonferroni correction for multiple testing was applied. Specific sample numbers, including the numbers of cell culture, repeats or mice, are indicated in the figure legends. Declarations Acknowledgments: This work was supported by the National Institutes of Health (NIH) grant NS118378, a Cleveland State University Startup grant, a FRAXA research grant, and the NARSAD Young Investigator Award Grant to JY; the NIH grant ES028960 to ZZ; a Cleveland State University Startup grant to PJ; the NIH grant NS116766 to BS; the NIH grant MH092877, the NARSAD Distinguished Investigator Award to RSZ; RSZ is the FM Kirby Professor in Neural Repair and Protection; and the NIH shared instrument grant, S10 OD030398 to Cleveland Clinic. The authors declare no conflict of interest. Data availability. Source Data for all figures are provided with the paper, and reagents and all other data are available from the corresponding author upon reasonable request. The data of proteomics has been stored in Open Science Framework (OSF) ( https://osf.io ), associated with project osf.io/wqgcx. References Bhakar AL, Dolen G, Bear MF. The pathophysiology of fragile X (and what it teaches us about synapses). Annual review of neuroscience 2012; 35: 417-443. Bagni C, Tassone F, Neri G, Hagerman R. Fragile X syndrome: causes, diagnosis, mechanisms, and therapeutics. The Journal of clinical investigation 2012; 122 (12) : 4314-4322. Berry-Kravis EM, Lindemann L, Jonch AE, Apostol G, Bear MF, Carpenter RL et al. Drug development for neurodevelopmental disorders: lessons learned from fragile X syndrome. Nature reviews Drug discovery 2018; 17 (4) : 280-299. Penagarikano O, Mulle JG, Warren ST. The pathophysiology of fragile x syndrome. Annual review of genomics and human genetics 2007; 8: 109-129. Richter JD, Bassell GJ, Klann E. Dysregulation and restoration of translational homeostasis in fragile X syndrome. Nature reviews Neuroscience 2015; 16 (10) : 595-605. Rodriguez CM, Wright SE, Kearse MG, Haenfler JM, Flores BN, Liu Y et al. A native function for RAN translation and CGG repeats in regulating fragile X protein synthesis. Nat Neurosci 2020; 23 (3) : 386-397. Zhan X, Asmara H, Cheng N, Sahu G, Sanchez E, Zhang FX et al. FMRP(1-297)-tat restores ion channel and synaptic function in a model of Fragile X syndrome. Nature communications 2020; 11 (1) : 2755. Kelleher RJ, 3rd, Bear MF. The autistic neuron: troubled translation? Cell 2008; 135 (3) : 401-406. Darnell JC, Klann E. The translation of translational control by FMRP: therapeutic targets for FXS. Nat Neurosci 2013; 16 (11) : 1530-1536. Gross C, Chang CW, Kelly SM, Bhattacharya A, McBride SM, Danielson SW et al. Increased expression of the PI3K enhancer PIKE mediates deficits in synaptic plasticity and behavior in fragile X syndrome. Cell reports 2015; 11 (5) : 727-736. Vita DJ, Meier CJ, Broadie K. Neuronal fragile X mental retardation protein activates glial insulin receptor mediated PDF-Tri neuron developmental clearance. Nature communications 2021; 12 (1) : 1160. Monday HR, Kharod SC, Yoon YJ, Singer RH, Castillo PE. Presynaptic FMRP and local protein synthesis support structural and functional plasticity of glutamatergic axon terminals. Neuron 2022; 110 (16) : 2588-2606 e2586. He Q, Arroyo ED, Smukowski SN, Xu J, Piochon C, Savas JN et al. Critical period inhibition of NKCC1 rectifies synapse plasticity in the somatosensory cortex and restores adult tactile response maps in fragile X mice. Molecular psychiatry 2019; 24 (11) : 1732-1747. Goel A, Cantu DA, Guilfoyle J, Chaudhari GR, Newadkar A, Todisco B et al. Impaired perceptual learning in a mouse model of Fragile X syndrome is mediated by parvalbumin neuron dysfunction and is reversible. Nat Neurosci 2018; 21 (10) : 1404-1411. Seo SS, Louros SR, Anstey N, Gonzalez-Lozano MA, Harper CB, Verity NC et al. Excess ribosomal protein production unbalances translation in a model of Fragile X Syndrome. Nature communications 2022; 13 (1) : 3236. Bhaskaran AA, Gauvrit T, Vyas Y, Bony G, Ginger M, Frick A. Endogenous noise of neocortical neurons correlates with atypical sensory response variability in the Fmr1(-/y) mouse model of autism. Nature communications 2023; 14 (1) : 7905. Brown MR, Kronengold J, Gazula VR, Chen Y, Strumbos JG, Sigworth FJ et al. Fragile X mental retardation protein controls gating of the sodium-activated potassium channel Slack. Nat Neurosci 2010; 13 (7) : 819-821. Berry KP, Nedivi E. Spine Dynamics: Are They All the Same? Neuron 2017; 96 (1) : 43-55. Irwin SA, Patel B, Idupulapati M, Harris JB, Crisostomo RA, Larsen BP et al. Abnormal dendritic spine characteristics in the temporal and visual cortices of patients with fragile-X syndrome: a quantitative examination. American journal of medical genetics 2001; 98 (2) : 161-167. Nimchinsky EA, Oberlander AM, Svoboda K. Abnormal development of dendritic spines in FMR1 knock-out mice. J Neurosci 2001; 21 (14) : 5139-5146. Booker SA, Domanski APF, Dando OR, Jackson AD, Isaac JTR, Hardingham GE et al. Altered dendritic spine function and integration in a mouse model of fragile X syndrome. Nature communications 2019; 10 (1) : 4813. Licznerski P, Park HA, Rolyan H, Chen R, Mnatsakanyan N, Miranda P et al. ATP Synthase c-Subunit Leak Causes Aberrant Cellular Metabolism in Fragile X Syndrome. Cell 2020; 182 (5) : 1170-1185 e1179. Yan J, Porch MW, Court-Vazquez B, Bennett MVL, Zukin RS. Activation of autophagy rescues synaptic and cognitive deficits in fragile X mice. Proceedings of the National Academy of Sciences of the United States of America 2018; 115 (41) : E9707-E9716. Dolan BM, Duron SG, Campbell DA, Vollrath B, Shankaranarayana Rao BS, Ko HY et al. Rescue of fragile X syndrome phenotypes in Fmr1 KO mice by the small-molecule PAK inhibitor FRAX486. Proceedings of the National Academy of Sciences of the United States of America 2013; 110 (14) : 5671-5676. Udagawa T, Farny NG, Jakovcevski M, Kaphzan H, Alarcon JM, Anilkumar S et al. Genetic and acute CPEB1 depletion ameliorate fragile X pathophysiology. Nature medicine 2013; 19 (11) : 1473-1477. Gantois I, Khoutorsky A, Popic J, Aguilar-Valles A, Freemantle E, Cao R et al. Metformin ameliorates core deficits in a mouse model of fragile X syndrome. Nature medicine 2017; 23 (6) : 674-677. Busquets-Garcia A, Gomis-Gonzalez M, Guegan T, Agustin-Pavon C, Pastor A, Mato S et al. Targeting the endocannabinoid system in the treatment of fragile X syndrome. Nature medicine 2013; 19 (5) : 603-607. Mercaldo V, Vidimova B, Gastaldo D, Fernandez E, Lo AC, Cencelli G et al. Altered striatal actin dynamics drives behavioral inflexibility in a mouse model of fragile X syndrome. Neuron 2023; 111 (11) : 1760-1775 e1768. Shen M, Wang F, Li M, Sah N, Stockton ME, Tidei JJ et al. Reduced mitochondrial fusion and Huntingtin levels contribute to impaired dendritic maturation and behavioral deficits in Fmr1-mutant mice. Nat Neurosci 2019; 22 (3) : 386-400. Pyronneau A, He Q, Hwang JY, Porch M, Contractor A, Zukin RS. Aberrant Rac1-cofilin signaling mediates defects in dendritic spines, synaptic function, and sensory perception in fragile X syndrome. Science signaling 2017; 10 (504). Santini E, Huynh TN, Longo F, Koo SY, Mojica E, D'Andrea L et al. Reducing eIF4E-eIF4G interactions restores the balance between protein synthesis and actin dynamics in fragile X syndrome model mice. Science signaling 2017; 10 (504). Cingolani LA, Goda Y. Actin in action: the interplay between the actin cytoskeleton and synaptic efficacy. Nature reviews Neuroscience 2008; 9 (5) : 344-356. Hotulainen P, Hoogenraad CC. Actin in dendritic spines: connecting dynamics to function. The Journal of cell biology 2010; 189 (4) : 619-629. Forrest MP, Parnell E, Penzes P. Dendritic structural plasticity and neuropsychiatric disease. Nature reviews Neuroscience 2018; 19 (4) : 215-234. Pontrello CG, Sun MY, Lin A, Fiacco TA, DeFea KA, Ethell IM. Cofilin under control of beta-arrestin-2 in NMDA-dependent dendritic spine plasticity, long-term depression (LTD), and learning. Proceedings of the National Academy of Sciences of the United States of America 2012; 109 (7) : E442-451. Harris H, Rubinsztein DC. Control of autophagy as a therapy for neurodegenerative disease. Nature reviews Neurology 2011; 8 (2) : 108-117. Nixon RA. The role of autophagy in neurodegenerative disease. Nature medicine 2013; 19 (8) : 983-997. Mizushima N, Levine B, Cuervo AM, Klionsky DJ. Autophagy fights disease through cellular self-digestion. Nature 2008; 451 (7182) : 1069-1075. Shehata M, Matsumura H, Okubo-Suzuki R, Ohkawa N, Inokuchi K. Neuronal stimulation induces autophagy in hippocampal neurons that is involved in AMPA receptor degradation after chemical long-term depression. J Neurosci 2012; 32 (30) : 10413-10422. Linda K, Lewerissa EI, Verboven AHA, Gabriele M, Frega M, Klein Gunnewiek TM et al. Imbalanced autophagy causes synaptic deficits in a human model for neurodevelopmental disorders. Autophagy 2022; 18 (2) : 423-442. Compans B, Camus C, Kallergi E, Sposini S, Martineau M, Butler C et al. NMDAR-dependent long-term depression is associated with increased short term plasticity through autophagy mediated loss of PSD-95. Nature communications 2021; 12 (1) : 2849. Kallergi E, Daskalaki AD, Kolaxi A, Camus C, Ioannou E, Mercaldo V et al. Dendritic autophagy degrades postsynaptic proteins and is required for long-term synaptic depression in mice. Nature communications 2022; 13 (1) : 680. Shen H, Zhu H, Panja D, Gu Q, Li Z. Autophagy controls the induction and developmental decline of NMDAR-LTD through endocytic recycling. Nature communications 2020; 11 (1) : 2979. Nikoletopoulou V, Tavernarakis N. Regulation and Roles of Autophagy at Synapses. Trends Cell Biol 2018; 28 (8) : 646-661. Negrete-Hurtado A, Overhoff M, Bera S, De Bruyckere E, Schätzmüller K, Kye MJ et al. Autophagy lipidation machinery regulates axonal microtubule dynamics but is dispensable for survival of mammalian neurons. Nature communications 2020; 11 (1). Crawley O, Opperman KJ, Desbois M, Adrados I, Borgen MA, Giles AC et al. Autophagy is inhibited by ubiquitin ligase activity in the nervous system. Nature communications 2019; 10 (1) : 5017. Kiral FR, Linneweber GA, Mathejczyk T, Georgiev SV, Wernet MF, Hassan BA et al. Autophagy-dependent filopodial kinetics restrict synaptic partner choice during Drosophila brain wiring. Nature communications 2020; 11 (1) : 1325. Bagni C, Zukin RS. A Synaptic Perspective of Fragile X Syndrome and Autism Spectrum Disorders. Neuron 2019; 101 (6) : 1070-1088. Tang G, Gudsnuk K, Kuo SH, Cotrina ML, Rosoklija G, Sosunov A et al. Loss of mTOR-dependent macroautophagy causes autistic-like synaptic pruning deficits. Neuron 2014; 83 (5) : 1131-1143. Nikoletopoulou V, Sidiropoulou K, Kallergi E, Dalezios Y, Tavernarakis N. Modulation of Autophagy by BDNF Underlies Synaptic Plasticity. Cell metabolism 2017; 26 (1) : 230-242 e235. Guo Y, Shen M, Dong Q, Mendez-Albelo NM, Huang SX, Sirois CL et al. Elevated levels of FMRP-target MAP1B impair human and mouse neuronal development and mouse social behaviors via autophagy pathway. Nature communications 2023; 14 (1) : 3801. Vodicka P, Lim J, Williams DT, Kegel KB, Chase K, Park H et al. Assessment of chloroquine treatment for modulating autophagy flux in brain of WT and HD mice. J Huntingtons Dis 2014; 3 (2) : 159-174. Roncaglia P, Martone ME, Hill DP, Berardini TZ, Foulger RE, Imam FT et al. The Gene Ontology (GO) Cellular Component Ontology: integration with SAO (Subcellular Anatomy Ontology) and other recent developments. J Biomed Semantics 2013; 4 (1) : 20. Contractor A, Klyachko VA, Portera-Cailliau C. Altered Neuronal and Circuit Excitability in Fragile X Syndrome. Neuron 2015; 87 (4) : 699-715. Koopmans F, van Nierop P, Andres-Alonso M, Byrnes A, Cijsouw T, Coba MP et al. SynGO: An Evidence-Based, Expert-Curated Knowledge Base for the Synapse. Neuron 2019; 103 (2) : 217-234 e214. Rubinsztein DC, Codogno P, Levine B. Autophagy modulation as a potential therapeutic target for diverse diseases. Nature reviews Drug discovery 2012; 11 (9) : 709-730. Underwood BR, Green-Thompson ZW, Pugh PJ, Lazic SE, Mason SL, Griffin J et al. An open-label study to assess the feasibility and tolerability of rilmenidine for the treatment of Huntington's disease. J Neurol 2017; 264 (12) : 2457-2463. Bennett DF, Goyala A, Statzer C, Beckett CW, Tyshkovskiy A, Gladyshev VN et al. Rilmenidine extends lifespan and healthspan in Caenorhabditis elegans via a nischarin I1-imidazoline receptor. Aging Cell 2023; 22 (2) : e13774. Choi DH, Kim DH, Park YG, Chun BG, Choi SH. Protective effects of rilmenidine and AGN 192403 on oxidative cytotoxicity and mitochondrial inhibitor-induced cytotoxicity in astrocytes. Free Radic Biol Med 2002; 33 (10) : 1321-1333. Rose C, Menzies FM, Renna M, Acevedo-Arozena A, Corrochano S, Sadiq O et al. Rilmenidine attenuates toxicity of polyglutamine expansions in a mouse model of Huntington's disease. Hum Mol Genet 2010; 19 (11) : 2144-2153. Perera ND, Sheean RK, Lau CL, Shin YS, Beart PM, Horne MK et al. Rilmenidine promotes MTOR-independent autophagy in the mutant SOD1 mouse model of amyotrophic lateral sclerosis without slowing disease progression. Autophagy 2018; 14 (3) : 534-551. Klionsky DJ, Abdel-Aziz AK, Abdelfatah S, Abdellatif M, Abdoli A, Abel S et al. Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition)(1). Autophagy 2021; 17 (1) : 1-382. Palmer JE, Wilson N, Son SM, Obrocki P, Wrobel L, Rob M et al. Autophagy, aging, and age-related neurodegeneration. Neuron 2024. Fleming A, Bourdenx M, Fujimaki M, Karabiyik C, Krause GJ, Lopez A et al. The different autophagy degradation pathways and neurodegeneration. Neuron 2022; 110 (6) : 935-966. Bhattacharya A, Kaphzan H, Alvarez-Dieppa AC, Murphy JP, Pierre P, Klann E. Genetic removal of p70 S6 kinase 1 corrects molecular, synaptic, and behavioral phenotypes in fragile X syndrome mice. Neuron 2012; 76 (2) : 325-337. McCary LM, Roberts JE. Early identification of autism in fragile X syndrome: a review. Journal of intellectual disability research : JIDR 2013; 57 (9) : 803-814. Bear MF, Huber KM, Warren ST. The mGluR theory of fragile X mental retardation. Trends in neurosciences 2004; 27 (7) : 370-377. Luscher C, Huber KM. Group 1 mGluR-dependent synaptic long-term depression: mechanisms and implications for circuitry and disease. Neuron 2010; 65 (4) : 445-459. Stoppel LJ, Kazdoba TM, Schaffler MD, Preza AR, Heynen A, Crawley JN et al. R-Baclofen Reverses Cognitive Deficits and Improves Social Interactions in Two Lines of 16p11.2 Deletion Mice. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 2018; 43 (3) : 513-524. Kazdoba TM, Leach PT, Silverman JL, Crawley JN. Modeling fragile X syndrome in the Fmr1 knockout mouse. Intractable & rare diseases research 2014; 3 (4) : 118-133. Levine B, Packer M, Codogno P. Development of autophagy inducers in clinical medicine. The Journal of clinical investigation 2015; 125 (1) : 14-24. Wang N, Li T, Liu W, Lin J, Zhang K, Li Z et al. USP7- and PRMT5-dependent G3BP2 stabilization drives de novo lipogenesis and tumorigenesis of HNSC. Cell Death Dis 2023; 14 (3) : 182. Alard A, Fabre B, Anesia R, Marboeuf C, Pierre P, Susini C et al. NAD(P)H quinone-oxydoreductase 1 protects eukaryotic translation initiation factor 4GI from degradation by the proteasome. Molecular and cellular biology 2010; 30 (4) : 1097-1105. Colledge M, Snyder EM, Crozier RA, Soderling JA, Jin Y, Langeberg LK et al. Ubiquitination regulates PSD-95 degradation and AMPA receptor surface expression. Neuron 2003; 40 (3) : 595-607. Makkerh JP, Ceni C, Auld DS, Vaillancourt F, Dorval G, Barker PA. p75 neurotrophin receptor reduces ligand-induced Trk receptor ubiquitination and delays Trk receptor internalization and degradation. EMBO Rep 2005; 6 (10) : 936-941. Wang Y, Xie Y, Sun B, Guo Y, Song L, Mohammednur DE et al. The degradation of Rap1GAP via E6AP-mediated ubiquitin-proteasome pathway is associated with HPV16/18-infection in cervical cancer cells. Infect Agent Cancer 2021; 16 (1) : 71. Liu Z, Gu S, Wu K, Li L, Dong C, Wang W et al. CircRNA-DOPEY2 enhances the chemosensitivity of esophageal cancer cells by inhibiting CPEB4-mediated Mcl-1 translation. J Exp Clin Cancer Res 2021; 40 (1) : 361. Zhao J, Zhai B, Gygi SP, Goldberg AL. mTOR inhibition activates overall protein degradation by the ubiquitin proteasome system as well as by autophagy. Proceedings of the National Academy of Sciences of the United States of America 2015; 112 (52) : 15790-15797. Tsai NP, Wilkerson JR, Guo W, Maksimova MA, DeMartino GN, Cowan CW et al. Multiple autism-linked genes mediate synapse elimination via proteasomal degradation of a synaptic scaffold PSD-95. Cell 2012; 151 (7) : 1581-1594. Matt L, Kim K, Hergarden AC, Patriarchi T, Malik ZA, Park DK et al. alpha-Actinin Anchors PSD-95 at Postsynaptic Sites. Neuron 2018; 97 (5) : 1094-1109 e1099. Zhou Q, Homma KJ, Poo MM. Shrinkage of dendritic spines associated with long-term depression of hippocampal synapses. Neuron 2004; 44 (5) : 749-757. Bosch M, Castro J, Saneyoshi T, Matsuno H, Sur M, Hayashi Y. Structural and molecular remodeling of dendritic spine substructures during long-term potentiation. Neuron 2014; 82 (2) : 444-459. De Rubeis S, Pasciuto E, Li KW, Fernandez E, Di Marino D, Buzzi A et al. CYFIP1 coordinates mRNA translation and cytoskeleton remodeling to ensure proper dendritic spine formation. Neuron 2013; 79 (6) : 1169-1182. Marcotrigiano J, Gingras AC, Sonenberg N, Burley SK. Cap-dependent translation initiation in eukaryotes is regulated by a molecular mimic of eIF4G. Molecular cell 1999; 3 (6) : 707-716. Mariano V, Kanellopoulos AK, Ricci C, Di Marino D, Borrie SC, Dupraz S et al. Intellectual Disability and Behavioral Deficits Linked to CYFIP1 Missense Variants Disrupting Actin Polymerization. Biol Psychiatry 2024; 95 (2) : 161-174. Yan J, Zhang H, Yin Y, Li J, Tang Y, Purkayastha S et al. Obesity- and aging-induced excess of central transforming growth factor-β potentiates diabetic development via an RNA stress response. Nature medicine 2014; 20: 1001. Hagerman RJ, Hagerman PJ. Fragile X Syndrome: Lessons Learned and What New Treatment Avenues Are on the Horizon. Annu Rev Pharmacol Toxicol 2022; 62: 365-381. Doers ME, Musser MT, Nichol R, Berndt ER, Baker M, Gomez TM et al. iPSC-derived forebrain neurons from FXS individuals show defects in initial neurite outgrowth. Stem cells and development 2014; 23 (15) : 1777-1787. Liu XS, Wu H, Krzisch M, Wu X, Graef J, Muffat J et al. Rescue of Fragile X Syndrome Neurons by DNA Methylation Editing of the FMR1 Gene. Cell 2018; 172 (5) : 979-992 e976. Xie Y, Zhou B, Lin MY, Wang S, Foust KD, Sheng ZH. Endolysosomal Deficits Augment Mitochondria Pathology in Spinal Motor Neurons of Asymptomatic fALS Mice. Neuron 2015; 87 (2) : 355-370. Gupta VK, Scheunemann L, Eisenberg T, Mertel S, Bhukel A, Koemans TS et al. Restoring polyamines protects from age-induced memory impairment in an autophagy-dependent manner. Nat Neurosci 2013; 16 (10) : 1453-1460. Komatsu M, Waguri S, Chiba T, Murata S, Iwata J, Tanida I et al. Loss of autophagy in the central nervous system causes neurodegeneration in mice. Nature 2006; 441 (7095) : 880-884. Dong Z, Chen W, Chen C, Wang H, Cui W, Tan Z et al. CUL3 Deficiency Causes Social Deficits and Anxiety-like Behaviors by Impairing Excitation-Inhibition Balance through the Promotion of Cap-Dependent Translation. Neuron 2020; 105 (3) : 475-490 e476. Penzes P, Cahill ME, Jones KA, VanLeeuwen JE, Woolfrey KM. Dendritic spine pathology in neuropsychiatric disorders. Nat Neurosci 2011; 14 (3) : 285-293. Zhao H, Zhao YG, Wang X, Xu L, Miao L, Feng D et al. Mice deficient in Epg5 exhibit selective neuronal vulnerability to degeneration. The Journal of cell biology 2013; 200 (6) : 731-741. Dong S, Aguirre-Hernandez C, Scrivo A, Eliscovich C, Arias E, Bravo-Cordero JJ et al. Monitoring spatiotemporal changes in chaperone-mediated autophagy in vivo. Nature communications 2020; 11 (1) : 645. Zhang Z, Yan J, Bowman AB, Bryan MR, Singh R, Aschner M. Dysregulation of TFEB contributes to manganese-induced autophagic failure and mitochondrial dysfunction in astrocytes. Autophagy 2020; 16 (8) : 1506-1523. Kast DJ, Dominguez R. The Cytoskeleton-Autophagy Connection. Current biology : CB 2017; 27 (8) : R318-R326. Gkogkas CG, Khoutorsky A, Ran I, Rampakakis E, Nevarko T, Weatherill DB et al. Autism-related deficits via dysregulated eIF4E-dependent translational control. Nature 2013; 493 (7432) : 371-377. Zhang J, Abdel-Rahman AA. Nischarin as a functional imidazoline (I1) receptor. FEBS Lett 2006; 580 (13) : 3070-3074. Alahari SK. Nischarin inhibits Rac induced migration and invasion of epithelial cells by affecting signaling cascades involving PAK. Exp Cell Res 2003; 288 (2) : 415-424. Srdic-Rajic T, Nikolic K, Cavic M, Djokic I, Gemovic B, Perovic V et al. Rilmenidine suppresses proliferation and promotes apoptosis via the mitochondrial pathway in human leukemic K562 cells. Eur J Pharm Sci 2016; 81: 172-180. Reid JL. Rilmenidine: a clinical overview. Am J Hypertens 2000; 13 (6 Pt 2) : 106S-111S. Trimarco B, Rosiello G, Sarno D, Lorino G, Rubattu S, DeLuca N et al. Effects of one-year treatment with rilmenidine on systemic hypertension-induced left ventricular hypertrophy in hypertensive patients. Am J Cardiol 1994; 74 (13) : 36A-42A. Bauduceau B, Mayaudon H, Dupuy O. Rilmenidine in the hypertensive type-2 diabetic: a controlled pilot study versus captopril. J Cardiovasc Risk 2000; 7 (1) : 57-61. Fauvel JP, Najem R, Ryon B, Ducher M, Laville M. Effects of rilmenidine on stress-induced peak blood pressure and renal function. J Cardiovasc Pharmacol 1999; 34 (1) : 41-45. Vuu YM, Roberts CT, Rastegar M. MeCP2 Is an Epigenetic Factor That Links DNA Methylation with Brain Metabolism. International journal of molecular sciences 2023; 24 (4). Prem S, Dev B, Peng C, Mehta M, Alibutud R, Connacher RJ et al. Dysregulation of mTOR signaling mediates common neurite and migration defects in both idiopathic and 16p11.2 deletion autism neural precursor cells. Elife 2024; 13 . Zhou J, Blundell J, Ogawa S, Kwon CH, Zhang W, Sinton C et al. Pharmacological inhibition of mTORC1 suppresses anatomical, cellular, and behavioral abnormalities in neural-specific Pten knock-out mice. J Neurosci 2009; 29 (6) : 1773-1783. Spencer CM, Serysheva E, Yuva-Paylor LA, Oostra BA, Nelson DL, Paylor R. Exaggerated behavioral phenotypes in Fmr1/Fxr2 double knockout mice reveal a functional genetic interaction between Fragile X-related proteins. Hum Mol Genet 2006; 15 (12) : 1984-1994. Miyawaki T, Ofengeim D, Noh KM, Latuszek-Barrantes A, Hemmings BA, Follenzi A et al. The endogenous inhibitor of Akt, CTMP, is critical to ischemia-induced neuronal death. Nat Neurosci 2009; 12 (5) : 618-626. Chambers SM, Fasano CA, Papapetrou EP, Tomishima M, Sadelain M, Studer L. Highly efficient neural conversion of human ES and iPS cells by dual inhibition of SMAD signaling. Nat Biotechnol 2009; 27 (3) : 275-280. Li M, Zhao H, Ananiev GE, Musser MT, Ness KH, Maglaque DL et al. Establishment of Reporter Lines for Detecting Fragile X Mental Retardation (FMR1) Gene Reactivation in Human Neural Cells. Stem Cells 2017; 35 (1) : 158-169. Autar K, Guo X, Rumsey JW, Long CJ, Akanda N, Jackson M et al. A functional hiPSC-cortical neuron differentiation and maturation model and its application to neurological disorders. Stem Cell Reports 2022; 17 (1) : 96-109. Tost J, Dunker J, Gut IG. Analysis and quantification of multiple methylation variable positions in CpG islands by Pyrosequencing. Biotechniques 2003; 35 (1) : 152-156. Li J, Tang Y, Cai D. IKKbeta/NF-kappaB disrupts adult hypothalamic neural stem cells to mediate a neurodegenerative mechanism of dietary obesity and pre-diabetes. Nat Cell Biol 2012; 14 (10) : 999-1012. Dunkley PR, Jarvie PE, Robinson PJ. A rapid Percoll gradient procedure for preparation of synaptosomes. Nature protocols 2008; 3 (11) : 1718-1728. Zhang Y, Helm JS, Senatore A, Spafford JD, Kaczmarek LK, Jonas EA. PKC-induced intracellular trafficking of Ca(V)2 precedes its rapid recruitment to the plasma membrane. J Neurosci 2008; 28 (10) : 2601-2612. Rodenas-Ruano A, Chavez AE, Cossio MJ, Castillo PE, Zukin RS. REST-dependent epigenetic remodeling promotes the developmental switch in synaptic NMDA receptors. Nat Neurosci 2012; 15 (10) : 1382-1390. Huang W, Zhu PJ, Zhang S, Zhou H, Stoica L, Galiano M et al. mTORC2 controls actin polymerization required for consolidation of long-term memory. Nat Neurosci 2013; 16 (4) : 441-448. Schmidt EK, Clavarino G, Ceppi M, Pierre P. SUnSET, a nonradioactive method to monitor protein synthesis. Nat Methods 2009; 6 (4) : 275-277. Deacon RM. Assessing nest building in mice. Nat Protoc 2006; 1 (3) : 1117-1119. Gao XH, Li L, Parisien M, Wu J, Bederman I, Gao Z et al. Discovery of a Redox Thiol Switch: Implications for Cellular Energy Metabolism. Mol Cell Proteomics 2020; 19 (5) : 852-870. Additional Declarations The authors have declared there is NO conflict of interest to disclose Supplementary Files DatasetS6syngoontologiesBP.xlsx Data Set 6 DatasetS5syngoontologiesCC.xlsx Data Set 5 DatasetS742overlaped.xlsx Data Set 7 DatasetS3the289GOBP.xls Data Set 3 DatasetS9DNAMethylation.xlsx Data Set 9 DatasetS842overlapCCwithbackgroudmousebrainexpressiongenes.xlsx Data Set 8 DatasetS4289CCBPBackgroudmousebrainexpressiongenes.xlsx Data Set 4 DatasetS1.xlsx Data Set 1 DatasetS2289overlaped.xlsx Data Set 2 Supplementaryfigures.pdf SupplementalFigureLegends.docx Cite Share Download PDF Status: Published Journal Publication published 10 Sep, 2025 Read the published version in Molecular Psychiatry → Version 1 posted Editorial decision: revise 22 Jul, 2025 Submission checks completed at journal 14 Feb, 2025 First submitted to journal 11 Feb, 2025 Unknown event 11 Feb, 2025 Editor assigned by journal 10 Feb, 2025 You are reading this latest preprint version Research Square lets you share your work early, gain feedback from the community, and start making changes to your manuscript prior to peer review in a journal. As a division of Research Square Company, we’re committed to making research communication faster, fairer, and more useful. We do this by developing innovative software and high quality services for the global research community. Our growing team is made up of researchers and industry professionals working together to solve the most critical problems facing scientific publishing. Also discoverable on Platform About Our Team In Review Editorial Policies Advisory Board Help Center Resources Author Services Accessibility API Access RSS feed Manage Cookie Preferences © Research Square 2026 | ISSN 2693-5015 (online) Privacy Policy Terms of Service Do Not Sell My Personal Information {"props":{"pageProps":{"initialData":{"identity":"rs-4415392","acceptedTermsAndConditions":true,"allowDirectSubmit":false,"archivedVersions":[],"articleType":"Article","associatedPublications":[],"authors":[{"id":415818001,"identity":"3be4f830-2d32-40ba-8370-9eb32be516b0","order_by":0,"name":"Ziyan Zhang","email":"","orcid":"","institution":"Center for Gene Regulation in Health and Disease, Cleveland State University, Cleveland, OH 44115","correspondingAuthor":false,"prefix":"","firstName":"Ziyan","middleName":"","lastName":"Zhang","suffix":""},{"id":415818002,"identity":"9ab02157-d9d3-4ef1-bc14-747abebfd7b3","order_by":1,"name":"Cameron Keyser","email":"","orcid":"","institution":"Center for Gene Regulation in Health and Disease, Cleveland State University, Cleveland, OH 44115","correspondingAuthor":false,"prefix":"","firstName":"Cameron","middleName":"","lastName":"Keyser","suffix":""},{"id":415818003,"identity":"bad0e6cc-da8e-4fa9-a7a3-7a93097d8829","order_by":2,"name":"Yaxin Li","email":"","orcid":"","institution":"Department of Chemistry, Center for Gene Regulation in Health and Disease, Cleveland State University, Cleveland, OH 44115","correspondingAuthor":false,"prefix":"","firstName":"Yaxin","middleName":"","lastName":"Li","suffix":""},{"id":415818004,"identity":"68bf1707-3fb2-49cb-a5ff-b8801ebd92ee","order_by":3,"name":"Breandan J. Rosolia","email":"","orcid":"","institution":"Center for Gene Regulation in Health and Disease, Cleveland State University, Cleveland, OH 44115","correspondingAuthor":false,"prefix":"","firstName":"Breandan","middleName":"J.","lastName":"Rosolia","suffix":""},{"id":415818008,"identity":"b1165d60-8817-423d-aaea-300b3026ea05","order_by":4,"name":"Morgan W. Porch","email":"","orcid":"","institution":"Dominick P. Purpura Department of Neuroscience, Albert Einstein College of Medicine, Bronx, NY 10461","correspondingAuthor":false,"prefix":"","firstName":"Morgan","middleName":"W.","lastName":"Porch","suffix":""},{"id":415818007,"identity":"e1f5acea-bad6-405e-8f15-b98aa5f0f212","order_by":5,"name":"Wen Zhang","email":"","orcid":"","institution":"Department of Psychiatry, Friedman Brain Institute, and Department of Genetics and Genomic Science and Institute for Multiscale Biology, Icahn School of Medicine at Mount Sinai, New York, NY 10029","correspondingAuthor":false,"prefix":"","firstName":"Wen","middleName":"","lastName":"Zhang","suffix":""},{"id":415818006,"identity":"e2d6d78f-340a-4f64-9c7d-e4dcfafc4987","order_by":6,"name":"Bin Su","email":"","orcid":"","institution":"Department of Chemistry, Center for Gene Regulation in Health and Disease, Cleveland State University, Cleveland, OH 44115","correspondingAuthor":false,"prefix":"","firstName":"Bin","middleName":"","lastName":"Su","suffix":""},{"id":415818005,"identity":"46db3971-57e8-4dcf-a97d-ccc3863e1673","order_by":7,"name":"Peng Jiang","email":"","orcid":"","institution":"Center for Gene Regulation in Health and Disease, Cleveland State University, Cleveland, OH 44115","correspondingAuthor":false,"prefix":"","firstName":"Peng","middleName":"","lastName":"Jiang","suffix":""},{"id":415818009,"identity":"85ce90de-7e07-483c-8278-ceb10d10876a","order_by":8,"name":"R. Suzanne Zukin","email":"data:image/png;base64,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","orcid":"","institution":"Dominick P. Purpura Department of Neuroscience, Albert Einstein College of Medicine, Bronx, NY 10461","correspondingAuthor":true,"prefix":"","firstName":"R.","middleName":"Suzanne","lastName":"Zukin","suffix":""},{"id":415818000,"identity":"e4bb3ac1-2355-43ea-a444-b7c22a5620d4","order_by":9,"name":"Jingqi Yan","email":"data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAAZAAAAAyAQMAAABI0h/eAAAABlBMVEX///8AAABVwtN+AAAACXBIWXMAAA7EAAAOxAGVKw4bAAAA2ElEQVRIiWNgGAWjYBACxgYQ+eO/HIhiZjAAUQlEaGHsYTYmXgsEsDEnNoC1MBChhbmBx/BzAQ9ben//GcPHBQU2DPzsOQYEHMZjLD3Dgid3xo0cY+MZBmkMkj1vCGoxkObhkcjdIMFjJs1jcJjB4AYRtvzmYTNIN+A/A9FiT4QWoEq2hAQDhhyoLRKEtDSzlVnz9hwwnHEjrdiYxyCNR+LMswK8Wgzbmzff5vlxQJ6///DGxzx/bOT425M34NfSzIHqDB68ykFAnoH9AUFFo2AUjIJRMMIBAHulOg1gFwxsAAAAAElFTkSuQmCC","orcid":"https://orcid.org/0000-0002-7024-6423","institution":"Center for Gene Regulation in Health and Disease, Cleveland State University, Cleveland, OH 44115","correspondingAuthor":true,"prefix":"","firstName":"Jingqi","middleName":"","lastName":"Yan","suffix":""}],"badges":[],"createdAt":"2024-05-13 22:05:22","currentVersionCode":1,"declarations":"","doi":"10.21203/rs.3.rs-4415392/v1","doiUrl":"https://doi.org/10.21203/rs.3.rs-4415392/v1","draftVersion":[],"editorialEvents":[{"content":"https://doi.org/10.1038/s41380-025-03207-6","type":"published","date":"2025-09-10T04:00:00+00:00"}],"editorialNote":"","failedWorkflow":false,"files":[{"id":89997212,"identity":"e823a45b-629d-4c8c-b2eb-bad2433832e8","added_by":"auto","created_at":"2025-08-27 08:15:27","extension":"jpg","order_by":1,"title":"Figure 1","display":"","copyAsset":false,"role":"figure","size":565729,"visible":true,"origin":"","legend":"\u003cp\u003e\u003cstrong\u003eProteomic analysis on hippocampus of \u003c/strong\u003e\u003cem\u003e\u003cstrong\u003eFmr1 \u003c/strong\u003e\u003c/em\u003e\u003cstrong\u003eKO mice and mice with inhibited autophagy.\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003e\u0026nbsp;\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eHippocampal tissues were isolated from\u003cem\u003e Fmr1\u003c/em\u003e KO (\u003cem\u003eFmr1\u003c/em\u003e KO) \u003cem\u003evs.\u003c/em\u003e wild-type (WT) mice (5-week-old), and WT mice (5-week-old) injected (\u003cem\u003ei.p.) \u003c/em\u003ewith saline as vehicle (Veh) or Chloroquine (CQ, 50 mg/kg BW). Total protein lysates were analyzed by proteomics. (\u003cstrong\u003eA\u003c/strong\u003e) Venn diagram showing 289 overlapped proteins between proteins significantly increased (\u003cem\u003ep\u003c/em\u003e\u0026lt;0.05) in \u003cem\u003eFmr1 \u003c/em\u003eKO \u003cem\u003evs.\u003c/em\u003e WT mice and proteins significantly increased (\u003cem\u003ep\u003c/em\u003e\u0026lt;0.05) in mice injected with CQ \u003cem\u003evs.\u003c/em\u003e Veh. The significance of overlap: \u003cem\u003ep\u003c/em\u003e\u0026lt;10\u003csup\u003e-16\u003c/sup\u003e.\u0026nbsp; (\u003cstrong\u003eB\u003c/strong\u003e) GO “cellular component” analysis of 289 overlapped proteins (Mus musculus database of brain-expressed genes as the background, \u003cstrong\u003eDataset S4\u003c/strong\u003e; and top neuron-specific components were shown. Color intensity depicts −log10(\u003cem\u003ep\u003c/em\u003e value) and the size of circle denotes the number of proteins associated with each component. (\u003cstrong\u003eC\u003c/strong\u003e) Sunburst blot showing the SynGO\u003csup\u003e55\u003c/sup\u003e locations and enrichment in each term on a color-coded scale as indicated. The blot is organized from the parent term, ‘‘synapse’’ in the center, to successively more refined child terms in the outer shells. (\u003cstrong\u003eD\u003c/strong\u003e) Sunburst blot showing the SynGO biological processes and the number of proteins in each process on a color-coded scale as indicated. The blot is organized from the parent term, ‘‘synapse’’ in the center, to successively more refined child terms in the outer shells. n = 4 mice in each group.\u003c/p\u003e","description":"","filename":"fig1.jpg","url":"https://assets-eu.researchsquare.com/files/rs-4415392/v1/3e073f71d47e8e365e6b8860.jpg"},{"id":89996153,"identity":"19add9c6-2bf2-419e-970e-52f00dfc5aee","added_by":"auto","created_at":"2025-08-27 08:07:27","extension":"jpg","order_by":2,"title":"Figure 2","display":"","copyAsset":false,"role":"figure","size":652642,"visible":true,"origin":"","legend":"\u003cp\u003e\u003cstrong\u003eActivation of autophagy rescued the synaptic and cognitive deficits of \u003c/strong\u003e\u003cem\u003e\u003cstrong\u003eFmr1\u003c/strong\u003e\u003c/em\u003e\u003cstrong\u003e KO mice.\u0026nbsp;\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003e(\u003cstrong\u003eA\u003c/strong\u003e) Schematic for Rilmenidine treatment: Wild-type (WT) mice were injected daily with vehicle (saline) and \u003cem\u003eFmr1\u003c/em\u003e KO mice were injected daily with vehicle (\u003cem\u003eFmr1\u003c/em\u003e KO) or Rilmenidine (\u003cem\u003ei.p.,\u003c/em\u003e 10mg/kg BW) (\u003cem\u003eFmr1\u003c/em\u003e KO + Ril) for 1 week. (\u003cstrong\u003eB\u003c/strong\u003e) Hippocampal lysates from treated mice were assessed with Western blot for p62. (\u003cstrong\u003eC\u003c/strong\u003e) Bar graph shows summary of normalized data of B. (\u003cstrong\u003eD\u003c/strong\u003e) Brain frozen sections were subjected to immunostaining of p62 together with NeuN to mark neurons. Scale bar, 25 µm. (\u003cstrong\u003eE\u003c/strong\u003e) Summary bar graph shows the normalized fluorescent intensity of p62 puncta of D. (\u003cstrong\u003eF\u003c/strong\u003e) Primary neurons were cultured from the hippocampus of WT and \u003cem\u003eFmr1\u003c/em\u003e KO mice and treated with Veh (DMSO) or Rilmenidine (10 µM for 6 hr). Neurons from each group were treated with/without lysosomal inhibitors (Lys Inh, 20 mM NH\u003csub\u003e4\u003c/sub\u003eCl and 100 μM leupeptin) in the last 2 hr. Protein lysates were assessed with Western blot of LC3. \u0026nbsp;(\u003cstrong\u003eG\u003c/strong\u003e) Bar graph shows summary data of F. LC3-II flux is quantified by subtracting LC3-II densitometric value of samples without Lyso Inh from corresponding lysosomal inhibitors-treated samples. (\u003cstrong\u003eH\u003c/strong\u003e) Brains of treated mice were subjected to Golgi staining and all spines located on apical dendrites on CA1 pyramidal neurons were analyzed. Scale bar, 5 µm. (\u003cstrong\u003eI\u003c/strong\u003e) Spine number per 10 μm of dendrite. (5 mice, 25 neuron, and 2020 spines in WT; 5 mice, 25 neuron, and 3100 spines in \u003cem\u003eFmr1\u003c/em\u003e KO; 5 mice, 25 neuron, and 1900 spines in in \u003cem\u003eFmr1\u003c/em\u003e KO + Ril were analyzed).\u0026nbsp; (\u003cstrong\u003eJ\u003c/strong\u003e) Analysis of stubby/mushroom and filopodial spine fractions. (6 mice, 30 neuron, and 2424 spines in WT; 5 mice, 25 neuron, and 3100 spines in \u003cem\u003eFmr1\u003c/em\u003e KO; 5 mice, 25 neuron, and 1900 spines in in \u003cem\u003eFmr1\u003c/em\u003e KO + Ril were analyzed). (\u003cstrong\u003eK, L\u003c/strong\u003e) Visual memory was assessed by the novel object recognition task: (\u003cstrong\u003eK\u003c/strong\u003e) Representative heatmaps of mouse movement; (\u003cstrong\u003eL\u003c/strong\u003e) Preference index to novel object (n = 9 mice in WT, n = 10 in \u003cem\u003eFmr1\u003c/em\u003e KO, and n = 10 in \u003cem\u003eFmr1\u003c/em\u003e KO + Ril). (\u003cstrong\u003eM\u003c/strong\u003e) Design of contextual fear condition test. (\u003cstrong\u003eN\u003c/strong\u003e) Percentages of freezing response in familiar and novel contexts during the test session (n = 10 mice in each group). Significance was calculated by the t-test (unpaired, two-tailed) and one-way ANOVA followed by a Tukey’s test. * \u003cem\u003ep\u003c/em\u003e \u0026lt; 0.05. ** \u003cem\u003ep\u003c/em\u003e \u0026lt; 0.01. \u003cem\u003eN S\u003c/em\u003e: no significant difference. β-actin was used as a loading control. Values reflect mean ± s.e.m. Each circle represents data from an individual mouse (in C, E, I, J, L and N) or an independent culture (in G, n = 4 cultures). n = 4 mice in C and E. Mice are 5-week-old.\u003c/p\u003e","description":"","filename":"fig2.jpg","url":"https://assets-eu.researchsquare.com/files/rs-4415392/v1/5d66a1185e822809ba9c6c6d.jpg"},{"id":89997214,"identity":"ab4e4220-bbad-441f-8211-8ae1dbfee987","added_by":"auto","created_at":"2025-08-27 08:15:27","extension":"jpg","order_by":3,"title":"Figure 3","display":"","copyAsset":false,"role":"figure","size":822975,"visible":true,"origin":"","legend":"\u003cp\u003e\u003cstrong\u003eNeuronal specific \u003c/strong\u003e\u003cem\u003e\u003cstrong\u003eAtg7\u003c/strong\u003e\u003c/em\u003e\u003cstrong\u003e knockout attenuated the rescue effects of Rilmenidine.\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003e(\u003cstrong\u003eA\u003c/strong\u003e) Schematic showing breeding of \u003cem\u003eFmr1\u003c/em\u003e KO (\u003cem\u003eFmr1\u003c/em\u003e\u003csup\u003e\u003cem\u003e-/y\u003c/em\u003e\u003c/sup\u003e) mice with neuron-specific \u003cem\u003eAtg7\u003c/em\u003e knockout (\u003cem\u003eFmr1\u003c/em\u003e\u003csup\u003e\u003cem\u003e-/y\u003c/em\u003e\u003c/sup\u003e: Cre\u003csup\u003e+/-\u003c/sup\u003e: \u003cem\u003eAtg7\u003c/em\u003e\u003csup\u003ef/f\u003c/sup\u003e\u003cem\u003e \u003c/em\u003emice). (\u003cstrong\u003eB\u003c/strong\u003e) \u003cem\u003eFmr1\u003c/em\u003e\u003csup\u003e\u003cem\u003e-/y\u003c/em\u003e\u003c/sup\u003e: Cre\u003csup\u003e+/-\u003c/sup\u003e: \u003cem\u003eAtg7\u003c/em\u003e\u003csup\u003ef/f\u003c/sup\u003e\u003cem\u003e \u003c/em\u003emice\u003cem\u003e, Fmr1\u003c/em\u003e\u003csup\u003e-/y\u003c/sup\u003e: Cre\u003csup\u003e-/-\u003c/sup\u003e: \u003cem\u003eAtg7\u003c/em\u003e\u003csup\u003ef/f\u003c/sup\u003e mice (\u003cem\u003eFmr1\u003c/em\u003e KO control), and WT: Cre\u003csup\u003e-/-\u003c/sup\u003e: \u003cem\u003eAtg7\u003c/em\u003e\u003csup\u003ef/f\u003c/sup\u003e mice (WT control) were injected (\u003cem\u003ei.p.\u003c/em\u003e) with vehicle (Veh) or Rilmenidine (Ril) daily for one week and lysates of hippocampus were assessed with Western blot for p62. β-actin was used as a loading control. \u0026nbsp;(\u003cstrong\u003eC\u003c/strong\u003e) Bar graph shows normalized summary data of B (n = 4 mice in each group). (\u003cstrong\u003eD\u003c/strong\u003e) Brains were isolated and subjected to Golgi staining. Spines located on apical dendrites on CA1 pyramidal neurons were analyzed. Scale bar, 3 µm. (\u003cstrong\u003eE\u003c/strong\u003e) Spine numbers per 10 μm of dendrite. (\u003cstrong\u003eF\u003c/strong\u003e) Analysis of stubby/mushroom and filopodial spine fraction. (For E and F, 5 mice, 25 neuron, and 2092 spines in WT: Cre\u003csup\u003e-/-\u003c/sup\u003e: \u003cem\u003eAtg7\u003c/em\u003e\u003csup\u003ef/f\u003c/sup\u003e mice; 5 mice, 25 neuron, and 3580 spines in \u003cem\u003eFmr1\u003c/em\u003e\u003csup\u003e-/y\u003c/sup\u003e: Cre\u003csup\u003e-/-\u003c/sup\u003e: \u003cem\u003eAtg7\u003c/em\u003e\u003csup\u003ef/f\u003c/sup\u003e mice; 5 mice, 25 neuron, and 2540 spines in \u003cem\u003eFmr1\u003c/em\u003e\u003csup\u003e-/y\u003c/sup\u003e: Cre\u003csup\u003e-/-\u003c/sup\u003e: \u003cem\u003eAtg7\u003c/em\u003e\u003csup\u003ef/f\u003c/sup\u003e mice + Ril; \u0026nbsp;5 mice, 25 neuron, and 3780 spines in \u003cem\u003eFmr1\u003c/em\u003e\u003csup\u003e-/y\u003c/sup\u003e: Cre\u003csup\u003e+/-\u003c/sup\u003e: \u003cem\u003eAtg7\u003c/em\u003e\u003csup\u003ef/f\u003c/sup\u003e\u0026nbsp; + Ril mice were analyzed.) (\u003cstrong\u003eG-I\u003c/strong\u003e) Visual memory was assessed by means of the novel object recognition task: (\u003cstrong\u003eG\u003c/strong\u003e) Representative heatmaps of mouse movement. (\u003cstrong\u003eH\u003c/strong\u003e) Time spent exploring novel and familiar objects (n = 10 mice in each group). (\u003cstrong\u003eI\u003c/strong\u003e) Preference index to novel object. (\u003cstrong\u003eJ\u003c/strong\u003e) Percentages of freezing response in familiar and novel contexts during the contextual fear conditioning task (n = 10 mice in each group). Significance was calculated by the t-test (unpaired, two-tailed) and one-way ANOVA followed by a Tukey’s test. * \u003cem\u003ep\u003c/em\u003e \u0026lt; 0.05. ** \u003cem\u003ep\u003c/em\u003e \u0026lt; 0.01. *** \u003cem\u003ep\u003c/em\u003e \u0026lt; 0.001. \u003cem\u003eN S\u003c/em\u003e: no significant difference. Values reflect mean ± s.e.m. Each circle represents data from an individual mouse. Mice used are 5-week-old.\u003c/p\u003e","description":"","filename":"fig3.jpg","url":"https://assets-eu.researchsquare.com/files/rs-4415392/v1/2e14bb8977a9aa9f1c9c1129.jpg"},{"id":89996158,"identity":"a7f8ed5c-ab6d-4e18-9c81-75fa94a2529e","added_by":"auto","created_at":"2025-08-27 08:07:27","extension":"jpg","order_by":4,"title":"Figure 4","display":"","copyAsset":false,"role":"figure","size":650158,"visible":true,"origin":"","legend":"\u003cp\u003e\u003cstrong\u003eIdentifying the protein targets bridging autophagy to aberrant spines.\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eHippocampus were isolated from\u003cem\u003e Fmr1\u003c/em\u003e KO \u003cem\u003evs.\u003c/em\u003e WT mice with different treatments and protein lysis was subjected to proteomics. (\u003cstrong\u003eA\u003c/strong\u003e) Volcano plot for proteins significantly (\u003cem\u003ep \u003c/em\u003e\u0026lt; 0.05) up- (red) or down-regulated (blue) in \u003cem\u003eFmr1\u003c/em\u003e KO \u003cem\u003evs.\u003c/em\u003e WT mice. (\u003cstrong\u003eB\u003c/strong\u003e) Volcano plot for proteins significantly (\u003cem\u003ep \u003c/em\u003e\u0026lt; 0.05) up- (red) or down-regulated (blue) in \u003cem\u003eFmr1 \u003c/em\u003eKO mice injected with Rilmenidine (Ril) \u003cem\u003evs.\u003c/em\u003e saline (Veh). (\u003cstrong\u003eC\u003c/strong\u003e) Volcano plot for proteins significantly (\u003cem\u003ep \u003c/em\u003e\u0026lt; 0.05) up- (red) or down-regulated (blue) in WT mice injected with CQ (autophagy inhibitor) \u003cem\u003evs.\u003c/em\u003e Veh\u003cem\u003e.\u003c/em\u003e (\u003cstrong\u003eD\u003c/strong\u003e) Venn diagram showing overlapped 42 proteins. Protein names are labeled in A, B, and C. Overlap between proteins increased in \u003cem\u003eFmr1\u003c/em\u003e KO vs. WT and proteins increased in WT by CQ \u003cem\u003evs\u003c/em\u003e. Veh: \u0026nbsp;\u003cem\u003ep\u003c/em\u003e \u0026lt; 10\u003csup\u003e-16\u003c/sup\u003e. \u003csup\u003e\u0026nbsp;\u003c/sup\u003eOverlap between proteins decreased by Rilmenidine in \u003cem\u003eFmr1\u003c/em\u003e KO and proteins increased in WT by CQ \u003cem\u003evs\u003c/em\u003e. Veh: \u003cem\u003ep\u003c/em\u003e = 1.4 X 10\u003csup\u003e-9\u003c/sup\u003e. Overlap between proteins increased in \u003cem\u003eFmr1\u003c/em\u003e KO vs. WT and proteins decreased by Rilmenidine in \u003cem\u003eFmr1\u003c/em\u003e KO: \u003cem\u003ep\u003c/em\u003e \u0026lt; 10\u003csup\u003e-16\u003c/sup\u003e. (\u003cstrong\u003eE\u003c/strong\u003e) GO biological processes analysis (\u003cem\u003eMus musculus\u003c/em\u003e database of brain-expressed genes as the background, \u003cstrong\u003eDataset S8\u003c/strong\u003e) of 42 overlapped proteins showing top nervous system-related processes (\u003cem\u003ep\u003c/em\u003e \u0026lt; 0.05). (X: Log5 scale of fold enrichment) (\u003cstrong\u003eF\u003c/strong\u003e) SFARI Gene database shows 7 of these 42 overlapped proteins are associated with reported autism cases. (\u003cstrong\u003eG\u003c/strong\u003e, \u003cstrong\u003eH\u003c/strong\u003e) Primary neurons were cultured from the hippocampus of WT and \u003cem\u003eFmr1\u003c/em\u003e KO mice and treated with labeled drugs: WT (WT neurons with DMSO); \u003cem\u003eFmr1\u003c/em\u003e KO (\u003cem\u003eFmr1\u003c/em\u003e KO neurons with DMSO); \u003cem\u003eFmr1\u003c/em\u003e KO + Ril (Rilmenidine, 10 µM for 6 hr) and WT + lyso Inhi (lysosomal inhibitors: 10 mM NH\u003csub\u003e4\u003c/sub\u003eCl with 50 μM leupeptin for 6 hr). Lysates were extracted and immunoprecipitated\u003cem\u003e \u003c/em\u003ewith an antibody to ubiquitin. Whole cell lysates (Input) and immunoprecipitants (IP) were immunoblotted (IB) for eIF4G1 and PSD-95. (\u003cstrong\u003eI, J\u003c/strong\u003e): Summary data for ubiquitinated eIF4G1 and PSD-95 in precipitates (normalized to\u003cem\u003e \u003c/em\u003eWT + DMSO). n = 4 mice (5-week-old) in each group of A-C. Significance were calculated by ANOVA followed by a Tukey’s test. * \u003cem\u003ep\u003c/em\u003e \u0026lt; 0.05, ** \u003cem\u003ep\u003c/em\u003e \u0026lt; 0.01. β-actin was used as a loading control. Each circle in I and J represents data from an independent culture (n = 4).\u003c/p\u003e","description":"","filename":"fig4.jpg","url":"https://assets-eu.researchsquare.com/files/rs-4415392/v1/c0d4c8d93145751681b04301.jpg"},{"id":89996172,"identity":"766e6475-8d50-4a95-ae7a-28a68bee5f7b","added_by":"auto","created_at":"2025-08-27 08:07:28","extension":"jpg","order_by":5,"title":"Figure 5","display":"","copyAsset":false,"role":"figure","size":731547,"visible":true,"origin":"","legend":"\u003cp\u003e\u003cstrong\u003eAutophagy regulates Cofilin1 activity and actin dynamics through eIF4G1.\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003ePrimary neurons were cultured from hippocampus of WT and \u003cem\u003eFmr1\u003c/em\u003e KO mice and treated with Veh (DMSO) or Rilmenidine (10 µM) for 6 hr. (\u003cstrong\u003eA\u003c/strong\u003e) Images show immunostaining of eIF4G1together with MAP2 to mark neurons. eIF4G1 staining at higher magnification is shown in the right panels. Scale bar, 15 µm. (\u003cstrong\u003eB\u003c/strong\u003e) Summary bar graph shows fluorescent intensity of eIF4G1 puncta in A. (\u003cstrong\u003eC\u003c/strong\u003e) Cultured neurons were infected with a lentivirus expressing Syn-RFP to image dendrites. Images show immunolabeling of eIF4G1 in dendrites. Scale bar, 3 µm. (\u003cstrong\u003eD\u003c/strong\u003e) Summary bar graph shows fluorescent intensity of eIF4G1 puncta in C. (\u003cstrong\u003eE\u003c/strong\u003e) Schematic illustrating activation of autophagy degrades eIF4G1, reduces eIF4G1/eIF4Einteraction, releases eIF4E to bind more CYFIP1, blocks the formation of WAVE complex, suppresses WAVE-induced Cofilin1 phosphorylation, and elevates F-actin depolymerization. (\u003cstrong\u003eF\u003c/strong\u003e) WT and \u003cem\u003eFmr1\u003c/em\u003e KO mice were injected with vehicle (as WT and \u003cem\u003eFmr1\u003c/em\u003e KO groups) or Rilmenidine (\u003cem\u003eFmr1\u003c/em\u003e KO + Ril). Protein lysates of hippocampal tissues were immunoprecipitated\u003cem\u003e \u003c/em\u003ewith an antibody to eIF4E. Lysates (Input) and immunoprecipitants (IP) were immunoblotted (IB) for eIF4E, eIF4G1, and CYFIP1. A naïve IgG antibody was used as negative control. (\u003cstrong\u003eG, H\u003c/strong\u003e) Bar graphs show summary data of F. (\u003cstrong\u003eI\u003c/strong\u003e) Protein lysates of hippocampus from treated mice were pulled down with PAK-PBD beads. Pulled-down proteins and lysates (input) were immunoblotted for CYFIP1 and Rac1. (\u003cstrong\u003eJ, K\u003c/strong\u003e) Bar graphs show summary data of CYFIP1 and Rac1 in pull-down. (\u003cstrong\u003eL\u003c/strong\u003e) Primary hippocampal neurons from WT and \u003cem\u003eFmr1\u003c/em\u003eKO mice were treated with Veh (DMSO) or Rilmenidine (10 µM) for 6 hr and then immunolabeled with p-Cofilin1(S3) and MAP2. Scale bar, 30 µm. (\u003cstrong\u003eM\u003c/strong\u003e) Summary bar graph shows fluorescent intensity of p-Cofilin1 puncta in L.\u003cstrong\u003e \u003c/strong\u003e(\u003cstrong\u003eN\u003c/strong\u003e) Synaptosome protein lysates from hippocampus of mice in labeled groups were assessed with F/G-actin ratio by Western blot. (\u003cstrong\u003eO\u003c/strong\u003e) Bar graph shows summarized ratio. (\u003cstrong\u003eP\u003c/strong\u003e) Primary hippocampal neurons from WT and \u003cem\u003eFmr1\u003c/em\u003e KO mice were treated with Veh or Rilmenidine (10 µM) for 6 hr and imaged with F-actin. Scale bar, 3 µm. (\u003cstrong\u003eQ\u003c/strong\u003e) Summary bar graph shows fluorescent intensity of F-actin. Significance was calculated by ANOVA followed by a Tukey’s test. * \u003cem\u003ep\u003c/em\u003e \u0026lt; 0.05, ** \u003cem\u003ep\u003c/em\u003e \u0026lt; 0.01. *** \u003cem\u003ep\u003c/em\u003e \u0026lt; 0.001. β-actin was used as a loading control. Values were normalized to WT and reflect mean ± s.e.m. Each circle represents data from an individual mouse (5-week-old, n= 4 in each group) in G, H, J, K and O; or data from an independent culture (n= 4) in B, D, M, and Q.\u003c/p\u003e","description":"","filename":"fig5.jpg","url":"https://assets-eu.researchsquare.com/files/rs-4415392/v1/14e9bc6e7b2b2b6d0eb32692.jpg"},{"id":89997217,"identity":"a851676d-24eb-4e00-85a4-0666988ca000","added_by":"auto","created_at":"2025-08-27 08:15:27","extension":"jpg","order_by":6,"title":"Figure 6","display":"","copyAsset":false,"role":"figure","size":739017,"visible":true,"origin":"","legend":"\u003cp\u003e\u003cstrong\u003eActivation of autophagy corrected the aberrant actin assembly in human FXS neurons.\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003e(\u003cstrong\u003eA\u003c/strong\u003e) Information of human iPSCs. (\u003cstrong\u003eB\u003c/strong\u003e) Average percentage of methylation on CpGs in the indicated promotor region of \u003cem\u003eFmr1 \u003c/em\u003egene. n = 3 samples in each group. (\u003cstrong\u003eC\u003c/strong\u003e) Neurons were differentiated from unaffected (control) and FXS iPSCs. FMRP expression was examined by immunostaining of FMRP and neuronal marker Tuj-1. Scale bar, 15 µm. (\u003cstrong\u003eD\u003c/strong\u003e) iPSCs-derived neurons were treated with DMSO as vehicle or Rilmenidine (Ril) (10µM for 6 hr), and immunostained with p62 together with Tuj-1. Scale bar, 15 µm. (\u003cstrong\u003eE\u003c/strong\u003e) Summary bar graph shows fluorescent intensity of p62 puncta in D (normalized to the value of control). (\u003cstrong\u003eF, H\u003c/strong\u003e) iPSCs-derived neurons were treated with DMSO as vehicle or Rilmenidine (Ril) (10µM for 6 hr), and immunostained with eIF4G1/PSD-95 together with Tuj-1. Scale bar, 20 µm. (\u003cstrong\u003eG\u003c/strong\u003e, \u003cstrong\u003eI\u003c/strong\u003e)Summary bar graphs show fluorescent intensities of eIF4G1 and PSD-95 puncta. (\u003cstrong\u003eJ\u003c/strong\u003e) F/G-actin ratio was assessed by Western blot with lysates from iPSCs derived neurons. (\u003cstrong\u003eK\u003c/strong\u003e) Bar graph shows summary ratio of F/G (normalized to the value of control, n = 4 experiments). (\u003cstrong\u003eL\u003c/strong\u003e) iPSCs derived neurons were treated with Veh or Rilmenidine (10 µM) for 6 hr and imaged with F-actin. Scale bar, 3 µm. (\u003cstrong\u003eM\u003c/strong\u003e) Summary bar graph shows fluorescent intensity of F-actin. Significance was calculated by ANOVA followed by a Tukey’s test. * \u003cem\u003ep\u003c/em\u003e \u0026lt; 0.05, ** \u003cem\u003ep\u003c/em\u003e \u0026lt; 0.01. Values reflect mean ± s.e.m. Each circle in E, G, I, K and M represents data from an individual experiment.\u003c/p\u003e","description":"","filename":"fig6.jpg","url":"https://assets-eu.researchsquare.com/files/rs-4415392/v1/adfa78fc80b9f4c0bbead5a0.jpg"},{"id":91149318,"identity":"e39c7dc2-f28b-46b5-8b64-dfbce20574cd","added_by":"auto","created_at":"2025-09-12 06:48:44","extension":"pdf","order_by":0,"title":"","display":"","copyAsset":false,"role":"manuscript-pdf","size":6670606,"visible":true,"origin":"","legend":"","description":"","filename":"manuscript.pdf","url":"https://assets-eu.researchsquare.com/files/rs-4415392/v1/56291503-b882-4e99-813e-7665bf5f48da.pdf"},{"id":89996152,"identity":"b2e65aaf-d681-4120-b28b-d050849c23b2","added_by":"auto","created_at":"2025-08-27 08:07:27","extension":"xlsx","order_by":1,"title":"","display":"","copyAsset":false,"role":"supplement","size":48658,"visible":true,"origin":"","legend":"Data Set 6","description":"","filename":"DatasetS6syngoontologiesBP.xlsx","url":"https://assets-eu.researchsquare.com/files/rs-4415392/v1/375c9bddaf32e283423aeb8e.xlsx"},{"id":89997211,"identity":"f8baa91d-aeca-468e-8e5e-bd31ad6db09d","added_by":"auto","created_at":"2025-08-27 08:15:27","extension":"xlsx","order_by":2,"title":"","display":"","copyAsset":false,"role":"supplement","size":48770,"visible":true,"origin":"","legend":"Data Set 5","description":"","filename":"DatasetS5syngoontologiesCC.xlsx","url":"https://assets-eu.researchsquare.com/files/rs-4415392/v1/95b37aa82394fbd5e95a3073.xlsx"},{"id":89997723,"identity":"956e358f-75a4-4316-9fd7-619d24e07d6c","added_by":"auto","created_at":"2025-08-27 08:23:27","extension":"xlsx","order_by":3,"title":"","display":"","copyAsset":false,"role":"supplement","size":10900,"visible":true,"origin":"","legend":"Data Set 7","description":"","filename":"DatasetS742overlaped.xlsx","url":"https://assets-eu.researchsquare.com/files/rs-4415392/v1/2edbd75ebab96e08a5ae0f3d.xlsx"},{"id":89996171,"identity":"7f0c6b9e-92ab-4ef6-9565-5e6ad4df9f6d","added_by":"auto","created_at":"2025-08-27 08:07:28","extension":"xls","order_by":4,"title":"","display":"","copyAsset":false,"role":"supplement","size":154112,"visible":true,"origin":"","legend":"Data Set 3","description":"","filename":"DatasetS3the289GOBP.xls","url":"https://assets-eu.researchsquare.com/files/rs-4415392/v1/3d1c4c3c61789dc819acea76.xls"},{"id":89997726,"identity":"cc830831-0d02-496c-be5c-13f6860a91ac","added_by":"auto","created_at":"2025-08-27 08:23:27","extension":"xlsx","order_by":5,"title":"","display":"","copyAsset":false,"role":"supplement","size":15893,"visible":true,"origin":"","legend":"Data Set 9","description":"","filename":"DatasetS9DNAMethylation.xlsx","url":"https://assets-eu.researchsquare.com/files/rs-4415392/v1/c11dbc912a985321adbd3d2a.xlsx"},{"id":89997724,"identity":"7144e871-c17a-43a5-ae82-2bc0eeae39ec","added_by":"auto","created_at":"2025-08-27 08:23:27","extension":"xlsx","order_by":6,"title":"","display":"","copyAsset":false,"role":"supplement","size":190491,"visible":true,"origin":"","legend":"Data Set 8","description":"","filename":"DatasetS842overlapCCwithbackgroudmousebrainexpressiongenes.xlsx","url":"https://assets-eu.researchsquare.com/files/rs-4415392/v1/0d2ccf3a9c4c43ab4887fec3.xlsx"},{"id":89996167,"identity":"ceaf9450-2bab-479b-8323-af8238c49c50","added_by":"auto","created_at":"2025-08-27 08:07:28","extension":"xlsx","order_by":7,"title":"","display":"","copyAsset":false,"role":"supplement","size":188338,"visible":true,"origin":"","legend":"Data Set 4","description":"","filename":"DatasetS4289CCBPBackgroudmousebrainexpressiongenes.xlsx","url":"https://assets-eu.researchsquare.com/files/rs-4415392/v1/7f5e2d578972f33a59975bd1.xlsx"},{"id":89996174,"identity":"cd04ec7f-a9cd-46bb-9126-fb34fb3385b4","added_by":"auto","created_at":"2025-08-27 08:07:28","extension":"xlsx","order_by":8,"title":"","display":"","copyAsset":false,"role":"supplement","size":2578351,"visible":true,"origin":"","legend":"Data Set 1","description":"","filename":"DatasetS1.xlsx","url":"https://assets-eu.researchsquare.com/files/rs-4415392/v1/314078abbcc1699cd1b1b4a3.xlsx"},{"id":89996159,"identity":"8855f33a-1c8d-427e-bcc0-c07bc9579180","added_by":"auto","created_at":"2025-08-27 08:07:27","extension":"xlsx","order_by":9,"title":"","display":"","copyAsset":false,"role":"supplement","size":20586,"visible":true,"origin":"","legend":"Data Set 2","description":"","filename":"DatasetS2289overlaped.xlsx","url":"https://assets-eu.researchsquare.com/files/rs-4415392/v1/a3265fd3b1f9b52c9d7503f8.xlsx"},{"id":89996177,"identity":"a87f1a70-5ca1-41da-b252-5b8434b38a7a","added_by":"auto","created_at":"2025-08-27 08:07:28","extension":"pdf","order_by":10,"title":"","display":"","copyAsset":false,"role":"supplement","size":4273855,"visible":true,"origin":"","legend":"","description":"","filename":"Supplementaryfigures.pdf","url":"https://assets-eu.researchsquare.com/files/rs-4415392/v1/9d7ba527693032aff6fa9c3b.pdf"},{"id":89997219,"identity":"ad5c6807-56c5-46ab-9695-7eff5d83f722","added_by":"auto","created_at":"2025-08-27 08:15:28","extension":"docx","order_by":11,"title":"","display":"","copyAsset":false,"role":"supplement","size":23872,"visible":true,"origin":"","legend":"","description":"","filename":"SupplementalFigureLegends.docx","url":"https://assets-eu.researchsquare.com/files/rs-4415392/v1/7e17d86d9a7af9f124df34dd.docx"}],"financialInterests":"The authors have declared there is \u003cb\u003eNO\u003c/b\u003e conflict of interest to disclose","formattedTitle":"\u003cp\u003eAutophagy controls the hippocampal postsynaptic organization and affects cognition in a mouse model of Fragile X syndrome\u003c/p\u003e","fulltext":[{"header":"Introduction","content":"\u003cp\u003eFragile X syndrome (FXS) is the most frequent form of heritable intellectual disability and the leading genetic cause of autism\u003csup\u003e\u003cspan additionalcitationids=\"CR2\" citationid=\"CR1\" class=\"CitationRef\"\u003e1\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR3\" class=\"CitationRef\"\u003e3\u003c/span\u003e\u003c/sup\u003e. In patients with Fragile X syndrome, a CGG trinucleotide repeat located in the 5\u0026rsquo;-UTR of the fragile X messenger ribonucleoprotein 1 (\u003cem\u003eFmr1\u003c/em\u003e) gene expands from ~\u0026thinsp;50 to \u0026gt;\u0026thinsp;200, resulting in hypermethylation of the promoter region and epigenetic silencing of the \u003cem\u003eFmr1\u003c/em\u003e gene\u003csup\u003e\u003cspan additionalcitationids=\"CR5 CR6\" citationid=\"CR4\" class=\"CitationRef\"\u003e4\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR7\" class=\"CitationRef\"\u003e7\u003c/span\u003e\u003c/sup\u003e. Fragile X Messenger Ribonucleoprotein 1 (FMRP), the gene expression product of \u003cem\u003eFmr1\u003c/em\u003e, is an RNA binding protein that tightly regulates the trafficking, localization, and translation of a vast number of neuronal mRNAs critical to neural development, synaptic plasticity, and dendritic spine architecture\u003csup\u003e\u003cspan citationid=\"CR1\" class=\"CitationRef\"\u003e1\u003c/span\u003e, \u003cspan additionalcitationids=\"CR9 CR10 CR11\" citationid=\"CR8\" class=\"CitationRef\"\u003e8\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR12\" class=\"CitationRef\"\u003e12\u003c/span\u003e\u003c/sup\u003e. Loss of FMRP and subsequent overabundance of neuronal proteins in the brains of patients and mouse models of FXS induces a complex and debilitating neurological phenotype, including impaired cognition and social interactions, hyperactivity, attentional deficits, seizures, hypersensitivity, autistic behaviors, and autonomic dysfunction\u003csup\u003e\u003cspan citationid=\"CR1\" class=\"CitationRef\"\u003e1\u003c/span\u003e, \u003cspan citationid=\"CR2\" class=\"CitationRef\"\u003e2\u003c/span\u003e, \u003cspan additionalcitationids=\"CR14 CR15 CR16\" citationid=\"CR13\" class=\"CitationRef\"\u003e13\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR17\" class=\"CitationRef\"\u003e17\u003c/span\u003e\u003c/sup\u003e. However, effective treatment for FXS in humans remains unmet.\u003c/p\u003e\u003cp\u003eDendritic spines are the postsynaptic compartments that receive most of the excitatory input in the brain\u003csup\u003e\u003cspan citationid=\"CR18\" class=\"CitationRef\"\u003e18\u003c/span\u003e\u003c/sup\u003e. The neuroanatomical hallmark of Fragile X is an overabundance of long and thin (immature) dendritic spines\u003csup\u003e\u003cspan additionalcitationids=\"CR20 CR21\" citationid=\"CR19\" class=\"CitationRef\"\u003e19\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR22\" class=\"CitationRef\"\u003e22\u003c/span\u003e\u003c/sup\u003e, which is associated with dysregulated group 1 mGluR-dependent long-term depression (LTD) in hippocampal neurons\u003csup\u003e\u003cspan additionalcitationids=\"CR24 CR25 CR26 CR27\" citationid=\"CR23\" class=\"CitationRef\"\u003e23\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR28\" class=\"CitationRef\"\u003e28\u003c/span\u003e\u003c/sup\u003e. Correcting the aberrant spines has been shown to rescue, at least partially, the deficits of cognition, social behaviors, behavioral flexibility, and sensory processing in mouse models of FXS\u003csup\u003e\u003cspan additionalcitationids=\"CR23 CR24 CR25 CR26 CR27 CR28\" citationid=\"CR22\" class=\"CitationRef\"\u003e22\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR29\" class=\"CitationRef\"\u003e29\u003c/span\u003e\u003c/sup\u003e. Importantly, recent findings reported that the altered actin dynamics critically account for the aberrant spines and related symptoms in FXS\u003csup\u003e\u003cspan citationid=\"CR28\" class=\"CitationRef\"\u003e28\u003c/span\u003e, \u003cspan citationid=\"CR30\" class=\"CitationRef\"\u003e30\u003c/span\u003e, \u003cspan citationid=\"CR31\" class=\"CitationRef\"\u003e31\u003c/span\u003e\u003c/sup\u003e. Actin is the most abundant cytoskeletal protein in dendritic spines and exists in dynamics between two states: monomeric globular (G-actin) or polymeric filamentous actin (F-actin)\u003csup\u003e\u003cspan citationid=\"CR32\" class=\"CitationRef\"\u003e32\u003c/span\u003e, \u003cspan citationid=\"CR33\" class=\"CitationRef\"\u003e33\u003c/span\u003e\u003c/sup\u003e. F-actin provides structural support for the stability and morphology of spines\u003csup\u003e\u003cspan citationid=\"CR32\" class=\"CitationRef\"\u003e32\u003c/span\u003e, \u003cspan citationid=\"CR33\" class=\"CitationRef\"\u003e33\u003c/span\u003e\u003c/sup\u003e. Dendritic spine morphogenesis, neurite formation, synapse formation/elimination, and synaptic plasticity all require fine-tuned remodeling of the actin cytoskeleton through the upstream signaling pathways \u003csup\u003e\u003cspan additionalcitationids=\"CR33 CR34\" citationid=\"CR32\" class=\"CitationRef\"\u003e32\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR35\" class=\"CitationRef\"\u003e35\u003c/span\u003e\u003c/sup\u003e. Mouse models of FXS indicated an abnormally increased level of F-actin in the spines at cortex and hippocampus, which is causally related to increased spine density, immature spine morphology, and behavioral deficits \u003csup\u003e\u003cspan citationid=\"CR24\" class=\"CitationRef\"\u003e24\u003c/span\u003e, \u003cspan citationid=\"CR30\" class=\"CitationRef\"\u003e30\u003c/span\u003e, \u003cspan citationid=\"CR31\" class=\"CitationRef\"\u003e31\u003c/span\u003e\u003c/sup\u003e. To develop translational therapeutic strategies for FXS, mechanisms underlying the dysregulated spine density and morphology need to be explored.\u003c/p\u003e\u003cp\u003eAutophagy is a key regulator of cell growth, differentiation, and survival\u003csup\u003e\u003cspan additionalcitationids=\"CR37\" citationid=\"CR36\" class=\"CitationRef\"\u003e36\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR38\" class=\"CitationRef\"\u003e38\u003c/span\u003e\u003c/sup\u003e. In neurons, autophagy plays an important role in protein degradation, synapse elimination, axonal homeostasis, and synaptic plasticity\u003csup\u003e\u003cspan citationid=\"CR23\" class=\"CitationRef\"\u003e23\u003c/span\u003e, \u003cspan additionalcitationids=\"CR40 CR41 CR42 CR43 CR44 CR45 CR46\" citationid=\"CR39\" class=\"CitationRef\"\u003e39\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR47\" class=\"CitationRef\"\u003e47\u003c/span\u003e\u003c/sup\u003e. At presynaptic sites, autophagy is critical to vesicular release, and impaired autophagy results in increased size of the presynaptic compartment and enhanced neurotransmitter release\u003csup\u003e\u003cspan citationid=\"CR48\" class=\"CitationRef\"\u003e48\u003c/span\u003e\u003c/sup\u003e. On the postsynaptic side, autophagy is critical to spine elimination and synapse maturation\u003csup\u003e\u003cspan citationid=\"CR23\" class=\"CitationRef\"\u003e23\u003c/span\u003e, \u003cspan citationid=\"CR49\" class=\"CitationRef\"\u003e49\u003c/span\u003e, \u003cspan citationid=\"CR50\" class=\"CitationRef\"\u003e50\u003c/span\u003e\u003c/sup\u003e. Cargo adaptor molecules such as p62, which bind components of the autophagic machinery, recognize and bind ubiquitinated proteins, enabling their engulfment by autophagosomes targeted for degradation\u003csup\u003e\u003cspan citationid=\"CR36\" class=\"CitationRef\"\u003e36\u003c/span\u003e\u003c/sup\u003e. Reduced autophagy in the brains of humans diagnosed with autism is associated with an accumulation of ubiquitinated proteins\u003csup\u003e\u003cspan citationid=\"CR49\" class=\"CitationRef\"\u003e49\u003c/span\u003e\u003c/sup\u003e. Recent findings revealed that autophagy is downregulated in neurons at hippocampus of a FXS mouse model\u003csup\u003e\u003cspan citationid=\"CR23\" class=\"CitationRef\"\u003e23\u003c/span\u003e\u003c/sup\u003e and in neurons derived from FXS patients\u003csup\u003e\u003cspan citationid=\"CR51\" class=\"CitationRef\"\u003e51\u003c/span\u003e\u003c/sup\u003e. Activation of autophagy leads to rescued synaptic morphology and behavioral deficits\u003csup\u003e\u003cspan citationid=\"CR23\" class=\"CitationRef\"\u003e23\u003c/span\u003e, \u003cspan citationid=\"CR51\" class=\"CitationRef\"\u003e51\u003c/span\u003e\u003c/sup\u003e. However, it is still unclear how dysregulated autophagy could affect synapses and behaviors.\u003c/p\u003e\u003cp\u003eA critical mechanism implicated in the defects of spine morphology, exaggerated mGluR-LTD, and impaired cognition associated with Fragile X is the overabundance of neuronal proteins\u003csup\u003e\u003cspan citationid=\"CR1\" class=\"CitationRef\"\u003e1\u003c/span\u003e, \u003cspan citationid=\"CR8\" class=\"CitationRef\"\u003e8\u003c/span\u003e, \u003cspan citationid=\"CR9\" class=\"CitationRef\"\u003e9\u003c/span\u003e\u003c/sup\u003e. In this study, our initial analysis with proteomics revealed that 289 of the 549 overabundant proteins in the hippocampus of \u003cem\u003eFmr1\u003c/em\u003e KO mice are targets of autophagic protein degradation, indicating a strong correlation between autophagy and pathology of FXS. Further analysis indicates that these 289 proteins may mediate the correlation by affecting postsynaptic organization. Activation of autophagy rescued the aberrant postsynaptic morphology and cognitive behaviors. Proteomics analysis further narrowed that 42 of the 289 proteins may mediate the rescuing effects. Mechanistic studies revealed that among the protein targets, eukaryotic initiation factor 4G1 (eIF4G1) and postsynaptic density protein-95 (PSD-95) are critical. Autophagy degrades eIF4G1 and PSD-95 proteins, corrects the dysregulated postsynaptic organization and actin dynamics, and rescues the spine and cognitive deficits. These findings are validated with FXS mouse model with neuron-specific autophagy deficit, FXS mouse model with brain-specific autophagy activation, and human FXS neurons derived from of patient pluripotent stem cells. Altogether, our findings reveal a critical role of autophagy in regulating structural synaptic plasticity in healthy and diseased conditions and identify autophagy as a novel therapeutic target for Fragile X syndrome.\u003c/p\u003e"},{"header":"Results","content":"\u003cp\u003e\u003cb\u003eProteomic analysis reveals the correlation between downregulated autophagy and FXS.\u003c/b\u003e\u003c/p\u003e\u003cp\u003eFXS individuals and animal models are characterized with overabundance of hundreds of neuronal proteins\u003csup\u003e\u003cspan citationid=\"CR1\" class=\"CitationRef\"\u003e1\u003c/span\u003e, \u003cspan citationid=\"CR8\" class=\"CitationRef\"\u003e8\u003c/span\u003e, \u003cspan citationid=\"CR9\" class=\"CitationRef\"\u003e9\u003c/span\u003e\u003c/sup\u003e. Although most of the overabundances are moderate, the affected proteins together crucially induce complex dysregulated signal pathways, aberrant synapses, and behavioral deficits in FXS\u003csup\u003e\u003cspan citationid=\"CR1\" class=\"CitationRef\"\u003e1\u003c/span\u003e, \u003cspan citationid=\"CR8\" class=\"CitationRef\"\u003e8\u003c/span\u003e, \u003cspan citationid=\"CR9\" class=\"CitationRef\"\u003e9\u003c/span\u003e\u003c/sup\u003e. To maintain the correct number of proteins, the balance between protein synthesis and degradation must be fine-tuned. In neurons, autophagy plays an important role in protein degradation\u003csup\u003e\u003cspan citationid=\"CR39\" class=\"CitationRef\"\u003e39\u003c/span\u003e\u003c/sup\u003e. Brains from humans diagnosed with autism show reduced autophagy and accumulated ubiquitinated proteins\u003csup\u003e\u003cspan citationid=\"CR49\" class=\"CitationRef\"\u003e49\u003c/span\u003e\u003c/sup\u003e. We previously reported that autophagy is downregulated in hippocampal neurons of \u003cem\u003eFmr1\u003c/em\u003e KO mice\u003csup\u003e\u003cspan citationid=\"CR23\" class=\"CitationRef\"\u003e23\u003c/span\u003e\u003c/sup\u003e. To estimate the role of downregulated autophagic protein degradation in synaptic defects of FXS, we compared proteins increased in hippocampus of \u003cem\u003eFmr1\u003c/em\u003e KO (\u003cem\u003eFmr1\u003c/em\u003e\u003csup\u003e\u0026minus;/y\u003c/sup\u003e) mice \u003cem\u003evs.\u003c/em\u003e WT mice with proteins increased in hippocampus of WT mice when autophagy was inhibited by a pharmacological inhibitor, Chloroquine (CQ)\u003csup\u003e\u003cspan citationid=\"CR52\" class=\"CitationRef\"\u003e52\u003c/span\u003e\u003c/sup\u003e. The results indicated that 549 proteins were significantly increased (\u003cem\u003ep\u003c/em\u003e\u0026thinsp;\u0026lt;\u0026thinsp;0.05) in hippocampus of \u003cem\u003eFmr1\u003c/em\u003e KO mice \u003cem\u003evs.\u003c/em\u003e WT mice (Fig.\u0026nbsp;\u003cspan refid=\"Fig1\" class=\"InternalRef\"\u003e1\u003c/span\u003eA \u003cb\u003eand Dataset S1\u003c/b\u003e). 289 of these 549 proteins (52.6%) overlapped with proteins significantly increased in hippocampus of mice injected with CQ \u003cem\u003evs.\u003c/em\u003e Vehicle (\u003cb\u003eDataset S2\u003c/b\u003e), indicating that these 289 proteins are either directly degraded by autophagy or indirectly affected by the downregulated autophagy. Thus, the result indicated that downregulated autophagy plays an important role in the protein overabundance and pathology of FXS.\u003c/p\u003e\u003cp\u003e\u003c/p\u003e\u003cp\u003eTo further estimate the contribution of autophagy to FXS, we performed a Gene Ontology (GO) biological processes enrichment analysis based on the 289 proteins. Fragile X syndrome is a neurodevelopmental disorder, and its pathology primarily affects synaptic functions and morphology in neurons\u003csup\u003e\u003cspan citationid=\"CR2\" class=\"CitationRef\"\u003e2\u003c/span\u003e, \u003cspan citationid=\"CR48\" class=\"CitationRef\"\u003e48\u003c/span\u003e\u003c/sup\u003e. The GO analysis results indicated that \u0026ldquo;Synaptic vesicle priming\u0026rdquo;, \u0026ldquo;Dendritic spine development\u0026rdquo;, \u0026ldquo;Dendrite development\u0026rdquo;, \u0026ldquo;Regulation of synapse structure or activity\u0026rdquo;, and \u0026ldquo;Synapse organization\u0026rdquo; are among the most statistically enriched GO terms (\u003cb\u003eSupplemental Fig.\u0026nbsp;1 and Dataset S3\u003c/b\u003e), suggesting that these 289 proteins are tightly related to the morphology and functions of synapses and dendritic spines, where most of the post-synaptic sites located. Proteins need to be located at certain cellular components to execute the relevant biological processes. Thus, profiling the subcellular components where proteins are located can further explore their roles\u003csup\u003e\u003cspan citationid=\"CR53\" class=\"CitationRef\"\u003e53\u003c/span\u003e\u003c/sup\u003e. GO analysis on Cellular Component (GOCC) with background of brain expression genes demonstrated that synapses and spines are the top (Fold enrichment\u0026thinsp;\u0026gt;\u0026thinsp;1 and \u003cem\u003ep\u003c/em\u003e\u0026thinsp;\u0026lt;\u0026thinsp;0.05) neuronal subcellular components where these 289 proteins are located (Fig.\u0026nbsp;\u003cspan refid=\"Fig1\" class=\"InternalRef\"\u003e1\u003c/span\u003eB \u003cb\u003eand Dataset S4\u003c/b\u003e). The aberrant spines, synapses and neural circuits are considered as neurological basis for cognitive and behavioral deficits in FXS\u003csup\u003e\u003cspan citationid=\"CR48\" class=\"CitationRef\"\u003e48\u003c/span\u003e, \u003cspan citationid=\"CR54\" class=\"CitationRef\"\u003e54\u003c/span\u003e\u003c/sup\u003e. Indeed, the Synaptic Gene Ontologies (SynGO) database (version 20231201)\u003csup\u003e\u003cspan citationid=\"CR55\" class=\"CitationRef\"\u003e55\u003c/span\u003e\u003c/sup\u003e shows the most enriched synaptic component for these 289 proteins is the postsynaptic site (Fig.\u0026nbsp;\u003cspan refid=\"Fig1\" class=\"InternalRef\"\u003e1\u003c/span\u003eC \u003cb\u003eand Dataset S5\u003c/b\u003e). SynGO biological process analysis further indicated that the biggest number of the genes are involved in the process of \u0026ldquo;organization\u0026rsquo; of synapses (Fig.\u0026nbsp;\u003cspan refid=\"Fig1\" class=\"InternalRef\"\u003e1\u003c/span\u003eD \u003cb\u003eand Dataset S6\u003c/b\u003e). Thus, our findings suggest that impaired autophagy crucially contributes to the pathology of FXS, and the protein targets affecting postsynaptic organization in hippocampus may mediate the process. Restoring the impaired autophagy may potentially rescue the synaptic and cognitive deficits.\u003c/p\u003e\u003cp\u003e\u003cb\u003ePharmacological activation of autophagy in hippocampal neurons of\u003c/b\u003e \u003cb\u003eFmr1\u003c/b\u003e \u003cb\u003eKO mice.\u003c/b\u003e\u003c/p\u003e\u003cp\u003eRilmenidine is an FDA-approved, blood-brain barrier (BBB) permeable anti-hypertensive agent by activating ADRA2/a2-adrenoceptors, imidazoline-1 receptors and sympathetic nervous system in the brain \u003csup\u003e\u003cspan citationid=\"CR56\" class=\"CitationRef\"\u003e56\u003c/span\u003e, \u003cspan citationid=\"CR57\" class=\"CitationRef\"\u003e57\u003c/span\u003e\u003c/sup\u003e. In addition, Rilmenidine also activates autophagy, improves energy metabolism, reduces oxidative stress, and affects ageing processes\u003csup\u003e\u003cspan additionalcitationids=\"CR57 CR58\" citationid=\"CR56\" class=\"CitationRef\"\u003e56\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR59\" class=\"CitationRef\"\u003e59\u003c/span\u003e\u003c/sup\u003e. Rilmenidine can significantly activate autophagy in neurons of a Huntington\u0026rsquo;s Disease mouse model and a mutant SOD1-induced amyotrophic lateral sclerosis mouse model\u003csup\u003e\u003cspan citationid=\"CR60\" class=\"CitationRef\"\u003e60\u003c/span\u003e, \u003cspan citationid=\"CR61\" class=\"CitationRef\"\u003e61\u003c/span\u003e\u003c/sup\u003e. Pharmacokinetic assay with HPLC-MS/MS shows after intraperitoneal (\u003cem\u003ei.p.\u003c/em\u003e) injection, Rilmenidine crossed the BBB, leading to comparable concentrations in the brain and plasma (\u003cb\u003eSupplemental Fig.\u0026nbsp;2A, B\u003c/b\u003e). To optimize the dose and timeline for Rilmenidine injection, we tested the dose and time effects of Rilmenidine on autophagy in mouse hippocampus. When autophagy flux is inhibited, the cargo adaptor protein, p62 accumulates\u003csup\u003e\u003cspan additionalcitationids=\"CR37\" citationid=\"CR36\" class=\"CitationRef\"\u003e36\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR38\" class=\"CitationRef\"\u003e38\u003c/span\u003e\u003c/sup\u003e. Two hours post injection, both 10 mg/kg and 100 mg/kg dosages significantly reduced p62 protein levels, indicating activated autophagy in the hippocampus (\u003cb\u003eSupplemental Fig.\u0026nbsp;3A\u003c/b\u003e). Time-course effect indicated that 10 mg/kg of Rilmenidine injection started to significantly reduce p62 levels 2 hr post injection, and the effect lasted until 8 hr post injection (\u003cb\u003eSupplemental Fig.\u0026nbsp;3B\u003c/b\u003e). Thus, to activate autophagy in brain, mice received daily \u003cem\u003ei.p.\u003c/em\u003e injection of Rilmenidine at 10 mg/kg for 1 week\u003csup\u003e\u003cspan citationid=\"CR60\" class=\"CitationRef\"\u003e60\u003c/span\u003e\u003c/sup\u003e (Fig.\u0026nbsp;\u003cspan refid=\"Fig2\" class=\"InternalRef\"\u003e2\u003c/span\u003eA). This treatment did not significantly affect the body weight and length of mice (\u003cb\u003eSupplemental Fig.\u0026nbsp;4\u003c/b\u003e).\u003c/p\u003e\u003cp\u003e\u003c/p\u003e\u003cp\u003eConsistent with the proteomics data, p62 was markedly increased in the hippocampus from \u003cem\u003eFmr1\u003c/em\u003e KO \u003cem\u003evs\u003c/em\u003e. WT mice (Fig.\u0026nbsp;\u003cspan refid=\"Fig2\" class=\"InternalRef\"\u003e2\u003c/span\u003eB, C). Rilmenidine reduced the elevated p62 abundance in \u003cem\u003eFmr1\u003c/em\u003e KO mice to a similar level as WT mice. Immunostaining of p62 with brain sections shows that Rilmenidine reduced the accumulated p62 proteins in CA1 neurons of \u003cem\u003eFmr1\u003c/em\u003e KO mice (Fig.\u0026nbsp;\u003cspan refid=\"Fig2\" class=\"InternalRef\"\u003e2\u003c/span\u003eD, E). Upon initiation of autophagy, LC3-II becomes associated with the autophagosomal membrane and is subsequently degraded in lysosomes as a part of autophagic cargo\u003csup\u003e\u003cspan citationid=\"CR36\" class=\"CitationRef\"\u003e36\u003c/span\u003e\u003c/sup\u003e. We next assessed autophagy flux as rates of LC3-II turnover by comparing LC3-II levels in the presence and absence of lysosomal inhibitors\u003csup\u003e\u003cspan citationid=\"CR62\" class=\"CitationRef\"\u003e62\u003c/span\u003e\u003c/sup\u003e. Net LC3-II flux decreased in hippocampal neurons cultured from \u003cem\u003eFmr1\u003c/em\u003e KO mice \u003cem\u003evs.\u003c/em\u003e WT mice, which was reversed by treating with Rilmenidine (Fig.\u0026nbsp;\u003cspan refid=\"Fig2\" class=\"InternalRef\"\u003e2\u003c/span\u003eF, G). Because neurons lack ability to dilute damaged material through cell division\u003csup\u003e\u003cspan citationid=\"CR63\" class=\"CitationRef\"\u003e63\u003c/span\u003e\u003c/sup\u003e, efficient and quick autophagic degradation of cargos are required to maintain the neuronal health\u003csup\u003e\u003cspan citationid=\"CR63\" class=\"CitationRef\"\u003e63\u003c/span\u003e, \u003cspan citationid=\"CR64\" class=\"CitationRef\"\u003e64\u003c/span\u003e\u003c/sup\u003e. In hippocampal neurons of wild type mice, where autophagy is already efficient in normal condition, Rilmenidine treatment only slightly reduced cargo protein p62 levels (\u003cb\u003eSupplemental Fig.\u0026nbsp;5A-D\u003c/b\u003e). Collectively, these findings indicate that Rilmenidine restores the downregulated autophagy in the hippocampus of \u003cem\u003eFmr1\u003c/em\u003e KO mice.\u003c/p\u003e\u003cp\u003e\u003cb\u003eActivation of autophagy mitigated the aberrant spine and cognitive deficits in\u003c/b\u003e \u003cb\u003eFmr1\u003c/b\u003e \u003cb\u003eKO mice.\u003c/b\u003e\u003c/p\u003e\u003cp\u003eHippocampal neurons of patients with FXS and \u003cem\u003eFmr1\u003c/em\u003e KO mice exhibit an excess of dendritic spines and immature spine morphology\u003csup\u003e\u003cspan citationid=\"CR27\" class=\"CitationRef\"\u003e27\u003c/span\u003e, \u003cspan citationid=\"CR65\" class=\"CitationRef\"\u003e65\u003c/span\u003e\u003c/sup\u003e. To examine the effect of pharmacological activation of autophagy on spine morphology, we first injected \u003cem\u003eFmr1\u003c/em\u003e KO mice and WT mice with Rilmenidine or vehicle as seen in Fig.\u0026nbsp;\u003cspan refid=\"Fig2\" class=\"InternalRef\"\u003e2\u003c/span\u003eA, and assessed dendritic spine morphology (Fig.\u0026nbsp;\u003cspan refid=\"Fig2\" class=\"InternalRef\"\u003e2\u003c/span\u003eH). \u003cem\u003eFmr1\u003c/em\u003e KO mice showed increased spine density on dendrites of CA1 pyramidal neurons compared with WT mice, while Rilmenidine corrected the increased spine density of \u003cem\u003eFmr1\u003c/em\u003e KO mice to near that of WT mice (Fig.\u0026nbsp;\u003cspan refid=\"Fig2\" class=\"InternalRef\"\u003e2\u003c/span\u003eI). Next, we examined the impact of Rilmenidine on spine maturation by classifying spines as stubby and mushroom-shaped (mature) or spindly, filopodial-like protrusions (immature). CA1 neurons from \u003cem\u003eFmr1\u003c/em\u003e KO mice exhibited a marked decrease in the percentage of mushroom/stubby spines and a marked increase in the percentage of long, filopodial-like protrusions, relative to that of WT (Fig.\u0026nbsp;\u003cspan refid=\"Fig2\" class=\"InternalRef\"\u003e2\u003c/span\u003eJ), consistent with previous findings \u003csup\u003e\u003cspan citationid=\"CR23\" class=\"CitationRef\"\u003e23\u003c/span\u003e, \u003cspan citationid=\"CR27\" class=\"CitationRef\"\u003e27\u003c/span\u003e, \u003cspan citationid=\"CR65\" class=\"CitationRef\"\u003e65\u003c/span\u003e\u003c/sup\u003e. Rilmenidine increased the percentage of mature spines of \u003cem\u003eFmr1\u003c/em\u003e KO mice to near WT levels (Fig.\u0026nbsp;\u003cspan refid=\"Fig2\" class=\"InternalRef\"\u003e2\u003c/span\u003eJ). Rilmenidine treatment did not significantly alter the spine density in WT hippocampal CA1 neurons and only slightly reduced percentage of immature spines (\u003cb\u003eSupplemental Fig.\u0026nbsp;5E-G\u003c/b\u003e). Thus, activation of autophagy by Rilmenidine corrected abnormalities in the spine density/morphology of hippocampal neurons in \u003cem\u003eFmr1\u003c/em\u003e KO mice.\u003c/p\u003e\u003cp\u003ePatients with FXS exhibit cognitive deficits\u003csup\u003e\u003cspan citationid=\"CR1\" class=\"CitationRef\"\u003e1\u003c/span\u003e, \u003cspan citationid=\"CR2\" class=\"CitationRef\"\u003e2\u003c/span\u003e, \u003cspan citationid=\"CR66\" class=\"CitationRef\"\u003e66\u003c/span\u003e\u003c/sup\u003e and \u003cem\u003eFmr1\u003c/em\u003e KO mice display deficits in visual memory \u003csup\u003e\u003cspan citationid=\"CR67\" class=\"CitationRef\"\u003e67\u003c/span\u003e, \u003cspan citationid=\"CR68\" class=\"CitationRef\"\u003e68\u003c/span\u003e\u003c/sup\u003e. We next examined the impact of activating autophagy on cognition of \u003cem\u003eFmr1\u003c/em\u003e KO mice. The novel object recognition task assesses visual memory and takes advantage of the innate tendency of wild-type mice to spend more time exploring a novel \u003cem\u003evs.\u003c/em\u003e a familiar object\u003csup\u003e\u003cspan citationid=\"CR69\" class=\"CitationRef\"\u003e69\u003c/span\u003e\u003c/sup\u003e. Vehicle-treated WT mice showed a strong preference for the novel object (Fig.\u0026nbsp;\u003cspan refid=\"Fig2\" class=\"InternalRef\"\u003e2\u003c/span\u003eK, L \u003cb\u003eand Supplemental Fig.\u0026nbsp;6\u003c/b\u003e). \u003cem\u003eFmr1\u003c/em\u003e KO mice injected with vehicle spent approximately equal times exploring the novel and familiar objects, indicating no preference for the novel object and impaired cognition. \u003cem\u003eFmr1\u003c/em\u003e KO mice injected with Rilmenidine spent more time exploring the novel \u003cem\u003evs.\u003c/em\u003e familiar object, indicating preference to novel object and rescued cognition (Fig.\u0026nbsp;\u003cspan refid=\"Fig2\" class=\"InternalRef\"\u003e2\u003c/span\u003eK, L \u003cb\u003eand Supplemental Fig.\u0026nbsp;6\u003c/b\u003e). We next examined the effects of Rilmenidine on contextual memory with the contextual fear condition test. In this assay, mice were exposed to a distinctive environmental context in which they received a shock. On the testing day (24 hr after the shock), they were returned to either the same (familiar) or a different (novel) context (Fig.\u0026nbsp;\u003cspan refid=\"Fig2\" class=\"InternalRef\"\u003e2\u003c/span\u003eM). \u003cem\u003eFmr1\u003c/em\u003e KO mice exhibited profound memory deficits on the testing day, as evidenced by lack of freezing response in the familiar context (Fig.\u0026nbsp;\u003cspan refid=\"Fig2\" class=\"InternalRef\"\u003e2\u003c/span\u003eN). \u003cem\u003eFmr1\u003c/em\u003e KO mice treated with Rilmenidine indicated a significantly higher percentage of freezing in the familiar context on testing day, comparable to \u003cem\u003eFmr1\u003c/em\u003e KO mice treated with the vehicle, demonstrating that activating autophagy enhanced the memory of the association between context and an aversive event. In addition to cognitive tests, effects of Rilmenidine on other behavioral deficits reported with \u003cem\u003eFmr1\u003c/em\u003e KO mice were also examined\u003csup\u003e\u003cspan citationid=\"CR25\" class=\"CitationRef\"\u003e25\u003c/span\u003e, \u003cspan citationid=\"CR70\" class=\"CitationRef\"\u003e70\u003c/span\u003e\u003c/sup\u003e. Rilmenidine treatment failed to rescue the impaired nest building behavior (\u003cb\u003eSupplemental Fig.\u0026nbsp;7A, B\u003c/b\u003e) and the increased center time (open field test, \u003cb\u003eSupplemental Fig.\u0026nbsp;7C, D\u003c/b\u003e) of \u003cem\u003eFmr1\u003c/em\u003e KO mice. \u003cem\u003eFmr1\u003c/em\u003e KO mice exhibited higher levels of self-grooming, a repetitive behavior\u003csup\u003e\u003cspan citationid=\"CR70\" class=\"CitationRef\"\u003e70\u003c/span\u003e\u003c/sup\u003e, which are significantly reduced by Rilmenidine (\u003cb\u003eSupplemental Fig.\u0026nbsp;7E\u003c/b\u003e). Collectively, Rilmenidine corrected abnormalities in spine density/structure and cognitive deficits associated with \u003cem\u003eFmr1\u003c/em\u003e KO mice.\u003c/p\u003e\u003cp\u003e\u003cb\u003eThe rescuing effects on FXS phenotypes rely on activation of autophagy in neurons.\u003c/b\u003e\u003c/p\u003e\u003cp\u003eTo identify the role of dysfunctional autophagy in cognitive deficits in FXS, we first knocked down \u003cem\u003eAtg\u003c/em\u003e7 (autophagy-related 7 gene), a key component of autophagy, in hippocampal neurons of wild type mice and then observed their cognitive behaviors. Adino-associated virus (AAV) expressing Syn-Cre-GFP were injected bilaterally to hippocampus of wild type (\u003cem\u003eAtg7\u003c/em\u003e\u003csup\u003ew/w\u003c/sup\u003e), heterozygous \u003cem\u003eAtg7\u003c/em\u003e floxed (f) mice (\u003cem\u003eAtg7\u003c/em\u003e\u003csup\u003ew/f\u003c/sup\u003e), and homozygous \u003cem\u003eAtg7\u003c/em\u003e\u003csup\u003ef/f\u003c/sup\u003e mice (\u003cb\u003eSupplemental Fig.\u0026nbsp;8A-C)\u003c/b\u003e. The expression of Cre significantly reduced ATG7 protein level and increased p62 levels in hippocampus of both heterozygous \u003cem\u003eAtg7\u003c/em\u003e\u003csup\u003ew/f\u003c/sup\u003e and homozygous \u003cem\u003eAtg7\u003c/em\u003e\u003csup\u003ef/f\u003c/sup\u003e mice, indicating compromised autophagy (\u003cb\u003eSupplemental Fig.\u0026nbsp;8D-F)\u003c/b\u003e. Hippocampal neuronal knockdown of \u003cem\u003eAtg\u003c/em\u003e7 induced deficits in the visual memory of \u003cem\u003eFmr1\u003c/em\u003e KO mice, demonstrated by the decreased preference to the novel object (\u003cb\u003eSupplemental Fig.\u0026nbsp;8G-I)\u003c/b\u003e. Expression of Cre in hippocampal neurons also lead to decreased freezing response in both heterozygous \u003cem\u003eAtg7\u003c/em\u003e\u003csup\u003ew/f\u003c/sup\u003e and homozygous \u003cem\u003eAtg7\u003c/em\u003e\u003csup\u003ef/f\u003c/sup\u003e mice, indicating cognitive deficits (\u003cb\u003eSupplemental Fig.\u0026nbsp;8J\u003c/b\u003e). Thus, knockdown of \u003cem\u003eAtg\u003c/em\u003e7 in hippocampal neurons leads to similar cognitive deficits as observed in FXS, suggesting that dysfunctional autophagy in hippocampal neurons plays a critical role in this process.\u003c/p\u003e\u003cp\u003eRilmenidine activates autophagy and affects several cellular processes, downstream of imidazoline receptors\u003csup\u003e\u003cspan citationid=\"CR56\" class=\"CitationRef\"\u003e56\u003c/span\u003e, \u003cspan citationid=\"CR71\" class=\"CitationRef\"\u003e71\u003c/span\u003e\u003c/sup\u003e. To distinguish the contribution of neuronal autophagy to the rescuing effect of Rilmenidine, we next examined whether neuron-specific knockdown of \u003cem\u003eAtg7\u003c/em\u003e can reverse the drug-induced rescue. To do so, we bred WT or \u003cem\u003eFmr1\u003c/em\u003e KO (\u003cem\u003eFmr1\u003c/em\u003e\u003csup\u003e\u0026minus;/y\u003c/sup\u003e) mice with \u003cem\u003eAtg7\u003c/em\u003e\u003csup\u003ef/f\u003c/sup\u003e mice and Synapsin1-Cre mice (\u003cem\u003eCre\u003c/em\u003e\u003csup\u003e\u003cem\u003e+/\u0026minus;\u003c/em\u003e\u003c/sup\u003e), resulting in WT and \u003cem\u003eFmr1\u003c/em\u003e KO mice with neuron-specific \u003cem\u003eAtg7\u003c/em\u003e knockout (Fig.\u0026nbsp;\u003cspan refid=\"Fig3\" class=\"InternalRef\"\u003e3\u003c/span\u003eA). From these crosses, we obtained the compound mice, termed WT: \u003cem\u003eCre\u003c/em\u003e\u003csup\u003e\u0026minus;/\u0026minus;\u003c/sup\u003e: \u003cem\u003eAtg7\u003c/em\u003e\u003csup\u003ef/f\u003c/sup\u003e (as WT control), \u003cem\u003eFmr1\u003c/em\u003e\u003csup\u003e\u0026minus;/y\u003c/sup\u003e: \u003cem\u003eCre\u003c/em\u003e\u003csup\u003e\u0026minus;/\u0026minus;\u003c/sup\u003e: \u003cem\u003eAtg7\u003c/em\u003e\u003csup\u003ef/f\u003c/sup\u003e (as \u003cem\u003eFmr1\u003c/em\u003e KO control), and \u003cem\u003eFmr1\u003c/em\u003e\u003csup\u003e\u0026minus;/y\u003c/sup\u003e: \u003cem\u003eCre\u003c/em\u003e\u003csup\u003e+/\u0026minus;\u003c/sup\u003e: \u003cem\u003eAtg7\u003c/em\u003e\u003csup\u003ef/f\u003c/sup\u003e (\u003cem\u003eFmr1\u003c/em\u003e KO mice with neuron-specific \u003cem\u003eAtg7\u003c/em\u003e knockout). We then injected Rilmenidine or vehicle into these mice as in Fig.\u0026nbsp;\u003cspan refid=\"Fig2\" class=\"InternalRef\"\u003e2\u003c/span\u003eA. \u003cem\u003eAtg7\u003c/em\u003e knockout was confirmed with reduced ATG7 protein expression in hippocampal tissues of the \u003cem\u003eFmr1\u003c/em\u003e\u003csup\u003e\u0026minus;/y\u003c/sup\u003e: \u003cem\u003eCre\u003c/em\u003e\u003csup\u003e+/\u0026minus;\u003c/sup\u003e: \u003cem\u003eAtg7\u003c/em\u003e\u003csup\u003ef/f\u003c/sup\u003e mice (\u003cb\u003eSupplemental Fig.\u0026nbsp;9\u003c/b\u003e). Then, we examined autophagy activity in the hippocampus. \u003cem\u003eFmr1\u003c/em\u003e KO control mice (\u003cem\u003eFmr1\u003c/em\u003e\u003csup\u003e\u0026minus;/y\u003c/sup\u003e: \u003cem\u003eCre\u003c/em\u003e\u003csup\u003e\u0026minus;/\u0026minus;\u003c/sup\u003e: \u003cem\u003eAtg7\u003c/em\u003e\u003csup\u003ef/f\u003c/sup\u003e) injected with the vehicle showed increased p62 levels in hippocampal tissues \u003cem\u003evs.\u003c/em\u003e WT controls (WT: \u003cem\u003eCre\u003c/em\u003e\u003csup\u003e\u0026minus;/\u0026minus;\u003c/sup\u003e: \u003cem\u003eAtg7\u003c/em\u003e\u003csup\u003ef/f\u003c/sup\u003e) injected with the vehicle (Fig.\u0026nbsp;\u003cspan refid=\"Fig3\" class=\"InternalRef\"\u003e3\u003c/span\u003eB, C). Rilmenidine significantly reduced p62 protein levels in \u003cem\u003eFmr1\u003c/em\u003e KO control (\u003cem\u003eFmr1\u003c/em\u003e\u003csup\u003e\u0026minus;/y\u003c/sup\u003e: \u003cem\u003eCre\u003c/em\u003e\u003csup\u003e\u0026minus;/\u0026minus;\u003c/sup\u003e: \u003cem\u003eAtg7\u003c/em\u003e\u003csup\u003ef/f\u003c/sup\u003e) mice but failed to do so when \u003cem\u003eAtg7\u003c/em\u003e is neuron-specifically knocked out (\u003cem\u003eFmr1\u003c/em\u003e\u003csup\u003e\u0026minus;/y\u003c/sup\u003e: \u003cem\u003eCre\u003c/em\u003e\u003csup\u003e+/\u0026minus;\u003c/sup\u003e: \u003cem\u003eAtg7\u003c/em\u003e\u003csup\u003ef/f\u003c/sup\u003e). Rilmenidine successfully corrected the increased spine density of \u003cem\u003eFmr1\u003c/em\u003e KO mice but failed to do so in the \u003cem\u003eFmr1\u003c/em\u003e KO mice with neuron-specific \u003cem\u003eAtg7\u003c/em\u003e knockout (Fig.\u0026nbsp;\u003cspan refid=\"Fig3\" class=\"InternalRef\"\u003e3\u003c/span\u003eD, E). Moreover, Rilmenidine failed to increase the percentage of mature spines in the \u003cem\u003eFmr1\u003c/em\u003e KO mice with neuron-specific \u003cem\u003eAtg7\u003c/em\u003e knockout (Fig.\u0026nbsp;\u003cspan refid=\"Fig3\" class=\"InternalRef\"\u003e3\u003c/span\u003eD, F). Behavioral tests indicated that Rilmenidine administration significantly improved cognition as measured by novel object recognition (Fig.\u0026nbsp;\u003cspan refid=\"Fig3\" class=\"InternalRef\"\u003e3\u003c/span\u003eG, H, I) and contextual fear conditioning (Fig.\u0026nbsp;\u003cspan refid=\"Fig3\" class=\"InternalRef\"\u003e3\u003c/span\u003eJ) and in \u003cem\u003eFmr1\u003c/em\u003e KO control mice but not in \u003cem\u003eFmr1\u003c/em\u003e KO mice with neuron-specific \u003cem\u003eAtg7\u003c/em\u003e knockout. Thus, inhibition of autophagy in neurons largely compromised the rescue effects, indicating that the rescuing relies on activation of autophagy in neurons.\u003c/p\u003e\u003cp\u003e\u003c/p\u003e\u003cp\u003e\u003cb\u003eIdentification of downstream protein targets mediating autophagy\u0026rsquo;s rescuing effects.\u003c/b\u003e\u003c/p\u003e\u003cp\u003eTo investigate the mechanisms underlying how activated autophagy regulates spine density/morphology, we conducted proteomics to profile the altered proteins in hippocampus of \u003cem\u003eFmr1\u003c/em\u003e KO mice injected with Rilmenidine. Indeed, we identified 549 proteins that significantly increased in the hippocampus of \u003cem\u003eFmr1\u003c/em\u003e KO mice \u003cem\u003evs.\u003c/em\u003e WT mice (Fig.\u0026nbsp;\u003cspan refid=\"Fig4\" class=\"InternalRef\"\u003e4\u003c/span\u003eA). Importantly, 42 of these 549 proteins were successfully reduced by Rilmenidine in \u003cem\u003eFmr1\u003c/em\u003e KO mice (Fig.\u0026nbsp;\u003cspan refid=\"Fig4\" class=\"InternalRef\"\u003e4\u003c/span\u003eB), and identified as direct or indirect targets of autophagic protein degradation as being significantly upregulated by the autophagy inhibitor in WT mice (Fig.\u0026nbsp;\u003cspan refid=\"Fig4\" class=\"InternalRef\"\u003e4\u003c/span\u003eC). Thus, these overlapped 42 proteins (Fig.\u0026nbsp;\u003cspan refid=\"Fig4\" class=\"InternalRef\"\u003e4\u003c/span\u003eD, \u003cb\u003eDataset S7\u003c/b\u003e, and labeled in Fig.\u0026nbsp;\u003cspan refid=\"Fig4\" class=\"InternalRef\"\u003e4\u003c/span\u003eA, B, \u003cb\u003eand C\u003c/b\u003e) may serve as the downstream targets of autophagy to rescue the synaptic and cognitive deficits of FXS. GO biological process analysis confirmed that these 42 proteins play important roles in neurons and synapses. \u0026ldquo;Glutamate secretion\u0026rdquo;, \u0026ldquo;Ionotropic glutamate receptor signaling pathway\u0026rdquo;, \u0026ldquo;Neuron recognition\u0026rdquo;, \u0026ldquo;Cell morphogenesis involved in neuron differentiation\u0026rdquo; and \u0026ldquo;Neuron projection morphogenesis\u0026rdquo; are among the most significant categories (Fig.\u0026nbsp;\u003cspan refid=\"Fig4\" class=\"InternalRef\"\u003e4\u003c/span\u003eE, \u003cb\u003eDataset S8\u003c/b\u003e). To further identify the relevance of these 42 proteins with autism-related synaptic and behavioral deficits, we searched the SFARI Gene database. Searching results revealed that mutations of 7 among these 42 genes (\u003cem\u003eDlg4, Eif4g1, G3bp2, Ntrk2, Rap1gap, Psmd6 and Cpeb4\u003c/em\u003e, as shown in Fig.\u0026nbsp;\u003cspan refid=\"Fig4\" class=\"InternalRef\"\u003e4\u003c/span\u003eF) are associated with autism cases and \u003cem\u003eDlg4\u003c/em\u003e (encoding PSD-95 protein) and \u003cem\u003eEif4g1\u003c/em\u003e (encoding eIF4G1 protein) are reported with the highest numbers of autism cases (Fig.\u0026nbsp;\u003cspan refid=\"Fig4\" class=\"InternalRef\"\u003e4\u003c/span\u003eF). According to the literature, PSD-95, eIF4G1, G3BP2, NTRK2, Rap1GAP, and CPEB4, may potentially be degraded by autophagy, because they can be ubiquitinated\u003csup\u003e\u003cspan additionalcitationids=\"CR73 CR74 CR75 CR76\" citationid=\"CR72\" class=\"CitationRef\"\u003e72\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR77\" class=\"CitationRef\"\u003e77\u003c/span\u003e\u003c/sup\u003e and autophagy degrades ubiquitinated proteins\u003csup\u003e\u003cspan citationid=\"CR78\" class=\"CitationRef\"\u003e78\u003c/span\u003e\u003c/sup\u003e. Thus, dysregulated PSD-95 and eIF4G1 may play strong roles in inducing autistic symptoms and behavioral deficits.\u003c/p\u003e\u003cp\u003e\u003c/p\u003e\u003cp\u003eTo validate the proteomic changes of PSD-95 and eIF4G1 in neurons, we performed Western blot analysis in cultured hippocampal neurons (\u003cb\u003eSupplemental Fig.\u0026nbsp;10A\u003c/b\u003e). Consistent with the proteomics data, PSD-95 and eIF4G1 protein levels are significantly increased in \u003cem\u003eFmr1\u003c/em\u003e KO \u003cem\u003evs.\u003c/em\u003e WT hippocampal neurons and decreased by Rilmenidine (\u003cb\u003eSupplemental Fig.\u0026nbsp;10B\u003c/b\u003e). Autophagy degrades ubiquitinated proteins\u003csup\u003e\u003cspan citationid=\"CR78\" class=\"CitationRef\"\u003e78\u003c/span\u003e\u003c/sup\u003e and downregulated autophagy in mouse brain is associated with accumulated ubiquitinated proteins\u003csup\u003e\u003cspan citationid=\"CR49\" class=\"CitationRef\"\u003e49\u003c/span\u003e\u003c/sup\u003e. Indeed, both total (Input) and ubiquitinated (IP) PSD-95 and eIF4G1 are increased in cultured hippocampal neurons when autophagy is inhibited by chemical inhibitors (Fig.\u0026nbsp;\u003cspan refid=\"Fig4\" class=\"InternalRef\"\u003e4\u003c/span\u003eG-J \u003cb\u003eand Supplemental Fig.\u0026nbsp;11\u003c/b\u003e), indicating that PSD-95 and eIF4G1 are direct protein targets of autophagic protein degradation. Neurons from \u003cem\u003eFmr1\u003c/em\u003e KO mice exhibited markedly elevated total and ubiquitinated PSD-95 and eIF4G1 (Fig.\u0026nbsp;\u003cspan refid=\"Fig4\" class=\"InternalRef\"\u003e4\u003c/span\u003eG-J), indicating that ubiquitinated PSD-95 and eIF4G1 are not degraded efficiently in \u003cem\u003eFmr1\u003c/em\u003e KO neurons. Rilmenidine treatment significantly accelerated the degradation of PSD-95 and eIF4G1, shown by both decreased total and ubiquitinated PSD-95 and eIF4G1 proteins in \u003cem\u003eFmr1\u003c/em\u003e KO neurons (Fig.\u0026nbsp;\u003cspan refid=\"Fig4\" class=\"InternalRef\"\u003e4\u003c/span\u003eG-J, \u003cb\u003eand Supplemental Fig.\u0026nbsp;11\u003c/b\u003e). In \u003cem\u003eFmr1\u003c/em\u003e KO mice with neuron-specific autophagy inhibition (\u003cem\u003eAtg7\u003c/em\u003e knockout), Rilmenidine failed to reduce the levels of PSD-95 and eIF4G1 proteins in the hippocampus (\u003cb\u003eSupplemental Fig.\u0026nbsp;12\u003c/b\u003e), further indicating that the Rilmenidine-induced degradation of PSD-95 and eIF4G1 requires autophagy. mRNA levels of PSD-95 and eIF4G1 were not affected by Rilmenidine, excluding the possibility that the altered protein levels are caused by changes in mRNAs (\u003cb\u003eSupplemental Fig.\u0026nbsp;13\u003c/b\u003e). Altogether, these results indicate that eIF4G1 and PSD-95 are downstream targets of autophagy and may be responsible for the regulation on synaptic morphology. PSD-95 is a synaptic scaffolding protein crucially contributing to the stabilization and organization of postsynaptic structure, as many neurotransmitter receptors and postsynaptic cytoskeleton molecules are anchored to it\u003csup\u003e\u003cspan citationid=\"CR23\" class=\"CitationRef\"\u003e23\u003c/span\u003e, \u003cspan citationid=\"CR79\" class=\"CitationRef\"\u003e79\u003c/span\u003e, \u003cspan citationid=\"CR80\" class=\"CitationRef\"\u003e80\u003c/span\u003e\u003c/sup\u003e. When PSD-95 is upregulated, it leads to an overabundance of immature spines in hippocampal neurons\u003csup\u003e\u003cspan citationid=\"CR23\" class=\"CitationRef\"\u003e23\u003c/span\u003e, \u003cspan citationid=\"CR79\" class=\"CitationRef\"\u003e79\u003c/span\u003e\u003c/sup\u003e. We previously reported that decreasing the PSD-95 levels by genetic manipulation of mTORC1 is associated with reduced spine density and increased maturation in hippocampal neurons\u003csup\u003e\u003cspan citationid=\"CR23\" class=\"CitationRef\"\u003e23\u003c/span\u003e\u003c/sup\u003e. Results from the current study indicated that Rilmenidine significantly reduces the PSD-95 level in the spine area (\u003cb\u003eSupplemental Fig.\u0026nbsp;14\u003c/b\u003e), demonstrating that degrading PSD-95 to affect postsynaptic stability is one pivotal mechanism through which autophagy rescues spine deficits in FXS.\u003c/p\u003e\u003cp\u003e\u003cb\u003eActivation of autophagy degrades eIF4G1 to regulate actin dynamics in spines.\u003c/b\u003e\u003c/p\u003e\u003cp\u003eWe next explored the role of eIF4G1 in autophagic regulation of spine morphology. Our results indicate that the protein level of eIF4G1 in \u003cem\u003eFmr1\u003c/em\u003e KO neurons is increased in the soma (Fig.\u0026nbsp;\u003cspan refid=\"Fig5\" class=\"InternalRef\"\u003e5\u003c/span\u003eA \u003cb\u003eand B\u003c/b\u003e), dendrites, and spines of neurons (Fig.\u0026nbsp;\u003cspan refid=\"Fig5\" class=\"InternalRef\"\u003e5\u003c/span\u003eC \u003cb\u003eand D\u003c/b\u003e). Importantly, the increase in spine area is more significant than in soma (increased by 276% in spines \u003cem\u003evs.\u003c/em\u003e 43% in soma), suggesting that eIF4G1 may locally mediate autophagy\u0026rsquo;s regulation on spine morphology. The spine structure and morphology are majorly supported and determined by polymeric filamentous actin (F-actin), and Cofilin1 protein critically and directly catalyze depolymerization of F-actin to monomeric G-actin (actin dynamics) to destabilize spines and modify spine morphology\u003csup\u003e\u003cspan citationid=\"CR35\" class=\"CitationRef\"\u003e35\u003c/span\u003e, \u003cspan citationid=\"CR81\" class=\"CitationRef\"\u003e81\u003c/span\u003e, \u003cspan citationid=\"CR82\" class=\"CitationRef\"\u003e82\u003c/span\u003e\u003c/sup\u003e. Ras-related C3 botulinum toxin substrate 1 (Rac1) is an upstream regulator of Cofilin1 activity by inducing serine-3 phosphorylation of Cofilin1, primarily through p21-activated kinase (PAK)/LIM kinase, as well as through forming the Rac1-WAVE regulatory complex\u003csup\u003e\u003cspan citationid=\"CR30\" class=\"CitationRef\"\u003e30\u003c/span\u003e, \u003cspan citationid=\"CR83\" class=\"CitationRef\"\u003e83\u003c/span\u003e\u003c/sup\u003e. eIF4G1 has been recently shown to crucially affect the assembly of Rac1-WAVE complex and downstream actin dynamics\u003csup\u003e\u003cspan citationid=\"CR31\" class=\"CitationRef\"\u003e31\u003c/span\u003e, \u003cspan citationid=\"CR84\" class=\"CitationRef\"\u003e84\u003c/span\u003e\u003c/sup\u003e. The assembled Rac1-WAVE complex inactivates Cofilin1 by phosphorylating serine-3 residue and slows down the F-actin depolymerization \u003csup\u003e\u003cspan citationid=\"CR30\" class=\"CitationRef\"\u003e30\u003c/span\u003e, \u003cspan citationid=\"CR83\" class=\"CitationRef\"\u003e83\u003c/span\u003e\u003c/sup\u003e. Thus, we hypothesized that activated autophagy degrades eIF4G1, reducing the interaction between eIF4G1 with eIF4E, to release eIF4E (Fig.\u0026nbsp;\u003cspan refid=\"Fig5\" class=\"InternalRef\"\u003e5\u003c/span\u003eE). The released eIF4E sequesters cytoplasmic FMRP-interacting protein 1 (CYFIP1), the essential component of Rac1\u0026ndash;WAVE regulatory complex, and subsequently halt the assembly of Rac1-WAVE complex, which reduces Cofilin1 phosphorylation and enhances F-actin depolymerization (Fig.\u0026nbsp;\u003cspan refid=\"Fig5\" class=\"InternalRef\"\u003e5\u003c/span\u003eE) \u003csup\u003e\u003cspan citationid=\"CR31\" class=\"CitationRef\"\u003e31\u003c/span\u003e, \u003cspan citationid=\"CR85\" class=\"CitationRef\"\u003e85\u003c/span\u003e\u003c/sup\u003e. Indeed, knockdown of eIF4G1 with shRNA in neurons significantly reduced the binding of eIF4G1 with eIF4E (\u003cb\u003eSupplemental Fig.\u0026nbsp;15A-E\u003c/b\u003e), and enhanced the binding of eIF4E with CYFIP1(\u003cb\u003eSupplemental Fig.\u0026nbsp;15A, F\u003c/b\u003e), indicating that manipulating eIF4G1 protein levels is able to affect the interaction of eIF4E/CYFIP1 to potentially regulate Rac1\u0026ndash;WAVE regulatory complex. Thus, we next examined the binding of eIF4E with eIF4G1 or CYFIP1 through co-immunoprecipitation in hippocampal tissues of WT and \u003cem\u003eFmr1\u003c/em\u003e KO mice with/without Rilmenidine treatment (Fig.\u0026nbsp;\u003cspan refid=\"Fig5\" class=\"InternalRef\"\u003e5\u003c/span\u003eF). The input protein level of eIF4G1 in vehicle-treated \u003cem\u003eFmr1\u003c/em\u003e KO mice (\u003cem\u003eFmr1\u003c/em\u003e KO) is significantly higher than vehicle-treated WT mice (WT) (\u003cb\u003eSupplemental Fig.\u0026nbsp;16A\u003c/b\u003e). Consistently, there is more eIF4G1 immunoprecipitated with eIF4E in \u003cem\u003eFmr1\u003c/em\u003e KO \u003cem\u003evs\u003c/em\u003e. WT mice, indicating an enhanced binding of eIF4E with eIF4G1 (Fig.\u0026nbsp;\u003cspan refid=\"Fig5\" class=\"InternalRef\"\u003e5\u003c/span\u003eG). Rilmenidine reduced the level of eIF4G1 in both input (\u003cb\u003eSupplemental Fig.\u0026nbsp;16A\u003c/b\u003e) and immunoprecipitants with eIF4E (Fig.\u0026nbsp;\u003cspan refid=\"Fig5\" class=\"InternalRef\"\u003e5\u003c/span\u003eG), indicating that, by degrading eIF4G1, Rilmenidine treatment releases eIF4E from its binding with eIF4G1 in \u003cem\u003eFmr1\u003c/em\u003e KO mice. Subsequently, although there is a marginally lower level of total CYFIP1 in \u003cem\u003eFmr1\u003c/em\u003e KO mice (\u003cb\u003eSupplemental Fig.\u0026nbsp;16B\u003c/b\u003e), more CYFIP1 proteins are co-immunoprecipitated with eIF4E in Rilmenidine treated \u003cem\u003evs.\u003c/em\u003e vehicle treated \u003cem\u003eFmr1\u003c/em\u003e KO mice (Fig.\u0026nbsp;\u003cspan refid=\"Fig5\" class=\"InternalRef\"\u003e5\u003c/span\u003eH), indicating that the released eIF4E from eIF4G1 binds and sequesters CYFIP1. We then used PAK-PBD beads to pull down Rac1-associated components of the Rac1-WAVE complex and examined whether sequestering CYFIP1 to eIF4E blocks the binding of CYFIP1 with Rac1 (Fig.\u0026nbsp;\u003cspan refid=\"Fig5\" class=\"InternalRef\"\u003e5\u003c/span\u003eI). The results show that more CYFIP1 was pulled down together with Rac1 in \u003cem\u003eFmr1\u003c/em\u003e KO \u003cem\u003evs.\u003c/em\u003e WT mice, and Rilmenidine significantly reduced the level of CYFIP1 interacting with Rac1 (Fig.\u0026nbsp;\u003cspan refid=\"Fig5\" class=\"InternalRef\"\u003e5\u003c/span\u003eJ, K), indicating that there is less CYFIP1 forming the Rac1\u0026ndash;WAVE regulatory complex in Rilmenidine treated \u003cem\u003eFmr1\u003c/em\u003e KO mice. As the assembly of Rac1\u0026ndash;WAVE complex was suppressed, Rilmenidine treatment subsequently reduced Cofilin1 S-3 phosphorylation in \u003cem\u003eFmr1\u003c/em\u003e KO mice (Fig.\u0026nbsp;\u003cspan refid=\"Fig5\" class=\"InternalRef\"\u003e5\u003c/span\u003eL, M by immunostaining and \u003cb\u003eSupplemental Fig.\u0026nbsp;17\u003c/b\u003e by Western blot), indicating increased Cofilin1 activity. The F-actin/G-actin ratio in the hippocampal synaptic fraction is increased in \u003cem\u003eFmr1\u003c/em\u003e KO mice \u003cem\u003evs.\u003c/em\u003e WT (Fig.\u0026nbsp;\u003cspan refid=\"Fig5\" class=\"InternalRef\"\u003e5\u003c/span\u003eN, O). As a result of the increased Cofilin1 activity, Rilmenidine significantly reduced the F-actin/G-actin ratio, indicating that Rilmenidine accelerates F-actin depolymerization to affect spine morphology. The direct imaging of F-actin also confirmed that Rilmenidine reduced the F-actin levels in the dendritic area of cultured hippocampal \u003cem\u003eFmr1\u003c/em\u003e KO neurons (Fig.\u0026nbsp;\u003cspan refid=\"Fig5\" class=\"InternalRef\"\u003e5\u003c/span\u003eP, Q). In summary, our findings indicated that autophagic degradation of eIF4G1 elevates Cofilin1 activity and F-actin depolymerization to mediate the rescuing effects on spine density/morphology in FXS.\u003c/p\u003e\u003cp\u003e\u003c/p\u003e\u003cp\u003e\u003cb\u003eBrain Rilmenidine infusion activates hippocampal autophagy and rescues deficits in FXS mice.\u003c/b\u003e\u003c/p\u003e\u003cp\u003eBecause Rilmenidine passes the blood-brain barrier freely as indicated by us and others \u003csup\u003e\u003cspan citationid=\"CR57\" class=\"CitationRef\"\u003e57\u003c/span\u003e\u003c/sup\u003e, systemic \u003cem\u003ei.p.\u003c/em\u003e injection of Rilmenidine activates autophagy in both peripheral tissues and the brain. To estimate the contribution of autophagy in the brain, especially in the hippocampus, to the rescue effects, we directly delivered Rilmenidine daily for 7 days to the lateral ventricles (close to the hippocampus) through cannulation (\u003cb\u003eSupplemental Fig.\u0026nbsp;18A, B\u003c/b\u003e) \u003csup\u003e\u003cspan citationid=\"CR86\" class=\"CitationRef\"\u003e86\u003c/span\u003e\u003c/sup\u003e. Rilmenidine significantly reduced p62 accumulation, indicating activated autophagy in the hippocampus of \u003cem\u003eFmr1\u003c/em\u003e KO mice \u003cem\u003evs. Fmr1\u003c/em\u003e KO mice infused with vehicle (\u003cb\u003eSupplemental Fig.\u0026nbsp;18C, D\u003c/b\u003e). Rilmenidine infusion also significantly reduced the protein levels of PSD-95 and eIF4G1 in the hippocampus of \u003cem\u003eFmr1\u003c/em\u003e KO mice (\u003cb\u003eSupplemental Fig.\u0026nbsp;18C, E, F\u003c/b\u003e). Since the hippocampus is the primary brain region for cognition, we next examined whether central delivery of Rilmenidine rescues the impaired cognition of \u003cem\u003eFmr1\u003c/em\u003e KO mice. Consistent with the results from the systemic injection, Rilmenidine infusion to the lateral ventricles significantly increased the freezing reaction time of \u003cem\u003eFmr1\u003c/em\u003e KO mice, indicating improved cognition (\u003cb\u003eSupplemental Fig.\u0026nbsp;18G\u003c/b\u003e). The infusion of Rilmenidine also improved the visual memory of \u003cem\u003eFmr1\u003c/em\u003e KO mice, demonstrated by increased interaction time with the novel object (\u003cb\u003eSupplemental Fig.\u0026nbsp;18H, I\u003c/b\u003e). Mechanistic analysis indicated that Rilmenidine infusion corrected the increased F-actin/G-actin ratio in the hippocampal synaptic fraction of \u003cem\u003eFmr1\u003c/em\u003e KO mice, which implies that Rilmenidine infusion targets actin assembly for the rescue effect (\u003cb\u003eSupplemental Fig.\u0026nbsp;18J, K\u003c/b\u003e). In general, our results demonstrate that central delivery of Rilmenidine activates autophagy and regulates actin assembly in the hippocampus of \u003cem\u003eFmr1\u003c/em\u003e KO mice, contributing to the rescued cognition.\u003c/p\u003e\u003cp\u003e\u003cb\u003eEffects of activation of autophagy on human FXS neurons.\u003c/b\u003e\u003c/p\u003e\u003cp\u003eCurrently, there are still no clinical trials that can unambiguously show efficacy on FXS, mostly because of the gap between animal models and humans\u003csup\u003e\u003cspan citationid=\"CR3\" class=\"CitationRef\"\u003e3\u003c/span\u003e, \u003cspan citationid=\"CR87\" class=\"CitationRef\"\u003e87\u003c/span\u003e\u003c/sup\u003e. Thus, we next assessed whether autophagy is downregulated in neurons derived from human FXS induced pluripotent stem cells (iPSCs), and neurons from an unaffected male individual were used as control (Fig.\u0026nbsp;\u003cspan refid=\"Fig6\" class=\"InternalRef\"\u003e6\u003c/span\u003eA)\u003csup\u003e\u003cspan citationid=\"CR88\" class=\"CitationRef\"\u003e88\u003c/span\u003e, \u003cspan citationid=\"CR89\" class=\"CitationRef\"\u003e89\u003c/span\u003e\u003c/sup\u003e. The human FXS iPSCs were created from fibroblasts isolated from a male patient diagnosed with FXS (full mutation) and intellectual disability\u003csup\u003e\u003cspan citationid=\"CR88\" class=\"CitationRef\"\u003e88\u003c/span\u003e\u003c/sup\u003e (Fig.\u0026nbsp;\u003cspan refid=\"Fig6\" class=\"InternalRef\"\u003e6\u003c/span\u003eA). As epigenetic silencing of the \u003cem\u003eFmr1\u003c/em\u003e gene in FXS is caused by hypermethylation in its promoter region, we examined methylation on CpG islands in the \u003cem\u003eFmr1\u003c/em\u003e promoter of the iPSCs. The results show that FXS iPSCs have highly methylated CpG islands in the promotor, while the control iPSCs show nearly zero (Fig.\u0026nbsp;\u003cspan refid=\"Fig6\" class=\"InternalRef\"\u003e6\u003c/span\u003eB, \u003cb\u003eDataset S9\u003c/b\u003e). Assessment of \u003cem\u003eFmr1\u003c/em\u003e gene expression with immunostaining of FMRP indicated that there is no FMRP expression in neurons derived from FXS iPSCs, while the neurons from control iPSCs show strong FMRP expression (Fig.\u0026nbsp;\u003cspan refid=\"Fig6\" class=\"InternalRef\"\u003e6\u003c/span\u003eC). Consistent with \u003cem\u003eFmr1\u003c/em\u003e KO mice, neurons derived from FXS iPSCs show increased p62 accumulation \u003cem\u003evs.\u003c/em\u003e control, indicating downregulated autophagy (Fig.\u0026nbsp;\u003cspan refid=\"Fig6\" class=\"InternalRef\"\u003e6\u003c/span\u003eD, E). Rilmenidine treatment significantly reduced the p62 accumulation, indicating activated autophagy. Protein levels of PSD-95 and eIF4G1 are also increased in neurons derived from FXS iPSCs \u003cem\u003evs.\u003c/em\u003e control human neurons (Fig.\u0026nbsp;\u003cspan refid=\"Fig6\" class=\"InternalRef\"\u003e6\u003c/span\u003eF-I). Consistent with the mouse data, PSD-95 and eIF4G1 protein levels are significantly decreased by Rilmenidine (Fig.\u0026nbsp;\u003cspan refid=\"Fig6\" class=\"InternalRef\"\u003e6\u003c/span\u003eF-I). Further, neurons derived from FXS iPSCs show upregulated phosphorylation of Cofilin1 at S3 and increased F-actin/G-actin ratio \u003cem\u003evs\u003c/em\u003e. control, indicating dysregulated actin assembly (\u003cb\u003eSupplemental Fig.\u0026nbsp;19, and\u003c/b\u003e Fig.\u0026nbsp;\u003cspan refid=\"Fig6\" class=\"InternalRef\"\u003e6\u003c/span\u003eJ, K). When activating autophagy \u003cem\u003evia\u003c/em\u003e Rilmenidine, both Cofilin1 phosphorylation and F-actin/G-actin ratio decreased to similar levels as control. F-actin imaging confirmed that Rilmenidine reduced the F-actin levels in the dendritic area of neurons derived from FXS iPSCs (Fig.\u0026nbsp;\u003cspan refid=\"Fig6\" class=\"InternalRef\"\u003e6\u003c/span\u003eL, M). We further validated our major findings with one more iPSC line (FX08-23) derived from a patient with FXS and diagnosis with intellectual disability (\u003cb\u003eSupplemental Fig.\u0026nbsp;20A, B\u003c/b\u003e). \u003csup\u003e\u003cspan citationid=\"CR88\" class=\"CitationRef\"\u003e88\u003c/span\u003e, \u003cspan citationid=\"CR89\" class=\"CitationRef\"\u003e89\u003c/span\u003e\u003c/sup\u003e The results indicated that Rilmenidine treatment significantly reduced p62 accumulation in neurons derived from FX08-23 iPSCs (\u003cb\u003eSupplemental Fig.\u0026nbsp;20C, D\u003c/b\u003e). Protein levels of PSD-95 and eIF4G1 are increased in neurons derived from FX08-23 FXS iPSCs \u003cem\u003evs.\u003c/em\u003e control, which are significantly decreased by Rilmenidine (\u003cb\u003eSupplemental Fig.\u0026nbsp;20E-H\u003c/b\u003e). F-actin imaging indicated that Rilmenidine significantly reduced the F-actin levels in dendritic area of neurons derived from FX08-23 iPSCs (\u003cb\u003eSupplemental Fig.\u0026nbsp;20I-J\u003c/b\u003e). Thus, our results indicated that human FXS neurons show downregulated autophagy and dysregulated actin assembly, and activating autophagy corrected these defects.\u003c/p\u003e\u003cp\u003e\u003c/p\u003e"},{"header":"Discussion","content":"\u003cp\u003eAutophagy plays crucial roles in regulating synaptic structure, development, and plasticity and dysregulated autophagy is involved in many neurological disorders such as autism, stroke, and neurodegenerative diseases \u003csup\u003e\u003cspan citationid=\"CR23\" class=\"CitationRef\"\u003e23\u003c/span\u003e, \u003cspan citationid=\"CR38\" class=\"CitationRef\"\u003e38\u003c/span\u003e, \u003cspan citationid=\"CR39\" class=\"CitationRef\"\u003e39\u003c/span\u003e, \u003cspan additionalcitationids=\"CR91\" citationid=\"CR90\" class=\"CitationRef\"\u003e90\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR92\" class=\"CitationRef\"\u003e92\u003c/span\u003e\u003c/sup\u003e. Autophagy critically affects the stability and morphology of postsynaptic structures \u003csup\u003e\u003cspan citationid=\"CR23\" class=\"CitationRef\"\u003e23\u003c/span\u003e, \u003cspan citationid=\"CR49\" class=\"CitationRef\"\u003e49\u003c/span\u003e, \u003cspan citationid=\"CR50\" class=\"CitationRef\"\u003e50\u003c/span\u003e\u003c/sup\u003e, yet the mechanism remains unclear. Activating autophagy with Rapamycin has been shown to activate the synaptic pruning and ameliorate the social deficits in \u003cem\u003eTsc2\u003c/em\u003e+/\u0026minus; ASD mice \u003csup\u003e\u003cspan citationid=\"CR49\" class=\"CitationRef\"\u003e49\u003c/span\u003e\u003c/sup\u003e. In this study, our findings revealed that activation of autophagy in the hippocampus of \u003cem\u003eFmr1\u003c/em\u003e KO mice rescued the aberrant spine morphology and improved cognition by affecting postsynaptic organization and actin dynamics. Currently, there is still no effective treatment for Fragile X in humans \u003csup\u003e\u003cspan citationid=\"CR87\" class=\"CitationRef\"\u003e87\u003c/span\u003e\u003c/sup\u003e and nearly all targeted treatments failed in clinical trials \u003csup\u003e\u003cspan citationid=\"CR3\" class=\"CitationRef\"\u003e3\u003c/span\u003e, \u003cspan citationid=\"CR87\" class=\"CitationRef\"\u003e87\u003c/span\u003e\u003c/sup\u003e. One explanation is that, because FMRP influences hundreds of proteins and signal pathways, single targeted treatments are insufficient to rescue the complex dysregulated pathways and symptoms in FXS \u003csup\u003e\u003cspan citationid=\"CR87\" class=\"CitationRef\"\u003e87\u003c/span\u003e\u003c/sup\u003e. Thus, it is believed that treatments targeting multiple proteins and pathways are more likely to effectively reverse the multitude of changes in FXS brain \u003csup\u003e\u003cspan citationid=\"CR87\" class=\"CitationRef\"\u003e87\u003c/span\u003e\u003c/sup\u003e. Our findings revealed that, in hippocampus of a FXS mouse model, autophagy degrades multiple protein targets to affect synapse structures and functions on different levels. Among the 42 protein targets, PSD-95 is a scaffolding protein regulating postsynaptic origination and stability \u003csup\u003e\u003cspan citationid=\"CR79\" class=\"CitationRef\"\u003e79\u003c/span\u003e\u003c/sup\u003e, and eIF4G1 regulates assembly of actin filaments, the major cytoskeletal elements of postsynaptic terminals \u003csup\u003e\u003cspan citationid=\"CR28\" class=\"CitationRef\"\u003e28\u003c/span\u003e, \u003cspan citationid=\"CR85\" class=\"CitationRef\"\u003e85\u003c/span\u003e\u003c/sup\u003e. It has been reported that PSD-95 is ubiquitinated by the E3 ligase Mdm2 and degraded by proteasome, when dysregulated, causing increased spine density \u003csup\u003e\u003cspan citationid=\"CR79\" class=\"CitationRef\"\u003e79\u003c/span\u003e\u003c/sup\u003e. Our results show that ubiquitinated PSD-95 is also degraded by autophagy to affect spine stability. In the brains of an autistic mouse model caused by \u003cem\u003eCullin3\u003c/em\u003e gene deficiency, elevated eIF4G1 protein levels lead to increased spine density and impaired social behaviors \u003csup\u003e\u003cspan citationid=\"CR93\" class=\"CitationRef\"\u003e93\u003c/span\u003e\u003c/sup\u003e. In addition to PSD-95 and eIF4G1, it is possible that others of these 42 proteins, such as NTRK2 and CPEB4, are also targets of autophagic degradation and regulate synaptic functions.\u003c/p\u003e\u003cp\u003eAltered dendritic spine density and morphology are associated with many brain disorders, including neuropsychiatric diseases, autism, and neurodegenerative diseases \u003csup\u003e\u003cspan citationid=\"CR94\" class=\"CitationRef\"\u003e94\u003c/span\u003e\u003c/sup\u003e. However, the therapeutic strategy to correct spines in these diseases is still lacking. Dysregulation of autophagy has been extensively reported in neurodevelopmental and neurodegenerative disorders \u003csup\u003e\u003cspan citationid=\"CR23\" class=\"CitationRef\"\u003e23\u003c/span\u003e, \u003cspan citationid=\"CR49\" class=\"CitationRef\"\u003e49\u003c/span\u003e, \u003cspan citationid=\"CR90\" class=\"CitationRef\"\u003e90\u003c/span\u003e, \u003cspan additionalcitationids=\"CR96\" citationid=\"CR95\" class=\"CitationRef\"\u003e95\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR97\" class=\"CitationRef\"\u003e97\u003c/span\u003e\u003c/sup\u003e. It has also been well established that the cytoskeleton system plays critical roles in regulating autophagy through affecting autophagosome biogenesis, trafficking of autophagic components, and other processes \u003csup\u003e\u003cspan citationid=\"CR98\" class=\"CitationRef\"\u003e98\u003c/span\u003e\u003c/sup\u003e. In this study, we revealed a previously unappreciated pathway in which organization of actin cytoskeleton is regulated by autophagy through the degradation of eIF4G1 to affect the WAVE complex, which subsequently affects the stability and morphology of synapses. Several studies have recently reported that inhibition of eIF4G1 affects actin assembly by regulating the competition between eIF4E and Rac1 to bind CYFIP1 \u003csup\u003e28, 31\u003c/sup\u003e. The fact that \u003cem\u003eCyfip1\u003c/em\u003e heterozygote mice mimic key aspects of the Fragile X phenotype, such as overabundance of filopodial spines and exaggerated mGluR-LTD further indicates that eIF4G1-CYFIP1-Rac1-Cofilin1 pathway is critical for the regulation of spine morphology and functions \u003csup\u003e\u003cspan citationid=\"CR85\" class=\"CitationRef\"\u003e85\u003c/span\u003e\u003c/sup\u003e. Besides their role in regulating actin assembly, eIF4G1 and eIF4E are also critical for the initiation of translation \u003csup\u003e\u003cspan citationid=\"CR84\" class=\"CitationRef\"\u003e84\u003c/span\u003e\u003c/sup\u003e. Thus, reduced eIF4E/eIF4G1 binding by Rilmenidine may also affect spine morphology by interfering with protein translation. Pharmacologically inhibiting the interaction between eIF4G1/eIF4E suppressed translation and has been used to affect spine morphology in autism mouse models\u003csup\u003e\u003cspan citationid=\"CR93\" class=\"CitationRef\"\u003e93\u003c/span\u003e, \u003cspan citationid=\"CR99\" class=\"CitationRef\"\u003e99\u003c/span\u003e\u003c/sup\u003e. Our results show that activation of autophagy by Rilmenidine reduced protein synthesis by ~\u0026thinsp;20% in primary hippocampal \u003cem\u003eFmr1\u003c/em\u003e KO neurons (\u003cb\u003eSupplemental Fig.\u0026nbsp;21\u003c/b\u003e). Thus, autophagy may affect spine morphology by regulating both actin assembly and protein translation. Rilmenidine is a classical imidazoline type 1 receptor (I1R/IRAS/Nischarin) agonist in mammals\u003csup\u003e\u003cspan citationid=\"CR100\" class=\"CitationRef\"\u003e100\u003c/span\u003e\u003c/sup\u003e. Nischarin can bind activated PAK1, the Rac1 effector, to inhibit Rac1/PAK1 activation\u003csup\u003e\u003cspan citationid=\"CR101\" class=\"CitationRef\"\u003e101\u003c/span\u003e\u003c/sup\u003e. Since activated Rac1/PAK1 phosphorylates and activates LIM kinase, which directly phosphorylates and inactivates Cofilin1, Rilmenidine may also modulate Cofilin1 and F-actin assembly through Rac1/PAK1 signaling. In addition, Rilmenidine has been reported to stimulate the proapoptotic protein Bax and induce the perturbation of the mitochondrial pathway\u003csup\u003e\u003cspan citationid=\"CR102\" class=\"CitationRef\"\u003e102\u003c/span\u003e\u003c/sup\u003e. Mitochondrial ATP synthase leak in synapses is causally related to the aberrant Fragile X associated spine morphology and behaviors\u003csup\u003e\u003cspan citationid=\"CR22\" class=\"CitationRef\"\u003e22\u003c/span\u003e\u003c/sup\u003e. Thus, potential effects of Rilmenidine on synaptic mitochondrial function should also be considered.\u003c/p\u003e\u003cp\u003eOur results demonstrated that activating autophagy through Rilmenidine treatment largely rescued the cognitive deficits in \u003cem\u003eFmr1\u003c/em\u003e KO FXS mouse model. However, loss of FMRP in FXS impacts\u0026thinsp;~\u0026thinsp;1,000 neuronal mRNAs and complex signal pathways which are critical to neural development, synaptic plasticity, and dendritic spine architecture\u003csup\u003e\u003cspan citationid=\"CR1\" class=\"CitationRef\"\u003e1\u003c/span\u003e, \u003cspan additionalcitationids=\"CR9 CR10 CR11\" citationid=\"CR8\" class=\"CitationRef\"\u003e8\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR12\" class=\"CitationRef\"\u003e12\u003c/span\u003e\u003c/sup\u003e. Many of these pathways independently and synergistically contribute to the diverse phenotypes and deficits observed in FXS. Thus, it is important to emphasize that dysfunctional autophagy in hippocampus is unlikely to be solely responsible for all deficits in FXS. Indeed, we observed that Rilmenidine treatment failed to rescue the deficits of nest building and open field tests associated with \u003cem\u003eFmr1\u003c/em\u003e KO mice. This suggests that effects of Rilmenidine treatment and activated autophagy in other brain regions and related behavioral deficits need to be further examined in future studies. Systemic administration of Rilmenidine may affect other tissues, such as heart and kidney, in addition to brain. Clinical trials show long-term administration of Rilmenidine is effective in both reducing left ventricular mass and decreasing blood pressure by decreasing vascular resistance\u003csup\u003e\u003cspan citationid=\"CR103\" class=\"CitationRef\"\u003e103\u003c/span\u003e, \u003cspan citationid=\"CR104\" class=\"CitationRef\"\u003e104\u003c/span\u003e\u003c/sup\u003e. In the kidney, clinical investigation reveals Rilmenidine reduces microalbuminuria in hypertensive type-2 diabetic patients, as well as preserve renal function during stress-induced high blood pressure\u003csup\u003e\u003cspan citationid=\"CR105\" class=\"CitationRef\"\u003e105\u003c/span\u003e, \u003cspan citationid=\"CR106\" class=\"CitationRef\"\u003e106\u003c/span\u003e\u003c/sup\u003e. Although our results indicated that there was no significant effect of Rilmenidine on body weight and growth of mice (\u003cb\u003eSupplemental Fig.\u0026nbsp;4A, B\u003c/b\u003e), caution still needs to be exercised when considering Rilmenidine as a possible treatment option. To further address translational relevance, we verified dysfunctional autophagy and downstream pathways with human neurons derived from iPSCs generated from two individuals with FXS. While this provides initial validation in a human system, the use of two iPSC lines remains a limitation, as it does not fully capture the variability across individuals with FXS.\u003c/p\u003e\u003cp\u003eIn summary, our study identified a new role of autophagy in actin assembly, spine morphology, and cognitive deficits in \u003cem\u003eFmr1\u003c/em\u003e KO mice. These findings identify autophagy as a therapeutic target for Fragile X syndrome. Dysregulated autophagy and its upstream regulator, mTORC1 signaling are implicated not only in FXS, but also in mouse models of other autism spectrum disorders, including Rett syndrome, \u003cem\u003eTSC, PTEN\u003c/em\u003e, and 16p11.2 deletion\u003csup\u003e\u003cspan citationid=\"CR49\" class=\"CitationRef\"\u003e49\u003c/span\u003e, \u003cspan additionalcitationids=\"CR108\" citationid=\"CR107\" class=\"CitationRef\"\u003e107\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR109\" class=\"CitationRef\"\u003e109\u003c/span\u003e\u003c/sup\u003e. Sulzer and colleagues show that overactivated mTOR suppresses autophagy in the brain of \u003cem\u003eTsc1\u003c/em\u003e\u003csup\u003e\u003cem\u003e+/\u0026minus;\u003c/em\u003e\u003c/sup\u003e and \u003cem\u003eTsc2\u003c/em\u003e\u003csup\u003e\u003cem\u003e+/\u0026minus;\u003c/em\u003e\u003c/sup\u003e mice, and that reduced autophagy impaired spine pruning of spines of cortical layer V pyramidal neurons and induced autistic behaviors\u003csup\u003e\u003cspan citationid=\"CR49\" class=\"CitationRef\"\u003e49\u003c/span\u003e\u003c/sup\u003e. Thus, findings in the present study suggest components of the autophagy pathway may represent promising therapeutic targets, not only for Fragile X syndrome, but also other ASDs.\u003c/p\u003e"},{"header":"MATERIALS AND METHODS","content":"\u003cp\u003e\u003cb\u003eAnimals.\u003c/b\u003e FVB.129P2-Pde6b\u003csup\u003e+\u003c/sup\u003e Tyr\u003csup\u003ec\u0026minus;ch\u003c/sup\u003e\u003cem\u003eFmr1\u003c/em\u003e\u003csup\u003etm1Cgr\u003c/sup\u003e/J (\u003cem\u003eFmr1\u003c/em\u003e KO) mice and FVB.129P2-Pde6b\u003csup\u003e+\u003c/sup\u003e Tyr\u003csup\u003ec\u0026minus;ch\u003c/sup\u003e/AntJ (WT) mice were obtained from The Jackson Laboratory as described. Floxed \u003cem\u003eAtg7\u003c/em\u003e (\u003cem\u003eAtg7\u003c/em\u003e\u003csup\u003eloxp/loxp\u003c/sup\u003e) mice (C57BL/6J background, from Dr. Ana Maria Cuervo\u0026rsquo;s lab in Albert Einstein College of Medicine) and Syn1-Cre mice (B6.Cg-Tg(Syn1-cre)671Jxm/J, Jackson lab, #003966) were bred with FVB background \u003cem\u003eFmr1\u003c/em\u003e KO or WT mice for at least 5 generations. All mice were housed in a standard, pathogen-free animal facility with a 12 hr/12 hr light and dark cycle, and only male mice were used, because Fragile X syndrome is an X-linked disorder. Standard PCR was performed with tail tissues for genotyping\u003csup\u003e\u003cspan citationid=\"CR110\" class=\"CitationRef\"\u003e110\u003c/span\u003e\u003c/sup\u003e. Animal protocols were approved by the Institutional Animal Care and Use Committees of the Cleveland State University and Albert Einstein College of Medicine.\u003c/p\u003e\u003cp\u003e\u003cb\u003eVectors and lentivirus\u003c/b\u003e. pLV-hSyn-RFP (Addgene, #22909) expressing RFP under control of Synapsin1 promoter was packaged into lentivirus with the third-generation system (VSVG, REV, and MDL, all from Addgene) and HEK293T cells (ATCC). Lenti viral vectors expressing shRNA for mouse \u003cem\u003eEif4g1\u003c/em\u003e gene (TRCN0000100577, Sigma) or control non-targeting shRNA (Sigma) were packaged into lentivirus with the second-generation system (psPAX2 and pMD2.G, from Addgene) and HEK293T cells (ATCC). High-titer lentiviral stocks were produced by calcium phosphate\u0026ndash;mediated transfection of HEK293T and purified \u003cem\u003evia\u003c/em\u003e ultra-centrifugation\u003csup\u003e\u003cspan citationid=\"CR86\" class=\"CitationRef\"\u003e86\u003c/span\u003e, \u003cspan citationid=\"CR111\" class=\"CitationRef\"\u003e111\u003c/span\u003e\u003c/sup\u003e. Viral titers were determined by transducing HeLA cells. RFP fluorescence was examined by flow cytometry (Becton Dickinson LSR II Flow Cytometer) 72 hr after transduction. Final virus titer was diluted to 1 x 10\u003csup\u003e6\u003c/sup\u003e transducing units/\u0026micro;l.\u003c/p\u003e\u003cp\u003e\u003cb\u003eCell culture, viral transduction, and immunocytochemistry.\u003c/b\u003e Primary hippocampal neurons were cultured from embryonic 18 (E18) mice, maintained in Neurobasal medium with B-27 supplement and GlutaMAX (Invitrogen), and used at DIV14\u003csup\u003e30\u003c/sup\u003e. Lentivirus expressing hSyn-RFP or shRNAs were added to medium at DIV10. For immunocytochemistry, neurons were fixed with 4% PFA, blocked with 5% normal goat serum (Vector Laboratories), and subjected to reaction with primary antibodies, followed with Alexa Fluor 488, 555 or 647 conjugated secondary antibodies (Invitrogen). After 3 washing with PBS, neurons were mounted with the VECTASHIELD\u0026reg; Antifade Mounting Media (Vector Laboratories) with DAPI. DAPI staining was used to reveal all cells. At least three coverslips per group and multiple areas per coverslip selected on a random basis were used for analysis. ZEISS LSM 980 with Airyscan 2 super-resolution confocal microscope (20 X and 60 X objectives, averaged four times and taken at 0.6 \u0026micro;m depth intervals) was used to obtain consecutive Z section images. Labeled neurons were chosen randomly for quantification and the integrated puncta fluorescent intensity for a given neuron was quantified/normalized to the area of the cell body. All images were processed using the Image J software (NIH). To ensure the comparability between preparations, the same staining procedure were used, and all corresponding groups were included in each experiment. Laser settings of the microscope were uniform across all preparations.\u003c/p\u003e\u003cp\u003e\u003cb\u003eHuman induced pluripotent stem cells (iPSCs) culture and neural differentiation.\u003c/b\u003e Human FXS iPSCs (WC005i-FX11-7) and (WC005i-FX08-23) were created by reprogramming fibroblasts from male patients with FXS, and control iPSCs (WC008i-C603-4) were created from an unaffected male individual as previously reported. iPSCs were purchased from WiCell Research Institute (WI, USA)\u003csup\u003e\u003cspan citationid=\"CR88\" class=\"CitationRef\"\u003e88\u003c/span\u003e\u003c/sup\u003e. According to the providers\u0026rsquo; protocol, the iPSCs were cultured and passaged in a culture medium including mTeSR\u0026trade;1 Medium (Stem Cell Technologies) in plates coated with Growth Factor Reduced Matrigel\u0026trade; (Corning). Neural differentiation of iPSCs was performed according to previously published methods\u003csup\u003e\u003cspan citationid=\"CR112\" class=\"CitationRef\"\u003e112\u003c/span\u003e, \u003cspan citationid=\"CR113\" class=\"CitationRef\"\u003e113\u003c/span\u003e\u003c/sup\u003e. Briefly, iPSCs were dissociated with TrypLE Express (Thermo Fisher Scientific), and plated on Matrigel (Corning)-coated plates in the MEF-conditioned medium with FGF-2 (Waisman Biomanufacturing), and ROCK inhibitor (Tocris Bioscience). When cells grew to nearly confluent, neural differentiation was induced with a medium including: DMEM/F12: Neurobasal medium (50%/50%) (Thermo Fisher Scientific), 200 mM L-Glutamine (Thermo Fisher Scientific), 1% N2 supplement (Thermo Fisher Scientific), 0.5% B-27 supplement minus vitamin A (Thermo Fisher Scientific), and TGFβ/Smad inhibitors (10 \u0026micro;M SB431542 (Selleck) and 100 nM LDN193189 (Selleck)). Cells were then disassociated and re-plated on Matrigel-coated plates with the neural progenitor cell (NPC) medium including: Neurobasal medium (Thermo Fisher Scientific), 1% GlutaMAX (Thermo Fisher Scientific), 1% N2 supplement (Thermo Fisher Scientific), 0.5% B-27 (Thermo Fisher Scientific), 10 ng/ml FGF-2 and 10 \u0026micro;M ROCK inhibitor when plating. For neural differentiation, NPCs were re-plated on Matrigel-coated coverslips in a medium including: Neurobasal medium, 1% GlutaMAX, 1% N2 supplement, 1% B-27 minus Vitamin A, 200 nM ascorbic acid (Sigma), 1 \u0026micro;M cAMP (Sigma), 10 ng/ml BDNF (Cell Sciences), 10 ng/ml GDNF (Cell Sciences), 10 \u0026micro;M ROCK inhibitor, and 0.1 \u0026micro;M Compound E (Calbiochem)\u003csup\u003e\u003cspan citationid=\"CR114\" class=\"CitationRef\"\u003e114\u003c/span\u003e\u003c/sup\u003e. After two weeks, cells were fixed for immunostaining with antibodies for Tuj-1 (Mouse, R\u0026amp;D SYSTEMS), eIF4G1 (Rabbit, Cell Signaling), p62 (Rabbit, MBL) and FMRP (Rabbit, Abcam). Images were acquired using a Nikon confocal microscope.\u003c/p\u003e\u003cp\u003eFor analysis of CpG methylation in \u003cem\u003eFmr1\u003c/em\u003e promoter region, FXS and control iPSCs (20,000 cells for each sample) were collected. The bisulfite treatment of genomic DNA and pyrosequencing analysis of the \u003cem\u003eFmr1\u003c/em\u003e promoter region was performed by EpigenDx Inc (Hopkinton, MA)\u003csup\u003e\u003cspan citationid=\"CR88\" class=\"CitationRef\"\u003e88\u003c/span\u003e, \u003cspan citationid=\"CR115\" class=\"CitationRef\"\u003e115\u003c/span\u003e\u003c/sup\u003e.\u003c/p\u003e\u003cp\u003e\u003cb\u003eCannulation and brain infusion.\u003c/b\u003e As we previously described\u003csup\u003e\u003cspan citationid=\"CR86\" class=\"CitationRef\"\u003e86\u003c/span\u003e, \u003cspan citationid=\"CR111\" class=\"CitationRef\"\u003e111\u003c/span\u003e\u003c/sup\u003e, using an ultra-precise mouse stereotactic frame (KOPF), a 26-gauge guide cannula (Plastics One, Inc.) was implanted into the lateral ventricle of anesthetized mice at the coordinates (Post bregma: 0.4 mm; Lateral to midline: 1 mm; Under bregma: 2 mm). Intra-lateral ventricular infusion was carried out with a 33-gauge internal cannula (Plastics One, Inc.) connected to a 10-\u0026micro;l Hamilton Syringe. Rilmenidine was dissolved in 1 \u0026micro;l artificial cerebrospinal fluid (aCSF) for injection. Injection of aCSF was used as vehicle control.\u003c/p\u003e\u003cp\u003e\u003cb\u003eIn vivo\u003c/b\u003e \u003cb\u003eadeno-associated virus (AAV) injection.\u003c/b\u003e Mice were anesthetized with 4% isoflurane and maintained in anesthesia with 1.5% isoflurane as described \u003csup\u003e\u003cspan citationid=\"CR111\" class=\"CitationRef\"\u003e111\u003c/span\u003e\u003c/sup\u003e. AAV encoding Syn-Cre-GFP (#105540, AAV9 from Addgene) was injected bi-laterally into hippocampus by means of a 10-\u0026micro;l Hamilton syringe with a 26-gauge needle with a stereotaxic frame (KOPF). The injection site was defined by the following coordinates: 2 mm posterior to bregma, 1.6 mm below the surface of the skull, and 1.8 mm lateral to the midline \u003csup\u003e\u003cspan citationid=\"CR111\" class=\"CitationRef\"\u003e111\u003c/span\u003e\u003c/sup\u003e. A total volume of 0.5 uL/ hemisphere at a flow rate of 0.1 \u0026micro;L/min were injected. The incision was closed with cyanoacrylate glue. After injection, animals were placed in a heated cage to recover.\u003c/p\u003e\u003cp\u003e\u003cb\u003eQuantitative RT-PCR.\u003c/b\u003e Total RNAs were isolated from hippocampal tissues using RNeasy\u0026reg; Mini Kit (Qiagen) and reverse-transcribed to cDNA using SuperScript\u0026trade; First-Strand Synthesis System (Thermo Fisher Scientific). RNA concentration was measured by means of a Nanodrop (NanoDrop Technologies). Real-time qPCR was performed with SYBR\u0026trade; Green PCR Master Mix (Thermo Fisher Scientific) for \u003cem\u003eDlg4\u003c/em\u003e (NM_001109752.1) and \u003cem\u003eEif4g1\u003c/em\u003e (NM_001005331), and normalized to \u003cem\u003eβ-actin\u003c/em\u003e (NM_007393). The primers used are: \u003cem\u003eDlg-4, Forward\u003c/em\u003e: 5\u0026rdquo;-TCCGGGAGGTGACCCATTC-3\u0026rsquo;; Reverse, 5\u0026rsquo;-TTTCCGGCGCATGACGTAG-3\u0026rsquo;; \u003cem\u003eEif4g1: Forward\u003c/em\u003e: 5\u0026rdquo;-AAGACCTCATCTCGCATCCG-3\u0026rsquo;; Reverse, 5\u0026rsquo;-TGTTCTCGGTGCTCTTCCATC-3\u0026rsquo;; \u003cem\u003eβ-actin\u003c/em\u003e: Forward, 5\u0026rdquo;-GGCTGTATTCCCCTCCATCG-3\u0026rsquo;; Reverse, 5\u0026rsquo;-CCAGTTGGTAACGCCATGT-3\u0026rsquo;. Reactions were performed in triplicate in a StepOnePlus real-time PCR system (Applied Biosystems)\u003csup\u003e\u003cspan citationid=\"CR34\" class=\"CitationRef\"\u003e34\u003c/span\u003e\u003c/sup\u003e.\u003c/p\u003e\u003cp\u003e\u003cb\u003eGolgi staining, spine morphology, immunolabeling and histology.\u003c/b\u003e The FD Rapid Golgi stain Kit (FD Neurotechnologies, MD, USA) was used to image spine morphology as described\u003csup\u003e\u003cspan citationid=\"CR23\" class=\"CitationRef\"\u003e23\u003c/span\u003e, \u003cspan citationid=\"CR30\" class=\"CitationRef\"\u003e30\u003c/span\u003e\u003c/sup\u003e. In brief, mouse brains were collected, quickly rinsed, immersed in Golgi impregnation solution, and stored in the dark at room temperature for 2 weeks. Brains were then transferred and stored in Solution C for 72 hr, and cut into 150 mm-thick sections with a cryostat at \u0026minus;\u0026thinsp;20\u0026ordm;C. Sections were transferred to microscope slides, rinsed, dehydrated, stained, and cleared. Spines on apical dendrites of hippocampal CA1 pyramidal neurons were imaged by means of a ZEISS LSM 980 with Airyscan 2 super-resolution confocal microscope with a 100 x oil immersion lens. Dendritic spine density was determined by counting the total number of spines along the apical dendrite from the soma to 130 \u0026micro;m distance on primary, secondary, and tertiary branches. Spines were classified as filopodial-like or mushroom-like/stubby in neurons using a categorization macro in Neurolucida software (MBF Bioscience), which excludes thin, branched, and detached spines\u003csup\u003e\u003cspan citationid=\"CR30\" class=\"CitationRef\"\u003e30\u003c/span\u003e, \u003cspan citationid=\"CR65\" class=\"CitationRef\"\u003e65\u003c/span\u003e\u003c/sup\u003e. Five CA1 pyramidal neurons per mouse and eight 10-\u0026micro;m segments per neuron were analyzed.\u003c/p\u003e\u003cp\u003eImmunohistochemistry was performed on frozen brain sections from \u003cem\u003eFmr1\u003c/em\u003e KO and WT mice as described\u003csup\u003e\u003cspan citationid=\"CR23\" class=\"CitationRef\"\u003e23\u003c/span\u003e\u003c/sup\u003e. Mice were anesthetized, transcardially perfused with 4% PFA, and brains were removed, post-fixed for 24 hr, and infiltrated with 20% \u0026ndash; 30% sucrose. 12 \u0026micro;m-thick brain sections were cut, blocked with normal goat serum (Vector Laboratories), incubated with primary antibodies, and then reacted with Alexa Fluor 488 or 555 secondary antibodies (Invitrogen). Na\u0026iuml;ve IgG of the appropriate species was used as a negative control. DAPI staining in mounting medium (Vector Laboratories) was used to reveal all cells in brain sections. Images were acquired using a ZEISS LSM 980 with Airyscan 2 super-resolution confocal microscope. For data analysis, serial brain sections across the hippocampus were made at the thickness of single cell (10 \u0026micro;m), and every 5 sections were represented by one section for staining and quantification. A minimum of three sections per mouse and multiple hippocampal CA1 regions per section were selected on a random basis and used for analysis\u003csup\u003e\u003cspan citationid=\"CR116\" class=\"CitationRef\"\u003e116\u003c/span\u003e\u003c/sup\u003e. Images were taken at 0.6-\u0026micro;m depth intervals. The integrated puncta fluorescent intensity for each given CA1 region was quantified and assessed using Image J software. The same staining procedure was used to ensure the comparability between preparations, and all corresponding groups were included in each experiment. Laser settings of the microscope were uniform across all preparations\u003csup\u003e\u003cspan citationid=\"CR23\" class=\"CitationRef\"\u003e23\u003c/span\u003e\u003c/sup\u003e.\u003c/p\u003e\u003cp\u003e\u003cb\u003eImmunoprecipitation.\u003c/b\u003e Primary neurons were homogenized in ice-cold lysis buffer as described\u003csup\u003e\u003cspan citationid=\"CR23\" class=\"CitationRef\"\u003e23\u003c/span\u003e\u003c/sup\u003e. Hippocampal tissues were isolated from mice 4 hr post treatment and homogenized with a glass homogenizer. Cell and tissue homogenates were incubated with an anti-ubiquitin (Mouse Santa Cruz) antibody or an anti-eIF4E (mouse, Santa Cruz) antibody, and gently shaken overnight at 4\u0026deg;C. Supernatant with antibody was added to a slurry of IgG bound to agarose beads (Protein A/G, Pierce) and incubated with rocking at 25\u0026deg;C for 2 hr. Efficiency of IP was determined by comparing the abundance of immunoprecipitated protein in the supernatant and wash fractions.\u003c/p\u003e\u003cp\u003e\u003cb\u003eSynaptosome preparation.\u003c/b\u003e Briefly, 4 hr post treatment, hippocampus of \u003cem\u003eFmr1\u003c/em\u003e KO and WT mice were removed, quickly rinsed with Milli-Q water, and homogenized in gradient buffer with protease and phosphatase inhibitors\u003csup\u003e\u003cspan citationid=\"CR117\" class=\"CitationRef\"\u003e117\u003c/span\u003e\u003c/sup\u003e. The homogenates were centrifuged at 1000g for 10 min. The supernatant was loaded on a Percoll discontinuous gradient (3%, 10%, 15%, and 23%) and centrifuged at 31,000g for 6 min in a Beckman centrifuge. Synaptosome fractions were collected from the 15\u0026ndash;23% interface and centrifuged again at 20,000g for 10 min. The pellets were resuspended for Western blot. Protein concentrations of collected synaptosome fractions were measured with a BCA kit (Thermo Fisher Scientific).\u003c/p\u003e\u003cp\u003e\u003cb\u003eF-actin imaging.\u003c/b\u003e F-actin in cultured neurons was imaged by a high-affinity F-actin probe, phalloidin conjugated to Alexa Fluor 488 dye (ThermoFisher Scientific)\u003csup\u003e\u003cspan citationid=\"CR118\" class=\"CitationRef\"\u003e118\u003c/span\u003e\u003c/sup\u003e. Briefly, neurons were fixed, permeabilized and incubated with phalloidin staining solution at room temperature for 20 min. After being washed with PBS for 3 times, neurons were mounted with the VECTASHIELD\u0026reg; Antifade Mounting Media (Vector Laboratories) with DAPI. F-actin in neurons were imaged with a Nikon confocal microscope.\u003c/p\u003e\u003cp\u003e\u003cb\u003eTissue preparation, Western blot, and antibodies.\u003c/b\u003e Hippocampal tissue was homogenized in RIPA lysis buffer supplemented with protease inhibitors (Thermo Fisher Scientific) and centrifuged at 12,000g for 10 min at 4\u0026deg;C to collect proteins. Primary neurons were lysed and centrifuged as above. Protein concentrations were measured with the BCA kit (Thermo Fisher Scientific) and Western blot were performed as described\u003csup\u003e\u003cspan citationid=\"CR23\" class=\"CitationRef\"\u003e23\u003c/span\u003e, \u003cspan citationid=\"CR119\" class=\"CitationRef\"\u003e119\u003c/span\u003e\u003c/sup\u003e. Band densities were quantified using Image J (NIH).\u003c/p\u003e\u003cp\u003eMouse hippocampus tissues were homogenized in lysis buffer with protease inhibitors as described in the manual (Cytoskeleton Inc). Large debris was removed by centrifugation at 12,000g (10 min, 4\u0026deg;C). The lysates were then incubated with GST-tagged PAK-PBD beads (Cytoskeleton Inc) for 2 hr at 4\u0026deg;C. GTP-Rac1 and associated proteins were precipitated from the lysates by the PAK-PBD beads. Finally, the beads were washed and resuspended in a SDS sample buffer for Western blot.\u003c/p\u003e\u003cp\u003eF/G-actin ratio in synaptosomes of hippocampus was assessed as previously described\u003csup\u003e\u003cspan citationid=\"CR30\" class=\"CitationRef\"\u003e30\u003c/span\u003e, \u003cspan citationid=\"CR120\" class=\"CitationRef\"\u003e120\u003c/span\u003e\u003c/sup\u003e. Briefly, the synaptosome fractions were resuspended in a cold lysis buffer (10 mM K\u003csub\u003e2\u003c/sub\u003eHPO\u003csub\u003e4\u003c/sub\u003e, 100 mM NaF, 50 mM KCl, 2 mM MgCl\u003csub\u003e2\u003c/sub\u003e, 1 mM EGTA, 0.2 mM DTT, 0.5% Triton X-100, 1 mM sucrose, pH 7.0). Because F-actin is insoluble whereas G-actin is soluble in this buffer, F-actin and G-actin were separated by centrifuge at 15,000g for 30 min. The F-actin pellet was resuspended in the lysis buffer mixed with another buffer (1.5 mM guanidine hydrochloride, 1 mM sodium acetate, 1 mM CaCl\u003csub\u003e2\u003c/sub\u003e, 1 mM ATP, 20 mM Tris-HCl, pH 7.5) at 1:1 and then incubated on ice for 1 hour to convert F-actin into G-actin. The samples containing G-actin converted from F-actin were centrifuged again at 15,000g for 30 min and the supernatant was collected for Western blot.\u003c/p\u003e\u003cp\u003ePrimary antibodies used for Western blot include: rabbit anti-LC3-I/II (Novus), rabbit anti-p62 (MBL), rabbit anti-PSD-95 (Cell Signaling), mouse anti-Ubiquitin (Enzo), rabbit anti-ATG7 (Cell Signaling), rabbit anti-Cofilin1 (Cell Signaling), rabbit anti-phospho-Cofilin1-Ser3 (Cell Signaling), rabbit anti-eIF4G1 (Cell Signaling), rabbit anti-CYFIP1 (Millipore), rabbit anti-eIF4E (Cell Signaling), mouse anti-Rac1 (Millipore), mouse anti-puromycin (DSHB), rabbit anti-GAPDH (Cell Signaling) and rabbit anti-β-actin (Sigma). Antibodies for PSD-95, RFP (Thermo Fisher Scientific), rabbit anti-phospho-Cofilin1-Ser3 (Cell Signaling), rabbit anti-FMRP (Abcam), and eIF4G1 were used for immunocytochemistry with primary antibodies of chicken anti-MAP2 (Millipore) or mouse anti-Tuj-1 (R\u0026amp;D SYSTEMS). Primary antibodies of p62 and mouse anti-NeuN (Millipore) were used for the immunochemistry of brain sections.\u003c/p\u003e\u003cp\u003e\u003cb\u003eSUnSET Assay\u003c/b\u003e. Protein synthesis was assessed with sensing of translation (SUnSET) technique as previously described with modifications\u003csup\u003e\u003cspan citationid=\"CR93\" class=\"CitationRef\"\u003e93\u003c/span\u003e, \u003cspan citationid=\"CR121\" class=\"CitationRef\"\u003e121\u003c/span\u003e\u003c/sup\u003e. Briefly, primary neurons were treated with 5 \u0026micro;g/mL puromycin (Sigma) for 30 min. Protein synthesis was examined as puromycin incorporation in new synthesized proteins of cell lysates by Western-blot using an anti-puromycin antibody (PMY-2A4, DSHB). Western-blot of GAPDH (Cell Signaling) was used as a loading control.\u003c/p\u003e\u003cp\u003e\u003cb\u003eNovel object recognition test.\u003c/b\u003e The novel object recognition task was conducted in an isolated arena (40 cm length x 40 cm width and x 40 cm height)\u003csup\u003e\u003cspan citationid=\"CR69\" class=\"CitationRef\"\u003e69\u003c/span\u003e\u003c/sup\u003e. For habituation before the testing day, mice were allowed to explore the empty arena for 10 min. On the testing day (training and familiarization session), the mouse was placed in the center of the arena between, and equidistant from, two identical objects and allowed to freely explore for 10 min. The mouse was then placed in a holding cage for 24 hr. The next day (test session), one of the objects was replaced with a novel object. The mouse was placed in the arena for an additional 10 min. The time spent exploring each object was recorded by investigators blind to the grouping information with stopwatches. Mice\u0026rsquo;s movements were also recorded with ANY-maze Video Tracking System. Mice that did not spend a minimum of 10 s investigating one or both objects were excluded from the study. The preference index was calculated by dividing the time exploring the novel object by the total time exploring the two objects. Exploration was defined as orienting the nose toward the object with a distance\u0026thinsp;\u0026lt;\u0026thinsp;2 cm between the nose and the object. Resting, grooming, or sitting on the object was not considered as exploration.\u003c/p\u003e\u003cp\u003e\u003cb\u003eContextual fear conditioning.\u003c/b\u003e Cognition test with contextual fear conditioning was performed in a Freezeframe Chamber and analyzed by Actimetrics Software (Actimetrics) as previously described\u003csup\u003e\u003cspan citationid=\"CR69\" class=\"CitationRef\"\u003e69\u003c/span\u003e\u003c/sup\u003e. On the day of fear conditioning (day 1), mice were habituated in chamber 1 for 3 min, followed by two shocks of 0.7 mA (1 s each). Mice then remained in chamber 1 for 15 s after the shock. On day 2, mice were separated into two groups: one group was tested in chamber 1 in the same context with day 1 (familiar context), and the others were tested in chamber 2 with a different (novel) context. The percentage of time that a mouse shows freezing response in the 3 min test session on day 2 was recorded by the software.\u003c/p\u003e\u003cp\u003e\u003cb\u003eNest building assay.\u003c/b\u003e Nest building was assessed as described \u003csup\u003e\u003cspan citationid=\"CR25\" class=\"CitationRef\"\u003e25\u003c/span\u003e, \u003cspan citationid=\"CR122\" class=\"CitationRef\"\u003e122\u003c/span\u003e\u003c/sup\u003e. Mice were single housed with a 2.5g Nestlet and left undisturbed for 24 hours. Nests were assessed on a rating scale of 1\u0026ndash;5 as described before \u003csup\u003e\u003cspan citationid=\"CR122\" class=\"CitationRef\"\u003e122\u003c/span\u003e\u003c/sup\u003e. Untorn nest pieces were weighed.\u003c/p\u003e\u003cp\u003e\u003cb\u003eOpen field and self-grooming tests.\u003c/b\u003e The open field test was performed in a 40 \u0026times; 40 \u0026times; 40 cm\u003csup\u003e\u003cspan citationid=\"CR3\" class=\"CitationRef\"\u003e3\u003c/span\u003e\u003c/sup\u003e arena for 10 mins \u003csup\u003e\u003cspan citationid=\"CR69\" class=\"CitationRef\"\u003e69\u003c/span\u003e\u003c/sup\u003e. The floor of the arena was divided into two zones: an \u0026lsquo;inner\u0026rsquo; zone (containing the inner 25 \u0026times; 25 cm\u003csup\u003e\u003cspan citationid=\"CR2\" class=\"CitationRef\"\u003e2\u003c/span\u003e\u003c/sup\u003e center square) and an \u0026lsquo;outer\u0026rsquo; zone (the outermost area 15 cm from the walls). The times spent in \u0026lsquo;inner\u0026rsquo; zone and \u0026lsquo;outer\u0026rsquo; zone were recorded by investigators blind to the grouping information with stopwatches. Mice\u0026rsquo;s movements were recorded with ANY-maze Video Tracking System. Times spent in self-grooming were also recorded by investigators blind to the grouping information with stopwatches during the test.\u003c/p\u003e\u003cp\u003e\u003cb\u003eHPLC-MS/MS.\u003c/b\u003e The HPLC-MS/MS method was performed with a Shimadzu UPLC system (Columbia, MD), which consisted of a Prominence DGU-20A\u003csub\u003e3R\u003c/sub\u003e inline degasser, two LC-30 AD pumps, a SIL-30 AC autosampler and a CBM-20A controller. The chromatographic separation was performed on a Kinetex C\u003csub\u003e18\u003c/sub\u003e column (50 mm \u0026times; 2.1 mm, 1.3 \u0026micro;m) with a mobile phase consisting of acetonitrile-0.1% formic acid and water (50:50, v/v) at a flow rate of 0.3 ml/min. The temperature of the column was maintained at 36\u0026deg;C. The injection volume was 5.0 \u0026micro;l. Mass spectrometric detection was operated on an AB Sciex Qtrap 5500 mass spectrometer (Toronto, Canada) with negative electrospray ionization mode. The multiple reaction monitoring (MRM) function was used for quantification with the transitions of Rilmenidine and IS trimipramine-d3, which were detected at m/z 180.9\u0026rarr;66.9 and m/z 297.8\u0026rarr;103.2, respectively. The optimized ion source parameters were set as follows: ion spray voltage, 2000 V; ion source temperature, 550\u0026deg;C; nebulization gas 40 psi; auxiliary gas, 40 psi; curtain gas, 30 psi. Compound parameters were as follows: Rilmenidine: declustering potential, 23V; entrance potential, 6.5V; collision energy, 28V; Collision entrance potential, 15V. Trimipramine-d3: declustering potential, 40V; entrance potential, 5V; collision energy, 25V; Collision entrance potential, 15V. The stock solutions were prepared by dissolving Rilmenidine and trimipramine-\u003cem\u003ed3\u003c/em\u003e in methanol at 1.0 mg/ml. Then, the stock solution of Rilmenidine was serially diluted with methanol into a concentration gradient: 0.5, 1.0, 2.0, 5.0, 10, 20, 50, 100, 200, 500, 1000 ng/ml. Also, a 500 ng/ml working solution of trimipramine-\u003cem\u003ed3\u003c/em\u003e (IS) was prepared in methanol from its stock solution. The calibration standards were prepared as follows: after spiking with 100 \u0026micro;l of the corresponding standards solutions, 40 \u0026micro;l of trimipramine-\u003cem\u003ed3\u003c/em\u003e working solution, 100 \u0026micro;l of blank mouse plasma or brain homogenates (0.4 g blank brain tissue mixed with 2 ml PBS), and 800 \u0026micro;l of methanol were transferred into a 1.5 ml tube, and the mixture was then vortexed and centrifuged at 12,000g for 10 min. The supernatant was collected and dried with nitrogen, and then the residue was stored at -80\u0026deg;C and dissolved with 50% acetonitrile before analysis. A protein precipitation method was applied to extract Rilmenidine from mouse plasma and brain homogenate (0.4 g brain tissue mix with 2 ml PBS). Briefly, 100 \u0026micro;l of each sample, 40 \u0026micro;l of trimipramine-\u003cem\u003ed3\u003c/em\u003e (IS, 500 ng/ml), and 800 \u0026micro;l of methanol were combined in a 1.5 ml tube. Then, it was vortexed and centrifuged, and the supernatant was collected and dried with nitrogen as the calibration standard. The residue was stored at -80\u0026deg;C and dissolved with 100 \u0026micro;l 50% acetonitrile before analysis.\u003c/p\u003e\u003cp\u003e\u003cb\u003eProteomics.\u003c/b\u003e Hippocampus were collected from mice 4 hr post treatments., homogenized, and analyzed with a tandem mass tags (TMT) labeling technique by Proteomics \u0026amp; Metabolomics Core, Lerner Research Institute, Cleveland Clinic\u003csup\u003e\u003cspan citationid=\"CR123\" class=\"CitationRef\"\u003e123\u003c/span\u003e\u003c/sup\u003e. Briefly, each of the mouse hippocampus was suspended in 150 \u0026micro;l 8 M urea Tris-HCl pH8 lysis buffer with freshly added protease inhibitor cocktail. Samples were homogenized by ultrasonication 15 s x 3 with 15 s intervals. Homogenized samples were centrifuged at 15000g for 15 min, and the supernatants were transferred to new 1.5 ml tubes. Protein concentrations of the samples were determined by a BCA kit. 50 \u0026micro;g of protein from each sample were taken. The samples were reduced by dithiothreitol, alkylated by iodoacetamide, and precipitated by cold acetone (-20\u0026deg;C) overnight. Samples were centrifuged at 8000g for 5 min at 4\u0026deg;C, and the supernatants were removed. Protein pellets were air-dried, dissolved, digested overnight. Digested peptide samples were labeled with TMTpro 16plex tags according to the protocol from the manufacture\u0026rsquo;s instruction. The Thermo Scientific Fusion Lumos mass spectrometry system with the Dionex 15 cm x 75 \u0026micro;m id Acclaim Pepmap C18, 2\u0026micro;m, 100 \u0026Aring; reversed-phase capillary chromatography column was used. 5 \u0026micro;l volumes of the extract were injected and the peptides eluted from the column by an acetonitrile/0.1% formic acid gradient at a flow rate of 0.3 \u0026micro;l/min were introduced into the source of the mass spectrometer on-line. The digest was analyzed using a TMT-MS2 method. Over 4900 proteins were identified in the samples. The results of proteomics were first subjected to overlap analysis. To assess the significance of the overlap between the protein lists, hypergeometric tests were performed. The hypergeometric distribution models show the probability of the number of overlapping genes between two subsets drawn without replacement. The null hypothesis posits that the overlap between each two lists is due to random chance. The cumulative distribution function (CDF) of the hypergeometric distribution was used to compute the probability of observing an overlap greater than or equal to the observed value. The lists of overlapped proteins were then analyzed by PANTHER Overrepresentation Test (PANTHER 18.0) with \u003cem\u003eMus Musculus\u003c/em\u003e database as a reference list. The protein candidates were classified into annotated GO categories of biological processes/cellular components and compared with the \u003cem\u003eMus Musculus\u003c/em\u003e database of brain-expressed genes (\u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://mouse.brain-map.org/\u003c/span\u003e\u003cspan address=\"https://mouse.brain-map.org/\" targettype=\"URL\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e) as the background to determine whether they are overrepresented or underrepresented for a given GO biological process/cellular component. For the SynGO ontology enrichment analyses, we uploaded 289 identified proteins (Gene ID) to the website (\u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://www.syngoportal.org/index.html\u003c/span\u003e\u003cspan address=\"https://www.syngoportal.org/index.html\" targettype=\"URL\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e) and compared with database of synaptic proteins (updated version 20231201). Fold enrichment is defined as the ratio of proteins classified in each GO category from the experimental dataset relative to the number of proteins predicted to be in the same GO category from the reference dataset. Bonferroni correction for multiple testing was applied for statistics.\u003c/p\u003e\u003cp\u003e\u003cb\u003eStatistical analysis.\u003c/b\u003e Statistical analysis used is detailed in figure legends. Data are presented as the mean\u0026thinsp;\u0026plusmn;\u0026thinsp;s.e.m. The expected sample sizes for primary cultures and animal studies were estimated based on analysis with G*Power 3.1 software and our previous studies. Mice that met the inclusion criteria (described in legends) were randomly assigned to experimental and control groups using a computer-generated random number sequence to ensure unbiased allocation. To minimize bias, researchers conducting tests and data collection were blinded to group allocation. Primary neurons were allocated to treatment or control groups using a random number. All plates and wells were labeled with anonymous codes, and experimenters were blinded to the treatment conditions until data analysis. The Kolmogorov\u0026ndash;Smirnov test was used to analyze normal distribution of data. The student\u0026rsquo;s t-test (unpaired) and one-way ANOVA with post hoc Tukey\u0026rsquo;s test, was used to establish statistical significance using Originpro (OriginLab). All tests are two-sided when applicable. The variance between groups was assessed with Levene\u0026rsquo;s test (\u003cem\u003ep\u003c/em\u003e\u0026thinsp;\u0026lt;\u0026thinsp;0.05) using Originpro (OriginLab), which indicated no significant differences in variance. \u003cem\u003en\u003c/em\u003e\u0026thinsp;=\u0026thinsp;the number of animals or biological repeats (cultures) used in the analysis. For animal experiments, animals exhibiting signs of illness or significant deviations in weight (\u0026gt;\u0026thinsp;10% deviation from group mean) were excluded. Cell samples were excluded if they met any of the following criteria: Low viability (\u0026lt;\u0026thinsp;90%), Microbial contamination, Morphological abnormalities. All the exclusion criteria were pre-established. Statistical significance was defined as \u003cem\u003ep\u003c/em\u003e\u0026thinsp;\u0026lt;\u0026thinsp;0.05. Bonferroni correction for multiple testing was applied. Specific sample numbers, including the numbers of cell culture, repeats or mice, are indicated in the figure legends.\u003c/p\u003e"},{"header":"Declarations","content":"\u003ch2\u003eAcknowledgments:\u003c/h2\u003e\u003cp\u003eThis work was supported by the National Institutes of Health (NIH) grant NS118378, a Cleveland State University Startup grant, a FRAXA research grant, and the NARSAD Young Investigator Award Grant to JY; the NIH grant ES028960 to ZZ; a Cleveland State University Startup grant to PJ; the NIH grant NS116766 to BS; the NIH grant MH092877, the NARSAD Distinguished Investigator Award to RSZ; RSZ is the FM Kirby Professor in Neural Repair and Protection; and the NIH shared instrument grant, S10 OD030398 to Cleveland Clinic.\u003c/p\u003e\u003cp\u003eThe authors declare no conflict of interest.\u003c/p\u003e\u003ch2\u003eData availability.\u003c/h2\u003e\u003cp\u003eSource Data for all figures are provided with the paper, and reagents and all other data are available from the corresponding author upon reasonable request. The data of proteomics has been stored in Open Science Framework (OSF) (\u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://osf.io\u003c/span\u003e\u003cspan address=\"https://osf.io\" targettype=\"URL\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e), associated with project osf.io/wqgcx.\u003c/p\u003e"},{"header":"References","content":"\u003col\u003e\n\u003cli\u003eBhakar AL, Dolen G, Bear MF. The pathophysiology of fragile X (and what it teaches us about synapses). \u003cem\u003eAnnual review of neuroscience\u003c/em\u003e 2012; \u003cstrong\u003e35: \u003c/strong\u003e417-443.\u003c/li\u003e\n\u003cli\u003eBagni C, Tassone F, Neri G, Hagerman R. Fragile X syndrome: causes, diagnosis, mechanisms, and therapeutics. \u003cem\u003eThe Journal of clinical investigation\u003c/em\u003e 2012; \u003cstrong\u003e122\u003c/strong\u003e(12)\u003cstrong\u003e: \u003c/strong\u003e4314-4322.\u003c/li\u003e\n\u003cli\u003eBerry-Kravis EM, Lindemann L, Jonch AE, Apostol G, Bear MF, Carpenter RL\u003cem\u003e et al.\u003c/em\u003e Drug development for neurodevelopmental disorders: lessons learned from fragile X syndrome. \u003cem\u003eNature reviews Drug discovery\u003c/em\u003e 2018; \u003cstrong\u003e17\u003c/strong\u003e(4)\u003cstrong\u003e: \u003c/strong\u003e280-299.\u003c/li\u003e\n\u003cli\u003ePenagarikano O, Mulle JG, Warren ST. The pathophysiology of fragile x syndrome. \u003cem\u003eAnnual review of genomics and human genetics\u003c/em\u003e 2007; \u003cstrong\u003e8: \u003c/strong\u003e109-129.\u003c/li\u003e\n\u003cli\u003eRichter JD, Bassell GJ, Klann E. Dysregulation and restoration of translational homeostasis in fragile X syndrome. \u003cem\u003eNature reviews Neuroscience\u003c/em\u003e 2015; \u003cstrong\u003e16\u003c/strong\u003e(10)\u003cstrong\u003e: \u003c/strong\u003e595-605.\u003c/li\u003e\n\u003cli\u003eRodriguez CM, Wright SE, Kearse MG, Haenfler JM, Flores BN, Liu Y\u003cem\u003e et al.\u003c/em\u003e A native function for RAN translation and CGG repeats in regulating fragile X protein synthesis. \u003cem\u003eNat Neurosci\u003c/em\u003e 2020; \u003cstrong\u003e23\u003c/strong\u003e(3)\u003cstrong\u003e: \u003c/strong\u003e386-397.\u003c/li\u003e\n\u003cli\u003eZhan X, Asmara H, Cheng N, Sahu G, Sanchez E, Zhang FX\u003cem\u003e et al.\u003c/em\u003e FMRP(1-297)-tat restores ion channel and synaptic function in a model of Fragile X syndrome. \u003cem\u003eNature communications\u003c/em\u003e 2020; \u003cstrong\u003e11\u003c/strong\u003e(1)\u003cstrong\u003e: \u003c/strong\u003e2755.\u003c/li\u003e\n\u003cli\u003eKelleher RJ, 3rd, Bear MF. The autistic neuron: troubled translation? \u003cem\u003eCell\u003c/em\u003e 2008; \u003cstrong\u003e135\u003c/strong\u003e(3)\u003cstrong\u003e: \u003c/strong\u003e401-406.\u003c/li\u003e\n\u003cli\u003eDarnell JC, Klann E. The translation of translational control by FMRP: therapeutic targets for FXS. \u003cem\u003eNat Neurosci\u003c/em\u003e 2013; \u003cstrong\u003e16\u003c/strong\u003e(11)\u003cstrong\u003e: \u003c/strong\u003e1530-1536.\u003c/li\u003e\n\u003cli\u003eGross C, Chang CW, Kelly SM, Bhattacharya A, McBride SM, Danielson SW\u003cem\u003e et al.\u003c/em\u003e Increased expression of the PI3K enhancer PIKE mediates deficits in synaptic plasticity and behavior in fragile X syndrome. \u003cem\u003eCell reports\u003c/em\u003e 2015; \u003cstrong\u003e11\u003c/strong\u003e(5)\u003cstrong\u003e: \u003c/strong\u003e727-736.\u003c/li\u003e\n\u003cli\u003eVita DJ, Meier CJ, Broadie K. Neuronal fragile X mental retardation protein activates glial insulin receptor mediated PDF-Tri neuron developmental clearance. \u003cem\u003eNature communications\u003c/em\u003e 2021; \u003cstrong\u003e12\u003c/strong\u003e(1)\u003cstrong\u003e: \u003c/strong\u003e1160.\u003c/li\u003e\n\u003cli\u003eMonday HR, Kharod SC, Yoon YJ, Singer RH, Castillo PE. Presynaptic FMRP and local protein synthesis support structural and functional plasticity of glutamatergic axon terminals. \u003cem\u003eNeuron\u003c/em\u003e 2022; \u003cstrong\u003e110\u003c/strong\u003e(16)\u003cstrong\u003e: \u003c/strong\u003e2588-2606 e2586.\u003c/li\u003e\n\u003cli\u003eHe Q, Arroyo ED, Smukowski SN, Xu J, Piochon C, Savas JN\u003cem\u003e et al.\u003c/em\u003e Critical period inhibition of NKCC1 rectifies synapse plasticity in the somatosensory cortex and restores adult tactile response maps in fragile X mice. \u003cem\u003eMolecular psychiatry\u003c/em\u003e 2019; \u003cstrong\u003e24\u003c/strong\u003e(11)\u003cstrong\u003e: \u003c/strong\u003e1732-1747.\u003c/li\u003e\n\u003cli\u003eGoel A, Cantu DA, Guilfoyle J, Chaudhari GR, Newadkar A, Todisco B\u003cem\u003e et al.\u003c/em\u003e Impaired perceptual learning in a mouse model of Fragile X syndrome is mediated by parvalbumin neuron dysfunction and is reversible. \u003cem\u003eNat Neurosci\u003c/em\u003e 2018; \u003cstrong\u003e21\u003c/strong\u003e(10)\u003cstrong\u003e: \u003c/strong\u003e1404-1411.\u003c/li\u003e\n\u003cli\u003eSeo SS, Louros SR, Anstey N, Gonzalez-Lozano MA, Harper CB, Verity NC\u003cem\u003e et al.\u003c/em\u003e Excess ribosomal protein production unbalances translation in a model of Fragile X Syndrome. \u003cem\u003eNature communications\u003c/em\u003e 2022; \u003cstrong\u003e13\u003c/strong\u003e(1)\u003cstrong\u003e: \u003c/strong\u003e3236.\u003c/li\u003e\n\u003cli\u003eBhaskaran AA, Gauvrit T, Vyas Y, Bony G, Ginger M, Frick A. Endogenous noise of neocortical neurons correlates with atypical sensory response variability in the Fmr1(-/y) mouse model of autism. \u003cem\u003eNature communications\u003c/em\u003e 2023; \u003cstrong\u003e14\u003c/strong\u003e(1)\u003cstrong\u003e: \u003c/strong\u003e7905.\u003c/li\u003e\n\u003cli\u003eBrown MR, Kronengold J, Gazula VR, Chen Y, Strumbos JG, Sigworth FJ\u003cem\u003e et al.\u003c/em\u003e Fragile X mental retardation protein controls gating of the sodium-activated potassium channel Slack. \u003cem\u003eNat Neurosci\u003c/em\u003e 2010; \u003cstrong\u003e13\u003c/strong\u003e(7)\u003cstrong\u003e: \u003c/strong\u003e819-821.\u003c/li\u003e\n\u003cli\u003eBerry KP, Nedivi E. Spine Dynamics: Are They All the Same? \u003cem\u003eNeuron\u003c/em\u003e 2017; \u003cstrong\u003e96\u003c/strong\u003e(1)\u003cstrong\u003e: \u003c/strong\u003e43-55.\u003c/li\u003e\n\u003cli\u003eIrwin SA, Patel B, Idupulapati M, Harris JB, Crisostomo RA, Larsen BP\u003cem\u003e et al.\u003c/em\u003e Abnormal dendritic spine characteristics in the temporal and visual cortices of patients with fragile-X syndrome: a quantitative examination. \u003cem\u003eAmerican journal of medical genetics\u003c/em\u003e 2001; \u003cstrong\u003e98\u003c/strong\u003e(2)\u003cstrong\u003e: \u003c/strong\u003e161-167.\u003c/li\u003e\n\u003cli\u003eNimchinsky EA, Oberlander AM, Svoboda K. Abnormal development of dendritic spines in FMR1 knock-out mice. \u003cem\u003eJ Neurosci\u003c/em\u003e 2001; \u003cstrong\u003e21\u003c/strong\u003e(14)\u003cstrong\u003e: \u003c/strong\u003e5139-5146.\u003c/li\u003e\n\u003cli\u003eBooker SA, Domanski APF, Dando OR, Jackson AD, Isaac JTR, Hardingham GE\u003cem\u003e et al.\u003c/em\u003e Altered dendritic spine function and integration in a mouse model of fragile X syndrome. \u003cem\u003eNature communications\u003c/em\u003e 2019; \u003cstrong\u003e10\u003c/strong\u003e(1)\u003cstrong\u003e: \u003c/strong\u003e4813.\u003c/li\u003e\n\u003cli\u003eLicznerski P, Park HA, Rolyan H, Chen R, Mnatsakanyan N, Miranda P\u003cem\u003e et al.\u003c/em\u003e ATP Synthase c-Subunit Leak Causes Aberrant Cellular Metabolism in Fragile X Syndrome. \u003cem\u003eCell\u003c/em\u003e 2020; \u003cstrong\u003e182\u003c/strong\u003e(5)\u003cstrong\u003e: \u003c/strong\u003e1170-1185 e1179.\u003c/li\u003e\n\u003cli\u003eYan J, Porch MW, Court-Vazquez B, Bennett MVL, Zukin RS. Activation of autophagy rescues synaptic and cognitive deficits in fragile X mice. \u003cem\u003eProceedings of the National Academy of Sciences of the United States of America\u003c/em\u003e 2018; \u003cstrong\u003e115\u003c/strong\u003e(41)\u003cstrong\u003e: \u003c/strong\u003eE9707-E9716.\u003c/li\u003e\n\u003cli\u003eDolan BM, Duron SG, Campbell DA, Vollrath B, Shankaranarayana Rao BS, Ko HY\u003cem\u003e et al.\u003c/em\u003e Rescue of fragile X syndrome phenotypes in Fmr1 KO mice by the small-molecule PAK inhibitor FRAX486. \u003cem\u003eProceedings of the National Academy of Sciences of the United States of America\u003c/em\u003e 2013; \u003cstrong\u003e110\u003c/strong\u003e(14)\u003cstrong\u003e: \u003c/strong\u003e5671-5676.\u003c/li\u003e\n\u003cli\u003eUdagawa T, Farny NG, Jakovcevski M, Kaphzan H, Alarcon JM, Anilkumar S\u003cem\u003e et al.\u003c/em\u003e Genetic and acute CPEB1 depletion ameliorate fragile X pathophysiology. \u003cem\u003eNature medicine\u003c/em\u003e 2013; \u003cstrong\u003e19\u003c/strong\u003e(11)\u003cstrong\u003e: \u003c/strong\u003e1473-1477.\u003c/li\u003e\n\u003cli\u003eGantois I, Khoutorsky A, Popic J, Aguilar-Valles A, Freemantle E, Cao R\u003cem\u003e et al.\u003c/em\u003e Metformin ameliorates core deficits in a mouse model of fragile X syndrome. \u003cem\u003eNature medicine\u003c/em\u003e 2017; \u003cstrong\u003e23\u003c/strong\u003e(6)\u003cstrong\u003e: \u003c/strong\u003e674-677.\u003c/li\u003e\n\u003cli\u003eBusquets-Garcia A, Gomis-Gonzalez M, Guegan T, Agustin-Pavon C, Pastor A, Mato S\u003cem\u003e et al.\u003c/em\u003e Targeting the endocannabinoid system in the treatment of fragile X syndrome. \u003cem\u003eNature medicine\u003c/em\u003e 2013; \u003cstrong\u003e19\u003c/strong\u003e(5)\u003cstrong\u003e: \u003c/strong\u003e603-607.\u003c/li\u003e\n\u003cli\u003eMercaldo V, Vidimova B, Gastaldo D, Fernandez E, Lo AC, Cencelli G\u003cem\u003e et al.\u003c/em\u003e Altered striatal actin dynamics drives behavioral inflexibility in a mouse model of fragile X syndrome. \u003cem\u003eNeuron\u003c/em\u003e 2023; \u003cstrong\u003e111\u003c/strong\u003e(11)\u003cstrong\u003e: \u003c/strong\u003e1760-1775 e1768.\u003c/li\u003e\n\u003cli\u003eShen M, Wang F, Li M, Sah N, Stockton ME, Tidei JJ\u003cem\u003e et al.\u003c/em\u003e Reduced mitochondrial fusion and Huntingtin levels contribute to impaired dendritic maturation and behavioral deficits in Fmr1-mutant mice. \u003cem\u003eNat Neurosci\u003c/em\u003e 2019; \u003cstrong\u003e22\u003c/strong\u003e(3)\u003cstrong\u003e: \u003c/strong\u003e386-400.\u003c/li\u003e\n\u003cli\u003ePyronneau A, He Q, Hwang JY, Porch M, Contractor A, Zukin RS. Aberrant Rac1-cofilin signaling mediates defects in dendritic spines, synaptic function, and sensory perception in fragile X syndrome. \u003cem\u003eScience signaling\u003c/em\u003e 2017; \u003cstrong\u003e10\u003c/strong\u003e(504).\u003c/li\u003e\n\u003cli\u003eSantini E, Huynh TN, Longo F, Koo SY, Mojica E, D\u0026apos;Andrea L\u003cem\u003e et al.\u003c/em\u003e Reducing eIF4E-eIF4G interactions restores the balance between protein synthesis and actin dynamics in fragile X syndrome model mice. \u003cem\u003eScience signaling\u003c/em\u003e 2017; \u003cstrong\u003e10\u003c/strong\u003e(504).\u003c/li\u003e\n\u003cli\u003eCingolani LA, Goda Y. Actin in action: the interplay between the actin cytoskeleton and synaptic efficacy. \u003cem\u003eNature reviews Neuroscience\u003c/em\u003e 2008; \u003cstrong\u003e9\u003c/strong\u003e(5)\u003cstrong\u003e: \u003c/strong\u003e344-356.\u003c/li\u003e\n\u003cli\u003eHotulainen P, Hoogenraad CC. Actin in dendritic spines: connecting dynamics to function. \u003cem\u003eThe Journal of cell biology\u003c/em\u003e 2010; \u003cstrong\u003e189\u003c/strong\u003e(4)\u003cstrong\u003e: \u003c/strong\u003e619-629.\u003c/li\u003e\n\u003cli\u003eForrest MP, Parnell E, Penzes P. Dendritic structural plasticity and neuropsychiatric disease. \u003cem\u003eNature reviews Neuroscience\u003c/em\u003e 2018; \u003cstrong\u003e19\u003c/strong\u003e(4)\u003cstrong\u003e: \u003c/strong\u003e215-234.\u003c/li\u003e\n\u003cli\u003ePontrello CG, Sun MY, Lin A, Fiacco TA, DeFea KA, Ethell IM. Cofilin under control of beta-arrestin-2 in NMDA-dependent dendritic spine plasticity, long-term depression (LTD), and learning. \u003cem\u003eProceedings of the National Academy of Sciences of the United States of America\u003c/em\u003e 2012; \u003cstrong\u003e109\u003c/strong\u003e(7)\u003cstrong\u003e: \u003c/strong\u003eE442-451.\u003c/li\u003e\n\u003cli\u003eHarris H, Rubinsztein DC. Control of autophagy as a therapy for neurodegenerative disease. \u003cem\u003eNature reviews Neurology\u003c/em\u003e 2011; \u003cstrong\u003e8\u003c/strong\u003e(2)\u003cstrong\u003e: \u003c/strong\u003e108-117.\u003c/li\u003e\n\u003cli\u003eNixon RA. The role of autophagy in neurodegenerative disease. \u003cem\u003eNature medicine\u003c/em\u003e 2013; \u003cstrong\u003e19\u003c/strong\u003e(8)\u003cstrong\u003e: \u003c/strong\u003e983-997.\u003c/li\u003e\n\u003cli\u003eMizushima N, Levine B, Cuervo AM, Klionsky DJ. Autophagy fights disease through cellular self-digestion. \u003cem\u003eNature\u003c/em\u003e 2008; \u003cstrong\u003e451\u003c/strong\u003e(7182)\u003cstrong\u003e: \u003c/strong\u003e1069-1075.\u003c/li\u003e\n\u003cli\u003eShehata M, Matsumura H, Okubo-Suzuki R, Ohkawa N, Inokuchi K. Neuronal stimulation induces autophagy in hippocampal neurons that is involved in AMPA receptor degradation after chemical long-term depression. \u003cem\u003eJ Neurosci\u003c/em\u003e 2012; \u003cstrong\u003e32\u003c/strong\u003e(30)\u003cstrong\u003e: \u003c/strong\u003e10413-10422.\u003c/li\u003e\n\u003cli\u003eLinda K, Lewerissa EI, Verboven AHA, Gabriele M, Frega M, Klein Gunnewiek TM\u003cem\u003e et al.\u003c/em\u003e Imbalanced autophagy causes synaptic deficits in a human model for neurodevelopmental disorders. \u003cem\u003eAutophagy\u003c/em\u003e 2022; \u003cstrong\u003e18\u003c/strong\u003e(2)\u003cstrong\u003e: \u003c/strong\u003e423-442.\u003c/li\u003e\n\u003cli\u003eCompans B, Camus C, Kallergi E, Sposini S, Martineau M, Butler C\u003cem\u003e et al.\u003c/em\u003e NMDAR-dependent long-term depression is associated with increased short term plasticity through autophagy mediated loss of PSD-95. \u003cem\u003eNature communications\u003c/em\u003e 2021; \u003cstrong\u003e12\u003c/strong\u003e(1)\u003cstrong\u003e: \u003c/strong\u003e2849.\u003c/li\u003e\n\u003cli\u003eKallergi E, Daskalaki AD, Kolaxi A, Camus C, Ioannou E, Mercaldo V\u003cem\u003e et al.\u003c/em\u003e Dendritic autophagy degrades postsynaptic proteins and is required for long-term synaptic depression in mice. \u003cem\u003eNature communications\u003c/em\u003e 2022; \u003cstrong\u003e13\u003c/strong\u003e(1)\u003cstrong\u003e: \u003c/strong\u003e680.\u003c/li\u003e\n\u003cli\u003eShen H, Zhu H, Panja D, Gu Q, Li Z. Autophagy controls the induction and developmental decline of NMDAR-LTD through endocytic recycling. \u003cem\u003eNature communications\u003c/em\u003e 2020; \u003cstrong\u003e11\u003c/strong\u003e(1)\u003cstrong\u003e: \u003c/strong\u003e2979.\u003c/li\u003e\n\u003cli\u003eNikoletopoulou V, Tavernarakis N. Regulation and Roles of Autophagy at Synapses. \u003cem\u003eTrends Cell Biol\u003c/em\u003e 2018; \u003cstrong\u003e28\u003c/strong\u003e(8)\u003cstrong\u003e: \u003c/strong\u003e646-661.\u003c/li\u003e\n\u003cli\u003eNegrete-Hurtado A, Overhoff M, Bera S, De Bruyckere E, Sch\u0026auml;tzm\u0026uuml;ller K, Kye MJ\u003cem\u003e et al.\u003c/em\u003e Autophagy lipidation machinery regulates axonal microtubule dynamics but is dispensable for survival of mammalian neurons. \u003cem\u003eNature communications\u003c/em\u003e 2020; \u003cstrong\u003e11\u003c/strong\u003e(1).\u003c/li\u003e\n\u003cli\u003eCrawley O, Opperman KJ, Desbois M, Adrados I, Borgen MA, Giles AC\u003cem\u003e et al.\u003c/em\u003e Autophagy is inhibited by ubiquitin ligase activity in the nervous system. \u003cem\u003eNature communications\u003c/em\u003e 2019; \u003cstrong\u003e10\u003c/strong\u003e(1)\u003cstrong\u003e: \u003c/strong\u003e5017.\u003c/li\u003e\n\u003cli\u003eKiral FR, Linneweber GA, Mathejczyk T, Georgiev SV, Wernet MF, Hassan BA\u003cem\u003e et al.\u003c/em\u003e Autophagy-dependent filopodial kinetics restrict synaptic partner choice during Drosophila brain wiring. \u003cem\u003eNature communications\u003c/em\u003e 2020; \u003cstrong\u003e11\u003c/strong\u003e(1)\u003cstrong\u003e: \u003c/strong\u003e1325.\u003c/li\u003e\n\u003cli\u003eBagni C, Zukin RS. A Synaptic Perspective of Fragile X Syndrome and Autism Spectrum Disorders. \u003cem\u003eNeuron\u003c/em\u003e 2019; \u003cstrong\u003e101\u003c/strong\u003e(6)\u003cstrong\u003e: \u003c/strong\u003e1070-1088.\u003c/li\u003e\n\u003cli\u003eTang G, Gudsnuk K, Kuo SH, Cotrina ML, Rosoklija G, Sosunov A\u003cem\u003e et al.\u003c/em\u003e Loss of mTOR-dependent macroautophagy causes autistic-like synaptic pruning deficits. \u003cem\u003eNeuron\u003c/em\u003e 2014; \u003cstrong\u003e83\u003c/strong\u003e(5)\u003cstrong\u003e: \u003c/strong\u003e1131-1143.\u003c/li\u003e\n\u003cli\u003eNikoletopoulou V, Sidiropoulou K, Kallergi E, Dalezios Y, Tavernarakis N. Modulation of Autophagy by BDNF Underlies Synaptic Plasticity. \u003cem\u003eCell metabolism\u003c/em\u003e 2017; \u003cstrong\u003e26\u003c/strong\u003e(1)\u003cstrong\u003e: \u003c/strong\u003e230-242 e235.\u003c/li\u003e\n\u003cli\u003eGuo Y, Shen M, Dong Q, Mendez-Albelo NM, Huang SX, Sirois CL\u003cem\u003e et al.\u003c/em\u003e Elevated levels of FMRP-target MAP1B impair human and mouse neuronal development and mouse social behaviors via autophagy pathway. \u003cem\u003eNature communications\u003c/em\u003e 2023; \u003cstrong\u003e14\u003c/strong\u003e(1)\u003cstrong\u003e: \u003c/strong\u003e3801.\u003c/li\u003e\n\u003cli\u003eVodicka P, Lim J, Williams DT, Kegel KB, Chase K, Park H\u003cem\u003e et al.\u003c/em\u003e Assessment of chloroquine treatment for modulating autophagy flux in brain of WT and HD mice. \u003cem\u003eJ Huntingtons Dis\u003c/em\u003e 2014; \u003cstrong\u003e3\u003c/strong\u003e(2)\u003cstrong\u003e: \u003c/strong\u003e159-174.\u003c/li\u003e\n\u003cli\u003eRoncaglia P, Martone ME, Hill DP, Berardini TZ, Foulger RE, Imam FT\u003cem\u003e et al.\u003c/em\u003e The Gene Ontology (GO) Cellular Component Ontology: integration with SAO (Subcellular Anatomy Ontology) and other recent developments. \u003cem\u003eJ Biomed Semantics\u003c/em\u003e 2013; \u003cstrong\u003e4\u003c/strong\u003e(1)\u003cstrong\u003e: \u003c/strong\u003e20.\u003c/li\u003e\n\u003cli\u003eContractor A, Klyachko VA, Portera-Cailliau C. Altered Neuronal and Circuit Excitability in Fragile X Syndrome. \u003cem\u003eNeuron\u003c/em\u003e 2015; \u003cstrong\u003e87\u003c/strong\u003e(4)\u003cstrong\u003e: \u003c/strong\u003e699-715.\u003c/li\u003e\n\u003cli\u003eKoopmans F, van Nierop P, Andres-Alonso M, Byrnes A, Cijsouw T, Coba MP\u003cem\u003e et al.\u003c/em\u003e SynGO: An Evidence-Based, Expert-Curated Knowledge Base for the Synapse. \u003cem\u003eNeuron\u003c/em\u003e 2019; \u003cstrong\u003e103\u003c/strong\u003e(2)\u003cstrong\u003e: \u003c/strong\u003e217-234 e214.\u003c/li\u003e\n\u003cli\u003eRubinsztein DC, Codogno P, Levine B. Autophagy modulation as a potential therapeutic target for diverse diseases. \u003cem\u003eNature reviews Drug discovery\u003c/em\u003e 2012; \u003cstrong\u003e11\u003c/strong\u003e(9)\u003cstrong\u003e: \u003c/strong\u003e709-730.\u003c/li\u003e\n\u003cli\u003eUnderwood BR, Green-Thompson ZW, Pugh PJ, Lazic SE, Mason SL, Griffin J\u003cem\u003e et al.\u003c/em\u003e An open-label study to assess the feasibility and tolerability of rilmenidine for the treatment of Huntington\u0026apos;s disease. \u003cem\u003eJ Neurol\u003c/em\u003e 2017; \u003cstrong\u003e264\u003c/strong\u003e(12)\u003cstrong\u003e: \u003c/strong\u003e2457-2463.\u003c/li\u003e\n\u003cli\u003eBennett DF, Goyala A, Statzer C, Beckett CW, Tyshkovskiy A, Gladyshev VN\u003cem\u003e et al.\u003c/em\u003e Rilmenidine extends lifespan and healthspan in Caenorhabditis elegans via a nischarin I1-imidazoline receptor. \u003cem\u003eAging Cell\u003c/em\u003e 2023; \u003cstrong\u003e22\u003c/strong\u003e(2)\u003cstrong\u003e: \u003c/strong\u003ee13774.\u003c/li\u003e\n\u003cli\u003eChoi DH, Kim DH, Park YG, Chun BG, Choi SH. Protective effects of rilmenidine and AGN 192403 on oxidative cytotoxicity and mitochondrial inhibitor-induced cytotoxicity in astrocytes. \u003cem\u003eFree Radic Biol Med\u003c/em\u003e 2002; \u003cstrong\u003e33\u003c/strong\u003e(10)\u003cstrong\u003e: \u003c/strong\u003e1321-1333.\u003c/li\u003e\n\u003cli\u003eRose C, Menzies FM, Renna M, Acevedo-Arozena A, Corrochano S, Sadiq O\u003cem\u003e et al.\u003c/em\u003e Rilmenidine attenuates toxicity of polyglutamine expansions in a mouse model of Huntington\u0026apos;s disease. \u003cem\u003eHum Mol Genet\u003c/em\u003e 2010; \u003cstrong\u003e19\u003c/strong\u003e(11)\u003cstrong\u003e: \u003c/strong\u003e2144-2153.\u003c/li\u003e\n\u003cli\u003ePerera ND, Sheean RK, Lau CL, Shin YS, Beart PM, Horne MK\u003cem\u003e et al.\u003c/em\u003e Rilmenidine promotes MTOR-independent autophagy in the mutant SOD1 mouse model of amyotrophic lateral sclerosis without slowing disease progression. \u003cem\u003eAutophagy\u003c/em\u003e 2018; \u003cstrong\u003e14\u003c/strong\u003e(3)\u003cstrong\u003e: \u003c/strong\u003e534-551.\u003c/li\u003e\n\u003cli\u003eKlionsky DJ, Abdel-Aziz AK, Abdelfatah S, Abdellatif M, Abdoli A, Abel S\u003cem\u003e et al.\u003c/em\u003e Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition)(1). \u003cem\u003eAutophagy\u003c/em\u003e 2021; \u003cstrong\u003e17\u003c/strong\u003e(1)\u003cstrong\u003e: \u003c/strong\u003e1-382.\u003c/li\u003e\n\u003cli\u003ePalmer JE, Wilson N, Son SM, Obrocki P, Wrobel L, Rob M\u003cem\u003e et al.\u003c/em\u003e Autophagy, aging, and age-related neurodegeneration. \u003cem\u003eNeuron\u003c/em\u003e 2024.\u003c/li\u003e\n\u003cli\u003eFleming A, Bourdenx M, Fujimaki M, Karabiyik C, Krause GJ, Lopez A\u003cem\u003e et al.\u003c/em\u003e The different autophagy degradation pathways and neurodegeneration. \u003cem\u003eNeuron\u003c/em\u003e 2022; \u003cstrong\u003e110\u003c/strong\u003e(6)\u003cstrong\u003e: \u003c/strong\u003e935-966.\u003c/li\u003e\n\u003cli\u003eBhattacharya A, Kaphzan H, Alvarez-Dieppa AC, Murphy JP, Pierre P, Klann E. Genetic removal of p70 S6 kinase 1 corrects molecular, synaptic, and behavioral phenotypes in fragile X syndrome mice. \u003cem\u003eNeuron\u003c/em\u003e 2012; \u003cstrong\u003e76\u003c/strong\u003e(2)\u003cstrong\u003e: \u003c/strong\u003e325-337.\u003c/li\u003e\n\u003cli\u003eMcCary LM, Roberts JE. Early identification of autism in fragile X syndrome: a review. \u003cem\u003eJournal of intellectual disability research : JIDR\u003c/em\u003e 2013; \u003cstrong\u003e57\u003c/strong\u003e(9)\u003cstrong\u003e: \u003c/strong\u003e803-814.\u003c/li\u003e\n\u003cli\u003eBear MF, Huber KM, Warren ST. The mGluR theory of fragile X mental retardation. \u003cem\u003eTrends in neurosciences\u003c/em\u003e 2004; \u003cstrong\u003e27\u003c/strong\u003e(7)\u003cstrong\u003e: \u003c/strong\u003e370-377.\u003c/li\u003e\n\u003cli\u003eLuscher C, Huber KM. Group 1 mGluR-dependent synaptic long-term depression: mechanisms and implications for circuitry and disease. \u003cem\u003eNeuron\u003c/em\u003e 2010; \u003cstrong\u003e65\u003c/strong\u003e(4)\u003cstrong\u003e: \u003c/strong\u003e445-459.\u003c/li\u003e\n\u003cli\u003eStoppel LJ, Kazdoba TM, Schaffler MD, Preza AR, Heynen A, Crawley JN\u003cem\u003e et al.\u003c/em\u003e R-Baclofen Reverses Cognitive Deficits and Improves Social Interactions in Two Lines of 16p11.2 Deletion Mice. \u003cem\u003eNeuropsychopharmacology : official publication of the American College of Neuropsychopharmacology\u003c/em\u003e 2018; \u003cstrong\u003e43\u003c/strong\u003e(3)\u003cstrong\u003e: \u003c/strong\u003e513-524.\u003c/li\u003e\n\u003cli\u003eKazdoba TM, Leach PT, Silverman JL, Crawley JN. Modeling fragile X syndrome in the Fmr1 knockout mouse. \u003cem\u003eIntractable \u0026amp; rare diseases research\u003c/em\u003e 2014; \u003cstrong\u003e3\u003c/strong\u003e(4)\u003cstrong\u003e: \u003c/strong\u003e118-133.\u003c/li\u003e\n\u003cli\u003eLevine B, Packer M, Codogno P. Development of autophagy inducers in clinical medicine. \u003cem\u003eThe Journal of clinical investigation\u003c/em\u003e 2015; \u003cstrong\u003e125\u003c/strong\u003e(1)\u003cstrong\u003e: \u003c/strong\u003e14-24.\u003c/li\u003e\n\u003cli\u003eWang N, Li T, Liu W, Lin J, Zhang K, Li Z\u003cem\u003e et al.\u003c/em\u003e USP7- and PRMT5-dependent G3BP2 stabilization drives de novo lipogenesis and tumorigenesis of HNSC. \u003cem\u003eCell Death Dis\u003c/em\u003e 2023; \u003cstrong\u003e14\u003c/strong\u003e(3)\u003cstrong\u003e: \u003c/strong\u003e182.\u003c/li\u003e\n\u003cli\u003eAlard A, Fabre B, Anesia R, Marboeuf C, Pierre P, Susini C\u003cem\u003e et al.\u003c/em\u003e NAD(P)H quinone-oxydoreductase 1 protects eukaryotic translation initiation factor 4GI from degradation by the proteasome. \u003cem\u003eMolecular and cellular biology\u003c/em\u003e 2010; \u003cstrong\u003e30\u003c/strong\u003e(4)\u003cstrong\u003e: \u003c/strong\u003e1097-1105.\u003c/li\u003e\n\u003cli\u003eColledge M, Snyder EM, Crozier RA, Soderling JA, Jin Y, Langeberg LK\u003cem\u003e et al.\u003c/em\u003e Ubiquitination regulates PSD-95 degradation and AMPA receptor surface expression. \u003cem\u003eNeuron\u003c/em\u003e 2003; \u003cstrong\u003e40\u003c/strong\u003e(3)\u003cstrong\u003e: \u003c/strong\u003e595-607.\u003c/li\u003e\n\u003cli\u003eMakkerh JP, Ceni C, Auld DS, Vaillancourt F, Dorval G, Barker PA. p75 neurotrophin receptor reduces ligand-induced Trk receptor ubiquitination and delays Trk receptor internalization and degradation. \u003cem\u003eEMBO Rep\u003c/em\u003e 2005; \u003cstrong\u003e6\u003c/strong\u003e(10)\u003cstrong\u003e: \u003c/strong\u003e936-941.\u003c/li\u003e\n\u003cli\u003eWang Y, Xie Y, Sun B, Guo Y, Song L, Mohammednur DE\u003cem\u003e et al.\u003c/em\u003e The degradation of Rap1GAP via E6AP-mediated ubiquitin-proteasome pathway is associated with HPV16/18-infection in cervical cancer cells. \u003cem\u003eInfect Agent Cancer\u003c/em\u003e 2021; \u003cstrong\u003e16\u003c/strong\u003e(1)\u003cstrong\u003e: \u003c/strong\u003e71.\u003c/li\u003e\n\u003cli\u003eLiu Z, Gu S, Wu K, Li L, Dong C, Wang W\u003cem\u003e et al.\u003c/em\u003e CircRNA-DOPEY2 enhances the chemosensitivity of esophageal cancer cells by inhibiting CPEB4-mediated Mcl-1 translation. \u003cem\u003eJ Exp Clin Cancer Res\u003c/em\u003e 2021; \u003cstrong\u003e40\u003c/strong\u003e(1)\u003cstrong\u003e: \u003c/strong\u003e361.\u003c/li\u003e\n\u003cli\u003eZhao J, Zhai B, Gygi SP, Goldberg AL. mTOR inhibition activates overall protein degradation by the ubiquitin proteasome system as well as by autophagy. \u003cem\u003eProceedings of the National Academy of Sciences of the United States of America\u003c/em\u003e 2015; \u003cstrong\u003e112\u003c/strong\u003e(52)\u003cstrong\u003e: \u003c/strong\u003e15790-15797.\u003c/li\u003e\n\u003cli\u003eTsai NP, Wilkerson JR, Guo W, Maksimova MA, DeMartino GN, Cowan CW\u003cem\u003e et al.\u003c/em\u003e Multiple autism-linked genes mediate synapse elimination via proteasomal degradation of a synaptic scaffold PSD-95. \u003cem\u003eCell\u003c/em\u003e 2012; \u003cstrong\u003e151\u003c/strong\u003e(7)\u003cstrong\u003e: \u003c/strong\u003e1581-1594.\u003c/li\u003e\n\u003cli\u003eMatt L, Kim K, Hergarden AC, Patriarchi T, Malik ZA, Park DK\u003cem\u003e et al.\u003c/em\u003e alpha-Actinin Anchors PSD-95 at Postsynaptic Sites. \u003cem\u003eNeuron\u003c/em\u003e 2018; \u003cstrong\u003e97\u003c/strong\u003e(5)\u003cstrong\u003e: \u003c/strong\u003e1094-1109 e1099.\u003c/li\u003e\n\u003cli\u003eZhou Q, Homma KJ, Poo MM. Shrinkage of dendritic spines associated with long-term depression of hippocampal synapses. \u003cem\u003eNeuron\u003c/em\u003e 2004; \u003cstrong\u003e44\u003c/strong\u003e(5)\u003cstrong\u003e: \u003c/strong\u003e749-757.\u003c/li\u003e\n\u003cli\u003eBosch M, Castro J, Saneyoshi T, Matsuno H, Sur M, Hayashi Y. Structural and molecular remodeling of dendritic spine substructures during long-term potentiation. \u003cem\u003eNeuron\u003c/em\u003e 2014; \u003cstrong\u003e82\u003c/strong\u003e(2)\u003cstrong\u003e: \u003c/strong\u003e444-459.\u003c/li\u003e\n\u003cli\u003eDe Rubeis S, Pasciuto E, Li KW, Fernandez E, Di Marino D, Buzzi A\u003cem\u003e et al.\u003c/em\u003e CYFIP1 coordinates mRNA translation and cytoskeleton remodeling to ensure proper dendritic spine formation. \u003cem\u003eNeuron\u003c/em\u003e 2013; \u003cstrong\u003e79\u003c/strong\u003e(6)\u003cstrong\u003e: \u003c/strong\u003e1169-1182.\u003c/li\u003e\n\u003cli\u003eMarcotrigiano J, Gingras AC, Sonenberg N, Burley SK. Cap-dependent translation initiation in eukaryotes is regulated by a molecular mimic of eIF4G. \u003cem\u003eMolecular cell\u003c/em\u003e 1999; \u003cstrong\u003e3\u003c/strong\u003e(6)\u003cstrong\u003e: \u003c/strong\u003e707-716.\u003c/li\u003e\n\u003cli\u003eMariano V, Kanellopoulos AK, Ricci C, Di Marino D, Borrie SC, Dupraz S\u003cem\u003e et al.\u003c/em\u003e Intellectual Disability and Behavioral Deficits Linked to CYFIP1 Missense Variants Disrupting Actin Polymerization. \u003cem\u003eBiol Psychiatry\u003c/em\u003e 2024; \u003cstrong\u003e95\u003c/strong\u003e(2)\u003cstrong\u003e: \u003c/strong\u003e161-174.\u003c/li\u003e\n\u003cli\u003eYan J, Zhang H, Yin Y, Li J, Tang Y, Purkayastha S\u003cem\u003e et al.\u003c/em\u003e Obesity- and aging-induced excess of central transforming growth factor-\u0026beta; potentiates diabetic development via an RNA stress response. \u003cem\u003eNature medicine\u003c/em\u003e 2014; \u003cstrong\u003e20: \u003c/strong\u003e1001.\u003c/li\u003e\n\u003cli\u003eHagerman RJ, Hagerman PJ. Fragile X Syndrome: Lessons Learned and What New Treatment Avenues Are on the Horizon. \u003cem\u003eAnnu Rev Pharmacol Toxicol\u003c/em\u003e 2022; \u003cstrong\u003e62: \u003c/strong\u003e365-381.\u003c/li\u003e\n\u003cli\u003eDoers ME, Musser MT, Nichol R, Berndt ER, Baker M, Gomez TM\u003cem\u003e et al.\u003c/em\u003e iPSC-derived forebrain neurons from FXS individuals show defects in initial neurite outgrowth. \u003cem\u003eStem cells and development\u003c/em\u003e 2014; \u003cstrong\u003e23\u003c/strong\u003e(15)\u003cstrong\u003e: \u003c/strong\u003e1777-1787.\u003c/li\u003e\n\u003cli\u003eLiu XS, Wu H, Krzisch M, Wu X, Graef J, Muffat J\u003cem\u003e et al.\u003c/em\u003e Rescue of Fragile X Syndrome Neurons by DNA Methylation Editing of the FMR1 Gene. \u003cem\u003eCell\u003c/em\u003e 2018; \u003cstrong\u003e172\u003c/strong\u003e(5)\u003cstrong\u003e: \u003c/strong\u003e979-992 e976.\u003c/li\u003e\n\u003cli\u003eXie Y, Zhou B, Lin MY, Wang S, Foust KD, Sheng ZH. Endolysosomal Deficits Augment Mitochondria Pathology in Spinal Motor Neurons of Asymptomatic fALS Mice. \u003cem\u003eNeuron\u003c/em\u003e 2015; \u003cstrong\u003e87\u003c/strong\u003e(2)\u003cstrong\u003e: \u003c/strong\u003e355-370.\u003c/li\u003e\n\u003cli\u003eGupta VK, Scheunemann L, Eisenberg T, Mertel S, Bhukel A, Koemans TS\u003cem\u003e et al.\u003c/em\u003e Restoring polyamines protects from age-induced memory impairment in an autophagy-dependent manner. \u003cem\u003eNat Neurosci\u003c/em\u003e 2013; \u003cstrong\u003e16\u003c/strong\u003e(10)\u003cstrong\u003e: \u003c/strong\u003e1453-1460.\u003c/li\u003e\n\u003cli\u003eKomatsu M, Waguri S, Chiba T, Murata S, Iwata J, Tanida I\u003cem\u003e et al.\u003c/em\u003e Loss of autophagy in the central nervous system causes neurodegeneration in mice. \u003cem\u003eNature\u003c/em\u003e 2006; \u003cstrong\u003e441\u003c/strong\u003e(7095)\u003cstrong\u003e: \u003c/strong\u003e880-884.\u003c/li\u003e\n\u003cli\u003eDong Z, Chen W, Chen C, Wang H, Cui W, Tan Z\u003cem\u003e et al.\u003c/em\u003e CUL3 Deficiency Causes Social Deficits and Anxiety-like Behaviors by Impairing Excitation-Inhibition Balance through the Promotion of Cap-Dependent Translation. \u003cem\u003eNeuron\u003c/em\u003e 2020; \u003cstrong\u003e105\u003c/strong\u003e(3)\u003cstrong\u003e: \u003c/strong\u003e475-490 e476.\u003c/li\u003e\n\u003cli\u003ePenzes P, Cahill ME, Jones KA, VanLeeuwen JE, Woolfrey KM. Dendritic spine pathology in neuropsychiatric disorders. \u003cem\u003eNat Neurosci\u003c/em\u003e 2011; \u003cstrong\u003e14\u003c/strong\u003e(3)\u003cstrong\u003e: \u003c/strong\u003e285-293.\u003c/li\u003e\n\u003cli\u003eZhao H, Zhao YG, Wang X, Xu L, Miao L, Feng D\u003cem\u003e et al.\u003c/em\u003e Mice deficient in Epg5 exhibit selective neuronal vulnerability to degeneration. \u003cem\u003eThe Journal of cell biology\u003c/em\u003e 2013; \u003cstrong\u003e200\u003c/strong\u003e(6)\u003cstrong\u003e: \u003c/strong\u003e731-741.\u003c/li\u003e\n\u003cli\u003eDong S, Aguirre-Hernandez C, Scrivo A, Eliscovich C, Arias E, Bravo-Cordero JJ\u003cem\u003e et al.\u003c/em\u003e Monitoring spatiotemporal changes in chaperone-mediated autophagy in vivo. \u003cem\u003eNature communications\u003c/em\u003e 2020; \u003cstrong\u003e11\u003c/strong\u003e(1)\u003cstrong\u003e: \u003c/strong\u003e645.\u003c/li\u003e\n\u003cli\u003eZhang Z, Yan J, Bowman AB, Bryan MR, Singh R, Aschner M. Dysregulation of TFEB contributes to manganese-induced autophagic failure and mitochondrial dysfunction in astrocytes. \u003cem\u003eAutophagy\u003c/em\u003e 2020; \u003cstrong\u003e16\u003c/strong\u003e(8)\u003cstrong\u003e: \u003c/strong\u003e1506-1523.\u003c/li\u003e\n\u003cli\u003eKast DJ, Dominguez R. The Cytoskeleton-Autophagy Connection. \u003cem\u003eCurrent biology : CB\u003c/em\u003e 2017; \u003cstrong\u003e27\u003c/strong\u003e(8)\u003cstrong\u003e: \u003c/strong\u003eR318-R326.\u003c/li\u003e\n\u003cli\u003eGkogkas CG, Khoutorsky A, Ran I, Rampakakis E, Nevarko T, Weatherill DB\u003cem\u003e et al.\u003c/em\u003e Autism-related deficits via dysregulated eIF4E-dependent translational control. \u003cem\u003eNature\u003c/em\u003e 2013; \u003cstrong\u003e493\u003c/strong\u003e(7432)\u003cstrong\u003e: \u003c/strong\u003e371-377.\u003c/li\u003e\n\u003cli\u003eZhang J, Abdel-Rahman AA. Nischarin as a functional imidazoline (I1) receptor. \u003cem\u003eFEBS Lett\u003c/em\u003e 2006; \u003cstrong\u003e580\u003c/strong\u003e(13)\u003cstrong\u003e: \u003c/strong\u003e3070-3074.\u003c/li\u003e\n\u003cli\u003eAlahari SK. Nischarin inhibits Rac induced migration and invasion of epithelial cells by affecting signaling cascades involving PAK. \u003cem\u003eExp Cell Res\u003c/em\u003e 2003; \u003cstrong\u003e288\u003c/strong\u003e(2)\u003cstrong\u003e: \u003c/strong\u003e415-424.\u003c/li\u003e\n\u003cli\u003eSrdic-Rajic T, Nikolic K, Cavic M, Djokic I, Gemovic B, Perovic V\u003cem\u003e et al.\u003c/em\u003e Rilmenidine suppresses proliferation and promotes apoptosis via the mitochondrial pathway in human leukemic K562 cells. \u003cem\u003eEur J Pharm Sci\u003c/em\u003e 2016; \u003cstrong\u003e81: \u003c/strong\u003e172-180.\u003c/li\u003e\n\u003cli\u003eReid JL. Rilmenidine: a clinical overview. \u003cem\u003eAm J Hypertens\u003c/em\u003e 2000; \u003cstrong\u003e13\u003c/strong\u003e(6 Pt 2)\u003cstrong\u003e: \u003c/strong\u003e106S-111S.\u003c/li\u003e\n\u003cli\u003eTrimarco B, Rosiello G, Sarno D, Lorino G, Rubattu S, DeLuca N\u003cem\u003e et al.\u003c/em\u003e Effects of one-year treatment with rilmenidine on systemic hypertension-induced left ventricular hypertrophy in hypertensive patients. \u003cem\u003eAm J Cardiol\u003c/em\u003e 1994; \u003cstrong\u003e74\u003c/strong\u003e(13)\u003cstrong\u003e: \u003c/strong\u003e36A-42A.\u003c/li\u003e\n\u003cli\u003eBauduceau B, Mayaudon H, Dupuy O. Rilmenidine in the hypertensive type-2 diabetic: a controlled pilot study versus captopril. \u003cem\u003eJ Cardiovasc Risk\u003c/em\u003e 2000; \u003cstrong\u003e7\u003c/strong\u003e(1)\u003cstrong\u003e: \u003c/strong\u003e57-61.\u003c/li\u003e\n\u003cli\u003eFauvel JP, Najem R, Ryon B, Ducher M, Laville M. Effects of rilmenidine on stress-induced peak blood pressure and renal function. \u003cem\u003eJ Cardiovasc Pharmacol\u003c/em\u003e 1999; \u003cstrong\u003e34\u003c/strong\u003e(1)\u003cstrong\u003e: \u003c/strong\u003e41-45.\u003c/li\u003e\n\u003cli\u003eVuu YM, Roberts CT, Rastegar M. MeCP2 Is an Epigenetic Factor That Links DNA Methylation with Brain Metabolism. \u003cem\u003eInternational journal of molecular sciences\u003c/em\u003e 2023; \u003cstrong\u003e24\u003c/strong\u003e(4).\u003c/li\u003e\n\u003cli\u003ePrem S, Dev B, Peng C, Mehta M, Alibutud R, Connacher RJ\u003cem\u003e et al.\u003c/em\u003e Dysregulation of mTOR signaling mediates common neurite and migration defects in both idiopathic and 16p11.2 deletion autism neural precursor cells. \u003cem\u003eElife\u003c/em\u003e 2024; \u003cstrong\u003e13\u003c/strong\u003e.\u003c/li\u003e\n\u003cli\u003eZhou J, Blundell J, Ogawa S, Kwon CH, Zhang W, Sinton C\u003cem\u003e et al.\u003c/em\u003e Pharmacological inhibition of mTORC1 suppresses anatomical, cellular, and behavioral abnormalities in neural-specific Pten knock-out mice. \u003cem\u003eJ Neurosci\u003c/em\u003e 2009; \u003cstrong\u003e29\u003c/strong\u003e(6)\u003cstrong\u003e: \u003c/strong\u003e1773-1783.\u003c/li\u003e\n\u003cli\u003eSpencer CM, Serysheva E, Yuva-Paylor LA, Oostra BA, Nelson DL, Paylor R. Exaggerated behavioral phenotypes in Fmr1/Fxr2 double knockout mice reveal a functional genetic interaction between Fragile X-related proteins. \u003cem\u003eHum Mol Genet\u003c/em\u003e 2006; \u003cstrong\u003e15\u003c/strong\u003e(12)\u003cstrong\u003e: \u003c/strong\u003e1984-1994.\u003c/li\u003e\n\u003cli\u003eMiyawaki T, Ofengeim D, Noh KM, Latuszek-Barrantes A, Hemmings BA, Follenzi A\u003cem\u003e et al.\u003c/em\u003e The endogenous inhibitor of Akt, CTMP, is critical to ischemia-induced neuronal death. \u003cem\u003eNat Neurosci\u003c/em\u003e 2009; \u003cstrong\u003e12\u003c/strong\u003e(5)\u003cstrong\u003e: \u003c/strong\u003e618-626.\u003c/li\u003e\n\u003cli\u003eChambers SM, Fasano CA, Papapetrou EP, Tomishima M, Sadelain M, Studer L. Highly efficient neural conversion of human ES and iPS cells by dual inhibition of SMAD signaling. \u003cem\u003eNat Biotechnol\u003c/em\u003e 2009; \u003cstrong\u003e27\u003c/strong\u003e(3)\u003cstrong\u003e: \u003c/strong\u003e275-280.\u003c/li\u003e\n\u003cli\u003eLi M, Zhao H, Ananiev GE, Musser MT, Ness KH, Maglaque DL\u003cem\u003e et al.\u003c/em\u003e Establishment of Reporter Lines for Detecting Fragile X Mental Retardation (FMR1) Gene Reactivation in Human Neural Cells. \u003cem\u003eStem Cells\u003c/em\u003e 2017; \u003cstrong\u003e35\u003c/strong\u003e(1)\u003cstrong\u003e: \u003c/strong\u003e158-169.\u003c/li\u003e\n\u003cli\u003eAutar K, Guo X, Rumsey JW, Long CJ, Akanda N, Jackson M\u003cem\u003e et al.\u003c/em\u003e A functional hiPSC-cortical neuron differentiation and maturation model and its application to neurological disorders. \u003cem\u003eStem Cell Reports\u003c/em\u003e 2022; \u003cstrong\u003e17\u003c/strong\u003e(1)\u003cstrong\u003e: \u003c/strong\u003e96-109.\u003c/li\u003e\n\u003cli\u003eTost J, Dunker J, Gut IG. Analysis and quantification of multiple methylation variable positions in CpG islands by Pyrosequencing. \u003cem\u003eBiotechniques\u003c/em\u003e 2003; \u003cstrong\u003e35\u003c/strong\u003e(1)\u003cstrong\u003e: \u003c/strong\u003e152-156.\u003c/li\u003e\n\u003cli\u003eLi J, Tang Y, Cai D. IKKbeta/NF-kappaB disrupts adult hypothalamic neural stem cells to mediate a neurodegenerative mechanism of dietary obesity and pre-diabetes. \u003cem\u003eNat Cell Biol\u003c/em\u003e 2012; \u003cstrong\u003e14\u003c/strong\u003e(10)\u003cstrong\u003e: \u003c/strong\u003e999-1012.\u003c/li\u003e\n\u003cli\u003eDunkley PR, Jarvie PE, Robinson PJ. A rapid Percoll gradient procedure for preparation of synaptosomes. \u003cem\u003eNature protocols\u003c/em\u003e 2008; \u003cstrong\u003e3\u003c/strong\u003e(11)\u003cstrong\u003e: \u003c/strong\u003e1718-1728.\u003c/li\u003e\n\u003cli\u003eZhang Y, Helm JS, Senatore A, Spafford JD, Kaczmarek LK, Jonas EA. PKC-induced intracellular trafficking of Ca(V)2 precedes its rapid recruitment to the plasma membrane. \u003cem\u003eJ Neurosci\u003c/em\u003e 2008; \u003cstrong\u003e28\u003c/strong\u003e(10)\u003cstrong\u003e: \u003c/strong\u003e2601-2612.\u003c/li\u003e\n\u003cli\u003eRodenas-Ruano A, Chavez AE, Cossio MJ, Castillo PE, Zukin RS. REST-dependent epigenetic remodeling promotes the developmental switch in synaptic NMDA receptors. \u003cem\u003eNat Neurosci\u003c/em\u003e 2012; \u003cstrong\u003e15\u003c/strong\u003e(10)\u003cstrong\u003e: \u003c/strong\u003e1382-1390.\u003c/li\u003e\n\u003cli\u003eHuang W, Zhu PJ, Zhang S, Zhou H, Stoica L, Galiano M\u003cem\u003e et al.\u003c/em\u003e mTORC2 controls actin polymerization required for consolidation of long-term memory. \u003cem\u003eNat Neurosci\u003c/em\u003e 2013; \u003cstrong\u003e16\u003c/strong\u003e(4)\u003cstrong\u003e: \u003c/strong\u003e441-448.\u003c/li\u003e\n\u003cli\u003eSchmidt EK, Clavarino G, Ceppi M, Pierre P. SUnSET, a nonradioactive method to monitor protein synthesis. \u003cem\u003eNat Methods\u003c/em\u003e 2009; \u003cstrong\u003e6\u003c/strong\u003e(4)\u003cstrong\u003e: \u003c/strong\u003e275-277.\u003c/li\u003e\n\u003cli\u003eDeacon RM. Assessing nest building in mice. \u003cem\u003eNat Protoc\u003c/em\u003e 2006; \u003cstrong\u003e1\u003c/strong\u003e(3)\u003cstrong\u003e: \u003c/strong\u003e1117-1119.\u003c/li\u003e\n\u003cli\u003eGao XH, Li L, Parisien M, Wu J, Bederman I, Gao Z\u003cem\u003e et al.\u003c/em\u003e Discovery of a Redox Thiol Switch: Implications for Cellular Energy Metabolism. \u003cem\u003eMol Cell Proteomics\u003c/em\u003e 2020; \u003cstrong\u003e19\u003c/strong\u003e(5)\u003cstrong\u003e: \u003c/strong\u003e852-870.\u003c/li\u003e\n\u003c/ol\u003e"}],"fulltextSource":"","fullText":"","funders":[],"hasAdminPriorityOnWorkflow":false,"hasManuscriptDocX":true,"hasOptedInToPreprint":true,"hasPassedJournalQc":"","hasAnyPriority":false,"hideJournal":false,"highlight":"","institution":"","isAcceptedByJournal":true,"isAuthorSuppliedPdf":false,"isDeskRejected":"","isHiddenFromSearch":false,"isInQc":false,"isInWorkflow":false,"isPdf":false,"isPdfUpToDate":true,"isWithdrawnOrRetracted":false,"journal":{"display":true,"email":"[email protected]","identity":"molecular-psychiatry","isNatureJournal":false,"hasQc":false,"allowDirectSubmit":false,"externalIdentity":"mp","sideBox":"Learn more about [Molecular Psychiatry](http://www.nature.com/mp/)","snPcode":"41380","submissionUrl":"https://mts-mp.nature.com/cgi-bin/main.plex","title":"Molecular Psychiatry","twitterHandle":"@molpsychiatry","acdcEnabled":true,"dfaEnabled":true,"editorialSystem":"ejp","reportingPortfolio":"Nature AJ","inReviewEnabled":true,"inReviewRevisionsEnabled":false},"keywords":"Fragile X syndrome, Autophagy, Cognition deficits, Postsynaptic organization","lastPublishedDoi":"10.21203/rs.3.rs-4415392/v1","lastPublishedDoiUrl":"https://doi.org/10.21203/rs.3.rs-4415392/v1","license":{"name":"CC BY 4.0","url":"https://creativecommons.org/licenses/by/4.0/"},"manuscriptAbstract":"\u003cp\u003eDysregulated spine morphology is a common feature in pathology of many neurodevelopmental and neuropsychiatric disorders. Overabundant immature dendritic spines in the hippocampus are causally related to cognitive deficits of Fragile X syndrome (FXS), the most common form of heritable intellectual disability. Recent findings from us and others indicate autophagy plays important roles in synaptic stability and morphology, and autophagy is downregulated in FXS neurons. However, the mechanism remains unclear. In this study, we identified that activated autophagy degrades the eukaryotic initiation factor 4G1 (eIF4G1) and postsynaptic density protein-95 (PSD-95) in hippocampal neurons of \u003cem\u003eFmr1\u003c/em\u003e KO mice and FXS neurons from patients, which subsequently corrected the dysregulated postsynaptic organization and actin assembly, the critical processes determining synaptic maturation and density. Centrally activating autophagy in hippocampus degrades eIF4G1 and PSD-95, restores actin dynamics, and improves cognition of \u003cem\u003eFmr1\u003c/em\u003e KO mice. In human neurons derived from patients diagnosed with both FXS and intellectual disability, activating autophagy corrected the aberrant actin assembly. Thus, our findings revealed a previously unappreciated mechanism through which autophagy affects actin assembly and synaptic organization, suggesting a critical role of autophagy in regulating structural synaptic plasticity in healthy and diseased conditions.\u003c/p\u003e","manuscriptTitle":"Autophagy controls the hippocampal postsynaptic organization and affects cognition in a mouse model of Fragile X syndrome","msid":"","msnumber":"","nonDraftVersions":[{"code":1,"date":"2025-08-27 08:07:22","doi":"10.21203/rs.3.rs-4415392/v1","editorialEvents":[{"type":"communityComments","content":0},{"type":"decision","content":"revise","date":"2025-07-22T10:00:57+00:00","index":"","fulltext":""},{"type":"checksComplete","content":"","date":"2025-02-14T11:52:05+00:00","index":"","fulltext":""},{"type":"submitted","content":"Molecular Psychiatry","date":"2025-02-11T17:58:24+00:00","index":"","fulltext":""},{"type":"checksFailed","content":"","date":"2025-02-11T13:15:02+00:00","index":"","fulltext":""},{"type":"editorAssigned","content":"","date":"2025-02-10T21:03:56+00:00","index":"","fulltext":""}],"status":"published","journal":{"display":true,"email":"[email protected]","identity":"molecular-psychiatry","isNatureJournal":false,"hasQc":false,"allowDirectSubmit":false,"externalIdentity":"mp","sideBox":"Learn more about [Molecular Psychiatry](http://www.nature.com/mp/)","snPcode":"41380","submissionUrl":"https://mts-mp.nature.com/cgi-bin/main.plex","title":"Molecular Psychiatry","twitterHandle":"@molpsychiatry","acdcEnabled":true,"dfaEnabled":true,"editorialSystem":"ejp","reportingPortfolio":"Nature AJ","inReviewEnabled":true,"inReviewRevisionsEnabled":false}}],"origin":"","ownerIdentity":"c5bac1c6-6fcc-4bed-aa6a-207ab2644dcd","owner":[],"postedDate":"August 27th, 2025","published":true,"recentEditorialEvents":[],"rejectedJournal":[],"revision":"","amendment":"","status":"published-in-journal","subjectAreas":[{"id":53763093,"name":"Biological sciences/Neuroscience"},{"id":53763094,"name":"Biological sciences/Drug discovery"}],"tags":[],"updatedAt":"2025-09-12T06:45:21+00:00","versionOfRecord":{"articleIdentity":"rs-4415392","link":"https://doi.org/10.1038/s41380-025-03207-6","journal":{"identity":"molecular-psychiatry","isVorOnly":false,"title":"Molecular Psychiatry"},"publishedOn":"2025-09-10 04:00:00","publishedOnDateReadable":"September 10th, 2025"},"versionCreatedAt":"2025-08-27 08:07:22","video":"","vorDoi":"10.1038/s41380-025-03207-6","vorDoiUrl":"https://doi.org/10.1038/s41380-025-03207-6","workflowStages":[]},"version":"v1","identity":"rs-4415392","journalConfig":"researchsquare"},"__N_SSP":true},"page":"/article/[identity]/[[...version]]","query":{"redirect":"/article/rs-4415392","identity":"rs-4415392","version":["v1"]},"buildId":"8U1c8b4HqxoKbykW_rLl7","isFallback":false,"isExperimentalCompile":false,"dynamicIds":[84888],"gssp":true,"scriptLoader":[]}